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Summary 
To plan a public health response to the hepatitis C virus (HCV) epidemic in Scotland, 
in terms of treatment needs and preventive measures, quantitative estimates of the 
current and future burden of HCV disease are required. The overwhelming majority of 
HCV infections in Scotland have been associated with injecting drug users (IDUs); 
therefore, the work described in this thesis focussed on this risk group. A forward 
projection model was used to estimate the numbers of, both current and former, IDUs 
who acquired HCV infection and progressed to mild, moderate and severe HCV 
disease in Glasgow and Scotland between 1960 and 2030. The model was developed 
initially for Glasgow because more epidemiological information exists for this region, 
than elsewhere in Scotland, to calibrate model outcomes with local data relating to 
HCV and its consequences. Insights gained from the model fitting process in Glasgow 
were then used to extend the model to the rest of Scotland. 
First, the incidence and cessation of injecting drug use in Glasgow during 
1960-2000 were derived through the use of a modified Delphi approach. Instead of 
the usual iterative process to refine experts' estimates, the elicitation of IDU incidence 
and cessation provided an opportunity to combine these data and examine coherence 
with capture-recapture IDU prevalence estimates. Coherent estimates indicated that 
incidence (median: 28 to 49) and cessation (1 to 2%) remained low and stable during 
1960-1975, rose steeply between 1975-1985 (incidence from 49 to 1,335; cessation 
from 2% to 6%), and by 2000 there had been a decline in incidence (1,195) but a 
further rise in cessation (15%). 
Secondly, stochastic simulation was used to model the transmission of HCV 
among current IDUs in Glasgow, according to their injecting risk behaviours, and 
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estimate the past incidence of HCV infection. The model that considered higher 
infectivity during acute viraemia following infection produced seroprevalences 
(median: 62-72%) and incidences (18-30 per 100 susceptible injector-years) 
consistent with observed data during the 1990s. The annual number of new HCV 
infections among current IDUs in Glasgow was estimated to be low during 1960-1976 
(median: 10-60), rise steeply during the early 1980s to peak in 1985 (1,120), stabilise 
during 1991-1997 (510-610) and rise again during 1998-2000 (710-780). Scenario 
analyses indicated that potentially as many as 4,500 HCV infections (10th and 90th 
percentiles: 2,400-7,700) had been prevented in Glasgow during 1988-2000 as a result 
of harm-reduction measures. 
Scenario analyses also permitted the gauging of changes in risk behaviours 
required to effect appreciable reductions in the incidence of HCV infection. Incidence 
can be successfully reduced if IDUs who, unavoidably, share needles/syringes confine 
their borrowing to one person; with this strategy alone, an estimated 5,300 HCV 
infections (10th and 90th percentiles: 4,100-6,700) could have been averted in Glasgow 
during 1988-2000. Such insights will inform those responsible for developing new 
ways to prevent HCV transmission among IDU populations. 
Thirdly, linkage of laboratory data on diagnosed HCV antibody positive 
persons in Scotland to clinical data from hospital and death records provided a unique 
national epidemiological dataset to estimate the number who had progressed to severe 
HCV disease. The number of persons with newly developed HCV-related 
decompensated cirrhosis in Scotland was estimated to have increased from 230 (95% 
CI 220-250) in 1996-1998 to 300 (280-320) in 1999-2001, highlighting HCV as a 
growing burden on healthcare resources. Alcohol was a prominent factor among 
persons who had died (78% of 134) or were hospitalised (72% of 442) with HCV- 
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related decompensated cirrhosis during 1996-2001 in Scotland. The younger age of 
decompensated patients presenting to hospital with both HCV and alcohol (78% of 
320 were aged <50 years old) suggests that the combined effect of these two factors 
accelerates liver disease progression more than if only one of these factors were 
present (HCV: 48% of 122; alcohol: 33% of 8,465). 
Fourthly, a meta-analysis was carried out to explore the relationship between 
HCV chronic liver disease and the consumption of alcohol. The pooled relative risk of 
cirrhosis associated with heavy alcohol intake (defined in the range of at least 210 to 
560g per week) was 2.33 (95% CI 1.67-3.26) by the random effects model. Studies 
investigating the risk of HCV-related cirrhosis include patients undergoing liver 
biopsy and therefore could under-represent heavy alcohol users; such selectivity may 
have under-estimated the regression effect of alcohol. 
Finally, the HCV projection model was designed to synthesize information on 
the incidence and cessation of injecting drug use, the incidence of HCV infection 
among current IDUs, the rate of HCV disease progression (including the influence of 
alcohol and other host factors), and the annual number of IDUs developing HCV- 
related decompensated cirrhosis. A total of 17,400 (95% CI 14,300-22,200) and 
42,900 (32,400-60,600) persons, who had ever injected drugs, were estimated to be 
living with HCV antibodies by the end of 2003 in Glasgow and Scotland, 
respectively. This compares with approximately 5,000 (29%) and 13,900 (32%) 
diagnosed, respectively. Of these HCV-infected IDUs in Glasgow and Scotland, 
13,200 (10,800-16,900) and 32,200 (24,300-45,500) were estimated to be living with 
chronic HCV and therefore at risk of developing cirrhosis. The number of IDUs 
developing HCV-related decompensated cirrhosis in Scotland is estimated to double 
between 2000 and 2020. As high as 16% and 27% of Glasgow former IDUs in 2005 
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aged 30-39 and 40-49 years, respectively, were estimated to have moderate disease 
(32% and 47% of those chronically infected, respectively), which highlights the 
potential benefit of targeting HCV testing at former IDUs who belong to these age 
groups. 
The treatment with antiviral therapy of 15,000 former IDUs in Glasgow with 
moderate HCV disease over the next 26 years (62% of those HCV infected) could 
potentially prevent between 24% and 86% of severe HCV-related events during 2005- 
2030 (based on 45% to 100% response and compliance to therapy, respectively). The 
identification and treatment of a larger proportion of former IDUs with HCV disease, 
education about the importance of minimal alcohol consumption, and the 
development of more effective therapies are needed now to help achieve a greater 
impact on the future morbidity and mortality of this disease. 
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Chapter 1: Introduction 
1.1 Background to the hepatitis C virus 
The hepatitis C virus (HCV) was first discovered in 19891 and diagnostic tests to 
reliably detect infection were subsequently developed2. Of those infected with HCV, 
60-85% fail to clear the virus3'4 and consequently are at risk of developing severe liver 
disease - decompensated cirrhosis and hepatocellular carcinoma (HCC) - over a long 
and variable incubation period depending on age at infection, gender, alcohol intake 
and co-infection with HIVS'6. There is no vaccine available at present to prevent 
infection with HCV; however, treatment with pegylated interferon alpha and ribavirin 
given in combination leads to sustained viral clearance in 50-60% of patients with 
moderate disease7'8. Liver transplantation is the only option to prolong life for patients 
who have reached severe HCV disease. 
HCV is a blood-borne virus that is transmitted primarily through direct 
percutaneous exposure. Since 1991, screening of blood donors and products for HCV 
has virtually eradicated transfusion-associated HCV in developed countries9. While 
this infection has been shown to be transmitted vertically from mother to child and 
through unprotected sexual intercourse 10, HCV in western countries is most 
commonly transmitted among injecting drug users (IDUs) who share injecting 
equipment II. HCV seroprevalence rates exceeding 50% have been detected among 
populations of IDUs throughout the world12 
The World Health Organisation estimated, on the basis of limited country- 
specific data, that around 170 million people worldwide were chronically infected 
with HCV in 199713; thus, HCV is more than four times as prevalent as the human 
immunodeficiency virus (HIV)14. In the United States, HCV has become the leading 
cause of cirrhosis and liver transplantation15,16,17 Scotland is likely to have one of the 
highest prevalences of HCV in Western Europe because of its high prevalences of (i) 
IDUs18"9 and (ii) HCV amongst its IDU population (described below, Table 1.1). 
Furthermore, HCV has been circulating among IDUs in Scotland since at least the 
early 1980s20; therefore, it is expected that increasing numbers of individuals will 
begin to present with HCV-related complications over the next 10 to 20 years. 
Accordingly, it is important that methods to forecast the extent and type of HCV- 
related disease in Scotland - which the National Health Service, local authorities and 
non-governmental organisations will need to respond to in future years - are 
developed. 
1.2 Prevalence of HCV infection in Scotland 
The prevalence of HCV in Scotland varies considerably depending on the population 
studied; as in other western countries10, the highest rates were reported among IDUs 
and recipients of blood and blood products (described below, Tables 1.1 and 1.2). Of 
14,390 persons diagnosed with HCV antibodies in Scotland by the end of June 2002, 
almost 90% (8,719/9,728) of those for whom at least one risk factor was known had 
injected drugs, 6% (584/9,728) had received blood or blood products and 4% reported 
occupational needlestick injuries, tattoos, body piercings or sexual contact21. These 
data, and those described below, clearly illustrate that the current, principal risk factor 
for HCV infection in Scotland is injecting drug use. 
1.2.1 Pregnant women 
The unlinked anonymous testing of residual dried blood spots on neonatal metabolic 
screening cards is regarded as the most cost-effective means of providing minimally 
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biased estimates of HCV prevalence in a large general population22. The overall 
prevalence of maternal HCV antibodies in Scotland during 2000 was low (0.4%); this 
rate was higher than that modelled for England/Wales (0.15%)23 though lower than 
regional estimates for the rest of Western Europe (1-2%)24, the United States (2- 
4%)25'26'27 and Australia (1.1%) 28. HCV seroprevalence among Scottish childbearing 
women is consistent with that expected from injecting drug use as primary route of 
exposure: highest (i) among 25-29 year olds (0.4-0.57%), (ii) in high deprivation areas 
(0.92-1.07%), and (iii) in Greater Glasgow (0.83-0.96%) and Grampian (0.38-0.62%) 
health-board areas. A study of pregnant women in Dundee during 1997 found a 
significantly higher HCV seroprevalence among those who reported injecting drug 
use (41% of only 17) than those who had not (0.45% of 3,531) (p<0.0001), and also 
highlighted the increased risk of HCV acquisition among the sexual partners of IDUs 
(15% of 33)29 
1.2.2 Children 
During June 2002, a pilot study to investigate the feasibility of surveying, 
anonymously, HCV infection among healthy children by means of an oral fluid 
specimen was undertaken in the Child Dental Health Department of Glasgow Dental 
Hospital and School. This study found a HCV seroprevalence of 3% (95% CI 0.4- 
10.3%) among a small sample of 70 children3o 
1.2.3 Blood donors 
The prevalence of HCV antibodies among Scottish blood donors in 1991-1992 was 
0.09%31, a rate which was similar to that detected in parts of England (e. g. London 
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(0.07%)32, North West (0.04%)33) but lower than that found in the United States 
0.36%)34. 
1.2.4 Recipients of blood and blood products 
Prior to 1985, most patients with clotting disorders were exposed to HCV through the 
receipt of contaminated blood products. Evidence of HCV infection was found in all 
but one of 78 haemophiliacs treated with non-virus inactivated clotting factor 
concentrates in Edinburgh35. In 1985, heat treatment of clotting factor concentrates for 
haemophiliacs was introduced in Scotland36 
In 1991, the estimated seroprevalence of HCV in three Glasgow Renal 
Dialysis Units was 3.9% (19/483)37. The number of blood transfusions received and 
the length of time on dialysis were positively associated with HCV antibody status. 
HCV antibody testing of all new entrants to dialysis units, and thereafter at six 
monthly intervals, has since been implemented. 
1.2.5 Other patient groups 
The HCV antibody prevalence for 16-49 year old males undergoing, or eligible to 
undergo, surgery was 3.8% (103/2,702)38. While the risk of HCV transmission from 
patient to surgeon is low, the prevalences observed among surgical patients indicate 
that surgeons working in areas of high injecting drug use prevalence and high HCV 
prevalence among IDUs will frequently operate on HCV infected patients. 
Of 80 patients with histologically confirmed liver cancer presenting to the 
Royal Infirmary of Edinburgh between 1985 and 1994,30% were found to be positive 
for HCV antibodies39. This study highlighted that chronic HCV infection could be a 
major risk factor for the development of HCC in Scotland. 
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1.2.6 Healthcare workers 
The overall prevalence of HCV antibodies among healthcare workers in Glasgow was 
low (0.28% of 8,412) 40 and comparable with that reported in England (0.21- 
0.28%)41'42. The Glasgow study indicated that the performance of exposure prone 
procedures does not necessarily result in an increased risk of HCV acquisition by 
healthcare workers (0.23% of 2,205 currently performing compared to 0.3% of 6,207 
not currently performing exposure prone procedures, p=0.6; no significant differences 
in HCV prevalence were found between these groups stratifying by age). A study of 
880 dental healthcare workers in the West of Scotland reported a seroprevalence of 
0.1 %, from which the authors suggested that HCV was not a significant occupational 
hazard in the dental setting either43 
1.2.7 Genitourinary Medicine Clinic Attenders 
The HCV seroprevalence among non-injecting heterosexual men and women was 0.8 
(32/4,135) and 0.3% (10/3,035), respectively, and 0.6% (4/668) among non-injecting 
homosexual/bisexual men attending genitourinary medicine clinics in Scotland during 
1996-199744. These findings are in keeping with the prevailing view that HCV is not 
easily transmitted through unprotected sexual intercourse. 
1.2.8 Prisoners 
HCV antibody prevalence was estimated at 58% and 3.5% among 536 injector and 
899 non-injector inmates, respectively, surveyed in five Scottish prisons during 1994- 
199645. Similarly, 53% and 4.0% of 173 injector and 406 non-injector inmates, 
respectively, surveyed at Shotts prison during 1999-2000 were estimated to be HCV 
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antibody positive (personal communication: Dr Jennifer Champion, SCIEH). The 
prevalence and potential transmissibility of HCV in injector-inmates are therefore 
both high. For inmates surveyed in 1999-2000 who reported ever having injected 
drugs, the HCV incidence was 12 (95% Cl 5-32) per 100 person-years of 
incarcerationa6 
1.2.9 Injecting drug users 
HCV has been circulating among IDUs in Scotland since at least the mid 1970s: 73% 
of 275 IDUs who had tested hepatitis B surface antibody positive in Glasgow during 
1973-1984 were HCV antibody positive (personal communication: Dr. Sheila 
Cameron, Glasgow Regional Virus Laboratory); similarly, 87% of 126 IDUs who had 
a hepatitis B surface antibody test in Edinburgh during 1984 were HCV antibody 
positive20. Of almost 2,000 current IDUs recruited during community-wide, multi-site 
surveys in Glasgow during 1990-1996, the overall estimated HCV seroprevalence was 
72%47. Seroprevalence rates per survey year ranged from the highest of 79% from 365 
IDUs in 1990 to the lowest of 66% from 195 IDUs in 1996. These data suggest that 
the incidence of HCV among IDUs in Glasgow had decreased during this period. 
In the late 1980s and throughout the 1990s, Scotland implemented, and 
continued to develop, interventions - including the provision of sterile injecting 
equipment - to reduce needle/syringe sharing and thus the transmission of blood- 
borne viruses among IDUsas'49 To determine if the prevalence of HCV antibodies 
among IDUs in Scotland had changed in this era of harm reduction, residual sera from 
IDUs who had undergone a named HIV antibody test during 1989-2000 were tested 
for HCV antibodies (Table 1.2)50; this survey approach revealed significant reductions 
in HCV seroprevalence among IDUs aged under 25 years from Glasgow and Lothian 
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between 1990 (Glasgow 91%; Lothian 69%) and 1995 (59%; 31%) and 1997 (43%; 
13%), suggesting that there had been a steady, continual decrease in the incidence of 
HCV. However, no further significant reductions in HCV seroprevalence were found 
among this group during the late 1990s (Glasgow 1997 and 1999-2000: 43% and 
41%, respectively; Lothian 1997 and 1999: 13% and 17%, respectively; Table 1.2). 
The most recent findings highlight that existing harm reduction measures, 
acknowledged as having helped to reduce the spread of HCV, are not sufficient to 
bring this epidemic under control. The high seroprevalence of HCV (58% of 466) 
detected among recently initiated IDUs (i. e. average of 2-3 years' injecting career) 
surveyed in Glasgow during 2001-2002 suggests that the incidence of HCV might be 
on the increase (personal communication: Dr. Sarah Wadd, SCIEH); such a trend 
would be consistent with the observed increase in injecting risk behaviours in 1999 
compared to previous years 1991-19945 1 
1.3 Public health relevance of projecting the future HCV-related disease burden 
Most of those infected with HCV in Scotland, as in many other developed countries, 
acquired their infection at a young adult age and during the past thirty years through 
the sharing of contaminated injecting equipment. Given that HCV progresses slowly, 
particularly among young adults, and does not result in major morbidity and mortality 
for many years, then Scotland has not yet experienced the full consequences of this 
epidemic. As the large pool of currently infected patients ages and their disease has 
time to progress, more patients will develop complications of liver disease and the 
burden on the healthcare system will increase as a result. 
As at the end of June 2002, a total of 14,390 persons had been diagnosed with 
HCV in Scotland21, of whom only 1,500-3,000 were likely to have been in active 
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follow-up with specialist care services and even fewer (1,000-1,500) had received 
antiviral treatment52. Plausibly, a major factor contributing to the low uptake of 
antiviral therapy was the ineligibility of many cases due to their current injecting 
status at the time of diagnosis. Based on a study among pregnant women53, it was 
estimated that 70-80% of HCV infected women (of childbearing age) in Scotland 
during 2000 were undiagnosed; accordingly such individuals were making few 
demands on HCV-related healthcare services. Overall, the current burden placed on 
the healthcare system in Scotland by HCV is relatively small when placed in the 
context of the large reservoir of infected persons. That said, waiting times for new 
patient appointments to see a specialist for evaluation of HCV disease in Scotland 
range, depending on region, between several months and several years. Strategies to 
diagnose, monitor and successfully treat chronic HCV infection need to be designed, 
evaluated, funded and implemented before large numbers of individuals start to 
develop severe liver disease, which is unresponsive to antiviral therapy. Treatment of 
severe liver disease is limited by the shortage of cadaveric donor livers for 
transplantations4 
Patients with chronic hepatitis use healthcare resources in obvious and direct 
ways, such as clinic visits, diagnostic tests, counselling, drug therapy, hospitalisation 
for the management of liver failure and HCC, and liver transplantation. Care of 
patients with HCV is provided by a wide range of professionals from many different 
disciplines including health promotion, primary care, drug addiction services, 
voluntary sector, social work services, prisons, blood transfusion service, genito- 
urinary medicine, obstetrics, neonatology, virology, gastroenterology, hepatology, 
infectious diseases, haematology, public health and occupational health. The high cost 
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of managing patients with HCV enforces the need for a systematic approach to this 
condition so that resources are used most effectively. 
Services provided for prevention, detection and management of chronic HCV 
in Scotland have so far been guided by a national needs assessment52 and regional 
strategies55. Projections (with uncertainty limits) of moderate and severe HCV-related 
disease will further inform the planning, and subsequent costing, of healthcare 
provision for HCV-infected patients. By producing projections with, and without, 
implementation of a range of treatment and prevention interventions, the effectiveness 
(and cost) of these strategies for reducing, or delaying, the incidence of severe HCV- 
related disease can be assessed and compared with similar data on competing 
treatment and prevention regimes associated with other conditions. These data will 
thus ultimately inform the Scottish Executive Health Department as to the level of 
priority to give HCV infection in the nation's healthcare budget. 
1.4 The role of modelling in the study of infectious diseases 
Mathematical and statistical models have played a significant role in shaping our 
understanding of the epidemiology of infectious diseases. Primarily, infectious disease 
models have been used to (i) quantify the relationships between characteristics of a 
specific disease, the contact patterns in the population which cause transmission and 
the resulting incidence and prevalence of the disease, (ii) estimate the potential impact 
of proposed interventions on the incidence and prevalence of the disease, and (iii) 
forecast future trends in disease burden. 
Transmission models have helped to determine the key factors influencing the 
spread of HIV and other sexually transmitted diseases56, such as the role of specific 
groups of individuals with high-risk injecting and sexual behaviours57. The natural 
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history of HIV infection has largely been informed from cohort studies, but the effect 
of possibly important biological parameters, which could not be easily studied 
empirically, has been postulated from modelling. For example, Longini et al. 58 argued 
based on modelling results that infectiousness is very high in the first acute phase of 
HIV infection, very low during the long asymptomatic phase and high again when the 
first symptoms of AIDS become manifest. The effect of this phenomenon was 
similarly explored in modelling work, presented in Chapter 3, undertaken to assess the 
transmission of HCV among IDUs in Glasgow. 
Transmission models have also been used to evaluate the effectiveness of 
behavioural and medical interventions on the spread of infectious diseases59. Kaplan60 
modelled the spread of HIV among IDUs via shared needles/syringes in shooting 
galleries and illustrated that the provision of sterile injecting equipment to this 
population by needle exchange programmes could significantly reduce the risk of new 
infections. Mathematical models of the transmission dynamics of the hepatitis B virus 
have provided the framework to assess the costs and benefits of different vaccination 
strategies61. In recent years, models have been developed to help explore the impact of 
control measures on the spread of hospital-acquired infections62, smallpox from a 
bioterrorism attack63, and the foot and mouth epidemic64. Chapter 3 presents the 
findings of a HCV transmission model among IDUs in Glasgow, which investigated 
the changes in injecting risk behaviours required to effect appreciable reductions in 
the incidence and prevalence of HCV infection in this population. Furthermore, 
Chapter 6 outlines the impact of different antiviral treatment strategies on the future 
incidence of severe HCV-related disease from modelling work undertaken among 
IDUs in Glasgow. 
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Statistical modelling techniques have been developed to forecast the future 
course of infectious disease epidemics. The back-calculation method has been most 
widely used in projections of acquired immune deficiency syndrome (AIDS)65'66 and, 
more recently, variant Creutzfeldt-Jakob disease67. This approach combines available 
data on the number of reported cases of disease (e. g. AIDS), after adjustment for 
reporting delays, with a mathematical representation of the time course between 
infection and disease diagnosis to back-calculate the number of persons infected in the 
past and then project forward to obtain predictions of the future incidence of disease. 
The application of the back-calculation technique, and other modelling approaches, to 
generate projections of HCV-related severe sequelae is discussed in Section 1.5 
below. 
1.5 Previous modelling approaches to projecting the future HCV-related disease 
burden 
Markov models have been developed to determine the cost-effectiveness of treating 
chronic HCV infection with antiviral therapy6s'69''0'71''2''3, the cost-effectiveness of 
pre-treatment management strategies 74 ' 75, and the future healthcare costs of not 
treating HCV infection among IDUs76'77. The prospect of an alarming rise in HCV- 
related sequelae over the next 10 to 20 years is generally recognized, and thus recently 
an increasing number of countries - namely France78'79, Australia 
80'81, the United 
States 82'83'84, Canada 85, Switzerland86 and Greece87 - 
have focussed attention on 
generating projections of their HCV epidemics. Few of these have however attempted 
to validate their projections by comparing model outcomes to past epidemiological 
trends relating to HCV and its consequences83 
Precise quantification of the future HCV-associated morbidity and mortality 
burden requires knowledge of both the past incidence of HCV infection and the 
natural history of the disease. Reliable data on the progression of HCV infection are 
beginning to accumulate as the length of follow-up in cohorts of chronically infected 
cases increases. However, determining the time of HCV acquisition for all currently 
infected subjects is problematic because most acute infections are asymptomatic, 
clinical disease is greatly under-reported, and a diagnostic test for HCV has been 
available only since 1991 yet epidemics have been established for many decades. 
Table 1.3 outlines the approaches used previously to model the future HCV- 
related disease burden in other countries, with emphasis on: (i) estimation of the past 
incidence of HCV infection, (ii) account for mortality from causes unrelated to HCV, 
(iii) assumptions used to model the progression of HCV disease, and (iv) data used to 
validate model results. 
1.5.1 Estimation of the past incidence of HCV infection 
In previous HCV projection models, the past incidence of HCV infection has been 
generated through different approaches: (1) back-calculation of HCV-related HCC 
deaths, (2) estimation of the past pattern of injecting drug use and HCV incidence 
among IDUs, (3) adjustment of surveillance data on acute HCV, and (4) calibration of 
HCV seroprevalence and HCC mortality data. Rather than gauge the past incidence of 
HCV infection, a fifth approach estimated the number of persons currently infected 
with HCV by stage of disease. These five approaches are described below. 
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1.5.1.1 Back-calculation from HCV-related HCC deaths 
Deuffic et al. 78 employed the back-calculation technique with French statistics on 
HCV-related HCC deaths during 1979-1995 (and 1979-1998 in an updated 
analysis79), in combination with data on the age distribution at infection and a general 
model of the natural history of HCV disease, to estimate the annual incidence of HCV 
through an optimisation process which essentially minimized the difference between 
modelled and observed HCC deaths data. 
Implementation of the back-calculation model relies on the proportion of HCC 
deaths attributed to HCV being known and also on the consistency and completeness 
of death statistics over the entire time-period. Even if this information, and other key 
data described above, were available, the slow progression of the virus is likely to 
hinder the wider application of this approach to other countries. Many decades can 
elapse before decompensated cirrhosis or HCC develops after primary HCV infection. 
France's HCV epidemic dated back to the 1940s, with 12,000 new infections 
estimated during its mid-epidemic year in 1955. As a result, France witnessed 
between 1,000 and 1,700 HCV-related HCC deaths per annum during the 1990s78 
Therefore, a country's HCV epidemic would need to have been established well 
before 1970 to culminate in substantial numbers of HCC deaths during the 1990s. 
1.5.1.2 Estimation of the past pattern of injecting drug use and HCV incidence 
among IDUs 
The approach adopted by Law et al. in 199980 and 200381 on behalf of the Hepatitis C 
Virus Projections Working Group in Australia focussed on the IDU population and 
applied the following strategy: (i) first, the number of people injecting drugs in 
Australia over the last three decades was estimated; (ii) based on this pattern of 
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injecting drug use and estimates of HCV incidence among IDUs derived from cohort 
studies, HCV incidence as a result of injecting drug use was estimated; (iii) these 
estimates of HCV incidence due to injecting drug use were then adjusted in 
accordance with the available epidemiological data to allow for HCV infections 
through other transmission routes, including receipt of blood and blood products. 
Lack of data on the prevalent number of IDUs in Australia at the time of the 
first HCV projection report meant that the Delphi technique was used to reach 
consensus estimates80. The second Australian projection report was able to refine 
these estimates based on data obtained through modelling of overdose deaths, 
methadone maintenance episodes and heroin arrests81. Law et al. acknowledged that 
the incidence of HCV infection estimated through this approach was particularly 
sensitive to assumptions regarding the numbers of IDUs and HCV incidence rates 
among IDUs and emphasised the need to corroborate model results with available 
epidemiological data. 
1.5.1.3 Adjustment of surveillance data on acute HCV 
The most recent model developed for the United States by Davis et al. 84 estimated the 
annual incidence of HCV infection during 1982-1995 according to the annual number 
of acute HCV infections reported to the Centre for Disease Control and Prevention 
(CDC) sentinel surveillance system, with adjustment for significant underreporting 
and the recognition of only symptomatic acute infection88'89. The annual incidence of 
infection for the years 1950 to 1981 was assumed the same as for 1982, which most 
likely overestimated infections during these years. 
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1.5.1.4 Calibration of HCV seroprevalence and HCC mortality data 
Another group in the United States applied a model fitting approach to estimate the 
past incidence of HCV infection using information on HCV seroprevalence and HCC 
mortality simultaneously. A comprehensive and complex model was designed to 
follow the entire population from birth to death, with acquisition of HCV assumed to 
occur through three major routes: mother-to-child transmission, transfusion-associated 
infection and community infection, including injection drug use and sexual 
transmission. Numerous assumptions were explored to depict the HCV incidence 
patterns through these three risk categories. A review of the literature was conducted 
to define plausible ranges around model parameters (on acquisition of infection, 
probability of persistence and risk of progression to end-stage liver disease), and 
multiple simulations of the model were undertaken using sampled values from these 
ranges. Model predictions produced by each set of sampled values were compared 
with data on HCV seroprevalence and HCC mortality and a range of HCV incidence 
curves, which produced consistent results, was identified. 
1.5.1.5 Estimating the number of persons currently infected with HCV by stage 
of disease 
Wong et al. 82 adopted a different approach for the United States to those described 
above; using national household survey data, this entailed the estimation of the 
number of persons infected with HCV by age group in 1991. The authors accepted 
that this approach had likely underestimated infection because of the household 
survey's non-representation of prisoners and homeless people. Further, this model did 
not consider new infections occurring after 1991. Estimates of the prevalent number 
of HCV infected persons by age were combined with liver biopsy data, from HCV- 
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infected patients presenting at liver clinics for treatment90, to determine the number of 
persons currently infected with HCV by stage of liver disease (i. e. mild hepatitis, 
moderate hepatitis and cirrhosis). Because these latter patients were involved in 
treatment trials and subject to selection bias, the authors adjusted the proportion of the 
simulated population with cirrhosis so that the simulated number of HCV-related 
deaths matched that estimated from other sources82 
Sagmeister et al. 86 used a similar approach for Switzerland, which combined 
(i) HCV antibody prevalence data from blood donors and pregnant women to estimate 
the number of HCV-infected persons in 1998, with (ii) liver biopsy data82 to estimate 
disease stage. The projection models developed for Canada85 and Greece87 were based 
also on the estimated number of persons who were infected with HCV in 1998 and 
1991, respectively; no details were provided of the methods used to derive these 
estimates. The Canadian and Greek models then estimated the dates of HCV 
acquisition, instead of the current stage of liver disease, for their currently HCV- 
infected populations; this was achieved by assignment of infected cases to either age 
or transmission groups and assignment of duration of HCV infection intervals to each 
infected case on the basis of their age or transmission group, according to data from 
various sources but mainly from patients enrolled in treatment studies. The Greek 
model acknowledged the potential under-representation of HCV-infected IDUs in the 
treatment studies and thus performed sensitivity analyses assuming a much higher 
proportion of this risk group 87 
1.5.2 Accounting for mortality from causes unrelated to HCV 
Seven of the ten previous projection models applied general population, some age and 
gender specific, rates of mortality to account for the death of simulated subjects from 
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causes unrelated to HCV (Table 1.3). The remaining three applications, more 
appropriately, have taken account of the additional non-HCV-related mortality risk for 
individuals who acquire HCV infection compared to the general population: the most 
recent Australian model assumed a 1% annual mortality due to injecting drug use81; 
Wong et al. explored the effect of an excess mortality risk for persons who acquired 
their HCV through injection drug use (i. e. relative risk of 14,10 and 4 for those aged 
<21,21-30, >30 years, respectively, compared to the general population) and blood 
transfusion (i. e. additive risk of 0.15 per year)82; and Salomon et al. assumed a2 to 5 
times higher risk of death among HCV-infected persons compared to the general 
population83 
1.5.3 Assumptions used to model the progression of HCV disease 
Several HCV projection models, undertaken in the United States82'84, Canada85 and 
Switzerland86, based their assumptions on the natural history of HCV on an early 
Markov model developed by Bennett et al. to determine the cost-effectiveness of 
treating chronic HCV infection with antiviral therapy68. In this model, 80% of newly 
HCV-infected persons developed chronic infection: this percentage has since been 
shown to vary between 60 and 90%3'4, although only the model proposed by Salomon 
et al. 83 accommodated this range. 
Bennett et al. estimated that approximately 30% of HCV chronically infected 
persons would progress to cirrhosis within 20 years of infection, according to three 
cohort studies involving only 126 patients91'9`. The disease progression parameters in 
this model have remained largely unchallenged, and have been applied 
elsewhere 82,84,85,86, despite an improved understanding of the natural history of 
HCV93. In a systematic review of 57 natural history studies, estimates of progression 
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to cirrhosis at 20 years among HCV chronically infected persons varied considerably 
depending on the methodology employed: 24% (95% CI 11-37%), 22% (18-26%), 7% 
(4-10%) and 4% (1-7%) among post-transfusion cohorts, liver clinic series, 
community-based cohorts, and blood donor cohorts, respectively 94. The community- 
based studies were generally longitudinal with known time of HCV infection, 
recruitment was not based on presence of symptomatic or established chronic liver 
disease, and their combined epidemiological characteristics - mean age of 26 years at 
infection and injecting drug use reported in 57% - were broadly representative of 
HCV-infected populations in most western countries. Thus, estimates of disease 
progression derived from the community-based studies would appear to be the most 
appropriate for population level HCV natural history models93 and have been used to 
produce HCV projections in Australia81. 
Estimates of higher liver disease progression rates may be seen in settings 
where the prevalence of cofactors for liver disease progression are higher than those 
observed in the community-based studies included in the systematic review (i. e. mean 
age at HCV acquisition was 26 years, heavy alcohol intake was reported in 10%, and 
co-infection with HIV was uncommon)95. In particular, settings with a high 
prevalence of heavy alcohol intake or HIV co-infection would be expected to have 
higher rates of HCV-related morbidity and mortality, and therefore population level 
models would need to be adjusted in line with prevalences of these factors and their 
influence on disease progression. Deuffic et al. found that progression to cirrhosis 
depended strongly on age at HCV infection and gender: for example, risk of 
progression to cirrhosis was 300 times higher for men aged 61-70 years than for those 
aged 21-40 years; and at any age, risk in men was ten times higher than in women78. 
Age and gender adjusted HCV progression rates have frequently been used in HCV 
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projection models78'79'83'87, but only Wong et a1.82 explored the influence of heavy 
alcohol use. 
Although some Markov models have overestimated rates of progression to 
cirrhosis, those from cirrhosis to advanced liver disease complications (i. e. 
decompensated cirrhosis and HCC) may be more accurate because estimates are less 
subject to clinic referral bias. The incidences of decompensated cirrhosis and HCC 
among people with compensated cirrhosis were estimated in the ranges 3-6% and 0.5- 
4% per year, respectively, although mortality from liver failure and HCC varied 
considerably in the ranges 14-40% and 30-90% per year, respectively (Table 1.3). 
Finally, as relatively few HCV chronically infected persons have received antiviral 
therapy in most western countries (e. g. less than 2.5% in Australia93), the impact of 
current treatment uptake has not been a major feature in HCV projection models. 
1.5.4 Data used to validate model results 
Several countries have developed models to forecast the future course of their HCV 
epidemic, but few have validated their predictions by fitting model outcomes to past 
epidemiological trends relating to HCV and its consequences (Table 1.3). Two of the 
approaches described above used a model fitting process to derive HCV projections: 
Deuffic et at. back-calculated from HCV-related HCC deaths data78'79 and Salomon et 
al. calibrated data on HCV seroprevalence and HCC mortality83. Others have only 
compared model outcomes with data on the prevalent number of IDUs and HCV- 
infected persons84'81. Salomon et al. suggested that in the development of future 
projections of HCV epidemics, a minimal requirement might be that models use 
parameter values that are consistent with past epidemiological data83. 
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1.6 Approach to HCV projections for Scotland: aims and overview of methods 
As presented in this thesis, a forward estimation and projection approach, similar to 
that adopted in Australia 80' 81, was used to model the past, current and future burden of 
HCV disease among IDUs in Scotland. The modelling focussed on the IDU 
population because, as established in Section 1.2, the overwhelming majority of HCV 
infections and much of the epidemiological data related to HCV in Scotland have 
been associated with this risk group. 
Development of an HCV projection model for Scotland was guided by two 
fundamental criteria: (a) that the model should accurately reflect both the knowledge 
and uncertainty about major parameters relating to the epidemiology and natural 
history of HCV on the basis of the best available local and international data, and (b) 
that modelled outcomes should be consistent with epidemiological data to date 
describing the population impact of the HCV epidemic in Scotland. A limitation of 
the majority of previous modelling efforts, as discussed above in Section 1.4.4, was 
the absence of the latter constraint in checking the validity of model predictions. 
The overall aim is to estimate the number of, both current and former, IDUs 
who have acquired HCV infection and will progress to mild, moderate and severe 
HCV disease now and in the future. Figure 1.1 outlines the division by chapters of the 
data which were used (a) as input parameters to and (b) to check the validity of the 
HCV projection model. The strategy was to capture the essential features of the HCV 
epidemic among IDUs initially in Glasgow, because more epidemiological data exist 
for this region than elsewhere in Scotland, and calibrate model outcomes with 
available data relating to HCV and its consequences. Insights gained from the model 
fitting process in Glasgow on the epidemiology and natural history of HCV were used 
to improve the basis for extending the model to the rest of Scotland. It was important 
20 
to distinguish between current and former IDUs not only for purposes of modelling 
the HCV epidemic, but also to help establish the number of HCV chronically infected 
IDUs eligible for antiviral therapy; current injecting drug use, generally, is a 
contraindication to antiviral therapy because of poor compliance and the risk of re- 
infection with HCV. 
The HCV progression model was designed to incorporate both the knowledge 
and uncertainty about major parameters relating to (i) the incidence and cessation of 
injecting drug use and mortality from causes unrelated to HCV, (ii) the incidence of 
HCV infection among current IDUs, and (iii) the rate of HCV disease progression, 
including the influence of host factors (Figure 1.1(a)). First, the incidence and 
cessation of injecting drug use in Glasgow were derived through the use of a modified 
Delphi approach, which combined expert opinion with capture-recapture IDU 
prevalence estimates, as described in Chapter 2. Mortality from causes unrelated to 
HCV among current and former IDUs was based on estimates from the literature, as 
detailed in Chapter 6. Secondly, stochastic simulation was developed to model the 
transmission of HCV among current IDUs in Glasgow, according to the injecting risk 
behaviours and the characteristics (i. e. transmissibility and chronicity) of the virus, 
and to estimate the incidence of HCV infection, as described in Chapter 3. The 
transmission model detailed in Chapter 3 was also used to examine the impact of 
changes in injecting risk behaviours on the incidence of HCV infection. For the third 
component of the projection model, the worldwide literature was reviewed to inform 
the rate of HCV disease progression, as detailed in Chapter 6. A meta-analysis was 
performed to quantify the effect of heavy alcohol use on progression to cirrhosis in 
persons with chronic HCV, as described in Chapter 5. 
21 
Modelled outcomes were fitted to epidemiological data on the prevalent 
number of current IDUs (based on published capture-recapture estimates described in 
Chapter 2), the prevalence of HCV infection among current IDUs (based on survey 
data described in Chapter 3), and the number of IDUs developing HCV-related 
decompensated cirrhosis each year (Figure 1.1 (b)). The latter data on the occurrence 
of HCV-related liver failure were obtained through record-linkage of Scotland's 
national surveillance system of all persons diagnosed HCV antibody positive with 
other national computerised databases on hospital discharges and deaths, as described 
in Chapter 4. Chapter 6 then synthesizes the data gathered in previous chapters to 
develop a comprehensive model to estimate the number of current and former IDUs 
who had acquired HCV infection and progressed to mild, moderate and severe HCV 
disease in Glasgow and Scotland, 1960-2030. Finally, this projection model was used 
to explore the impact of different antiviral treatment strategies on the future incidence 
of severe HCV-related disease. 
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Chapter 2: Estimating the prevalence, incidence and cessation of injecting 
drug use in Glasgow 1960-2000: combining expert opinion with capture- 
recapture prevalence data 
2.1 Introduction 
Estimation of the size, and trends in the size, of injecting drug user (IDU) populations, 
locally and nationally, is fundamental to the planning and development of health-care 
services for this group'o2°'03 Detection among IDUs of high prevalences of hepatitis C 
virus (HCV) infection (highlighted in Section 1.2), which can lead in the long-term to 
cirrhosis and hepatocellular carcinoma 104, has placed even greater emphasis on the 
importance of quantifying the dynamics of this population12'los Data on the incidence 
and cessation of injecting drug use are essential if the future burden of HCV disease is 
to be predicted through statistical modelling initiatives. 
Epidemiological studies of the epidemic spread of IDU in the United Kingdom 
(UK), generally, have been limited to those which use indirect methods to estimate 
prevalence for a specific calendar year 106 Log-linear modelling of capture-recapture 
data was first applied in Glasgow102 to estimate the prevalent number of current IDUs 
in 1989107 (central estimate 9,420; 95% Cl 6,960-11,880); further estimates were 
generated in 199018 (8,490; 7,490-9,720) and 2000100 (7,190; 6,090-8,620). The city 
was thereby identified as being home to approximately a third of Scotland's IDUs'°8 
and having one of the highest IDU prevalences in Europe' 9. Few studies have 
attempted to derive estimates of the incident number of IDUs due to the shortage of 
appropriate data sources109,110,111,112 
Lacking Scottish or UK data to generate an IDU epidemic curve for the past 
four decades (i. e. since the earliest reports of IDU), the use of expert opinion to elicit 
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one for Glasgow was investigated and presented in this chapter. Such elicitation has 
been used to gauge the prevalent number of IDUs in Australia80,14 13 and Canada' 
The study was confined to the Greater Glasgow Health Board area because of the 
added complexity of eliciting expert opinion at a national, rather than local, level and 
also due to the existence, for that area, of published data on IDU prevalence (as 
outlined above) to anchor experts' estimates. 
2.2 Methods 
2.2.1 Design and data collection 
A modification of the Delphi technique, originally described by Dalkey115, was used 
to reach consensus estimates on the prevalent and incident number of injectors and 
percentage ceasing IDU. Experts were defined as individuals whose extensive 
experience and knowledge about drug use was specific to Greater Glasgow. Five key 
informants, from different professions (academia, drugs service work, law 
enforcement, medicine, and sociology), were initially contacted to invite their 
participation and, in the first instance, nomination of other experts. All five informants 
were willing to participate and nominated a further 16 experts, who were subsequently 
contacted by telephone, where possible, or email to explain the study and to verify 
willingness to participate. The overall volunteer rate of experts was 95% (20/21): the 
five key informants and 15 of the 16 informant-nominated experts; one person refused 
because of concerns about the validity of the Delphi approach. 
The 20 experts were asked, in May 2001, to complete anonymously a postal 
questionnaire (attached in Appendix, Section 2.5). The questionnaire asked for central 
estimates, and 90% certainty ranges, per quinquennium during 1960-2000 of (i) 
prevalence (i. e. "the number of people injecting drugs during each year"), (ii) 
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incidence (derived from two questions, which asked: (1) "relative to an arbitrary 
benchmark of 1,000 initiates into IDU in 1990, estimate the number of initiates in 
other years", and (2) "given that the benchmark of 1,000 initiates was chosen for 
convenience, estimate the actual number of initiates into IDU in 1990"), and (iii) 
cessation of injecting (i. e. "out of 1,000 injectors at the start of a calendar year, who 
survive throughout the year, estimate the number who would have permanently 
stopped injecting in that year"). In addition, participants were asked to return, 
separately from their completed questionnaire, a named postcard, indicating that they 
had completed and returned their questionnaire, which allowed reminders, at least two 
in the form of letters and emails, to be sent to non-responders during June-July 2001. 
As a mark of appreciation, participating experts were included in a prize draw, by way 
of the named postcard, for a £30 book voucher. Twelve of the 20 experts (5/5 
informants and 7/15 informant-nominees) returned questionnaires by the end of 
August 2001. Unlike the classic Delphi technique 115, an iterative process was not used 
to refine these experts' opinions. Instead, results were compared with empirical 
estimates of the prevalent number of current injectors during 199018 and 2000100 and 
an adaptation of rejection sampling116 was substituted for the usual iterative process 
(described in Analyses below). 
2.2.2 Background on experts 
The professions of the 12 experts who returned questionnaires included academia, 
drugs service work, law enforcement, medicine and sociology. Participating experts 
reported their experience of the drug use field in Glasgow to be limited during the 
1960s and 1970s, and knowledgeable during 1985 onwards. Key data sources which 
experts indicated had shaped their opinions were: (i) early reports of the rise in drug 
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use 117,118,119; (ii) capture-recapture prevalence estimates'8; (iii) hepatitis B virus 
reports (from the early 1980s)120; (iv) registrations of new attendances at drug services 
(only available for the 1990s and influenced by the increased capacity to treat drug 
users over time)121; and (v) their own observations and discussions with people 
working in the field. Prevalence estimates from capture-recapture studies (ii) were 
intrinsic to the assessment of experts' consensus (described below); furthermore, 
comparisons were also drawn with data from (i) and (iii) (see Discussion). 
2.2.3 Analyses 
Using S-PLUS software122, data analysis consisted of: 
(a) An examination of experts' estimates including the identification of outlying 
values; an expert's set of responses (i. e. central, lower and upper estimates) to 
either prevalence, incidence or cessation in a particular calendar year was 
regarded as outlying if the central estimate lay beyond the median 90% certainty 
range for all experts by more than 50%. 
(b) Based on the restricted opinion of experts (i. e. with outlying values removed), 
their estimates were used to provide a single consensus distribution, which 
permitted the generation of an overall mean, median, and lower and upper 90% 
certainty limit for the three main parameters of (i) prevalence, (ii) incidence and 
(iii) cessation in each quinquennium. For each expert's reported range, their 
central value was assumed to be their most likely estimate for that parameter and, 
thus, a triangle distribution was applied to each expert's set of responses (i. e. 
central, lower and upper) for each parameter. A triangle distribution was used in 
preference to other standard probability distributions (e. g. normal or log-normal) 
due to the varying skewness of parameter estimates between experts. A consensus 
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distribution was then generated for each parameter by sampling 1,000 
observations randomly from available experts' triangle distributions; 
(c) To examine the coherency of experts' estimates, prevalences obtained from 
experts in (b)(i) and externally from other studies18,100 were compared with a 
constructed prevalence distribution derived by combining expert data on 
incidence from (b)(ii) and cessation from (b)(iii) and accounting for 1-2% per 
annum mortality 123 ' 124 The following expressions were used: 
Aj 
P#, -l,; 
+ q, j- ((r, 1+ s; ) x (pti-i, i + qi)) 
for i=1960; j=1,..., 1000; 
for i=1961,..., 2000; j=1,..., 1000; 
where, in a given calendar year i for thejth simulation,: 
p*; j represents the prevalent number of injectors; 
P1960j represents the prevalent number of injectors in 1960, which was randomly 
sampled from the prevalence distribution (b)(i) for 1960; 
s; j represents the mortality rate per annum, which was sampled from a uniform 
distribution with range 0.01 to 0.02; 
q ;j and r ;j represent the incident number of injectors and proportion ceasing 
injecting, respectively, per annum, which were randomly sampled from the 
respective incident and cessation distributions, (b)(ii) and (b)(iii), in each 
quinquennial year, with values in between these years deduced from linear 
interpolation (note: variations on the linear assumption were explored); 
(d) To derive coherent estimates, combinations of incidence and cessation values 
were sampled from the consensus distributions, generated in (b), and those which 
formed prevalence coherent both with published prevalence estimates (in 199018 
and 2000100) and with experts' consensus on prevalence (in the remaining 
quinquennia) were retained. Following on from methods described in (c), values 
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of q, r and s were therefore rejected if the formulated prevalence did not fall 
within the 95% confidence limits of prevalence reported from capture-recapture 
studies in 1990 and 2000 and within the 90% certainty range of consensus 
distributions, (a)(i), generated from expert opinion in years 1960,1965,1970, 
1975,1980,1985, and 1995. 
2.3 Results 
2.3.1 Experts' estimates: compliance and outliers 
Prevalence, incidence and cessation estimates were provided by a mean of 9 (standard 
deviation 1.7), 9 (1.7), and 6 (2.0) experts, respectively, for quinquennia during 1960- 
2000. Three of the 12 experts consistently provided estimates well beyond the general 
consensus. 
2.3.2 Experts' consensus estimates of prevalence, incidence and cessation 
Table 2.1(i) and (ii) provide a summary of experts' responses, with outlying values 
removed. According to expert opinion, prevalence, incidence and cessation of IDU 
remained relatively low and stable during 1960-1975, rising several fold between 
1975 and 1980 (3.3-4.0 times based on median prevalence; 5.5-8.8 times for 
incidence; and 5.0-6.0 times for cessation), rising again between 1980 and 1985 (4.7- 
5.0 times for prevalence; 1.9-2.4 times for incidence; and 1.2-1.3 times for cessation), 
and thereafter incidence declined marginally but prevalence and cessation both rose 
further. 
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2.3.3 Examining the coherence of experts' consensus estimates on prevalence, 
incidence and cessation 
Figure 2.1 illustrates that the prevalence distribution (3), constructed from combining 
experts' consensus on incidence and cessation, corresponds well with experts' 
consensus on prevalence (1) during 1960-1980, but then underestimates, during 1985- 
2000, both their own consensus on prevalence (1) and also capture-recapture 
estimates (2). 
2.3.4 Deriving coherent estimates on prevalence, incidence and cessation 
Figure 2.1 also shows the coherence prevalence distribution (4) constructed from 
experts' consensus on incidence and cessation, using rejection sampling to filter out 
combinations which were not coherent with prevalence estimates from experts (1) and 
capture-recapture studies (2). 
Table 2.1 summarises these data and highlights that experts had under- 
estimated the number of incident injectors in 1985,1990 and 2000 (median 
consensus: 1,120,1,095 and 948, compared to median coherence distribution: 1,335, 
1,375 and 1,195, respectively) and also over-estimated the percentage of current 
injectors permanently ceasing injecting in four quinquennia during 1985-2000 
(median consensus: 14%, 10%, 15% and 17%, median coherence distribution: 6%, 
10%, 12% and 15%, respectively). From the coherence distributions, the incident 
numbers of injectors obtained in 2000 from 1,000 simulations were greater than those 
in 1990 and 1995 in 36% and 69% of cases, respectively. Similarly, the percentages 
ceasing injecting during 2000 obtained from 1,000 simulations were greater than 
those in 1990 and 1995 in 93% and 67% of cases, respectively. 
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The constraint imposed on prevalence in the rejection sampling process for the 
year 2000 was altered from the range 6,085-8,515, based on capture-recapture data '°°9 
to 7,900-15,950 according to experts' consensus. This produced a coherent prevalence 
central estimate of 8,354 (90% certainty range 7,935-9,865) for 2000, which was still 
closer to that of the capture-recapture estimate (7,187) than that of the experts' central 
consensus (11,931). 
2.4 Discussion 
Models to estimate the future burden of HCV infection among injectors, recently 
acknowledged as a priority for future work in the Department of Health's "Hepatitis C 
Strategy for England" 125, require estimates of the number of people starting and 
ceasing to inject over time80'108. Whilst the importance of knowledge on incidence and 
cessation of IDU has long been recognisedlos, few attempts have been made to 
estimate these in the UK110'111 because of the limitations of available data sources 
which, generally, have been either incomplete in years or not representative of the 
whole population121 
The first indication of an injecting epidemic in Glasgow was evident in the 
early 1980s when a sharp rise was reported in the number of people seeking treatment 
at hospitals for heroin addiction"8. Further consideration of routine statistics and 
fieldwork data led Haw to estimate that there were approximately 5,000 problem drug 
users in Glasgow in 1983 1 19. In the early 1990s, Frischer et al., using capture- 
recapture methods which were applied to data from treatment centres, needle/syringe 
exchange schemes, HIV testing laboratories and the police in Glasgow, estimated a 
total of 8,490 (95% CI 7,490-9,720) current drug injectors'8. Glasgow, a city with an 
extensively studied drug problem, has been at the forefront of IDU prevalence 
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estimation102; hitherto, however, no consensus had been sought on the size and shape 
of its IDU epidemic curve. 
The Delphi approach, essentially, is a way to reach a consensus or a range of 
possible values for an uncertain parameter. The reliability of Delphi estimates, 
however, can only be judged in relation to other observed data. In previous studies, 
IDU prevalence estimates generated through the elicitation of expert opinion 
compared well with estimates derived using other methods. In Australia, Delphi 
estimates of the number of dependent injectors in 199780 were consistent, allowing for 
the difference in population groups, with estimates of the number of dependent heroin 
users, obtained through the use of three different methods (i. e. back-projection, 
capture-recapture, and multiplier)' 13. Similarly, Delphi estimates of the injector 
numbers in Toronto, Montreal and Vancouver during 1996 were of the same order as 
those obtained by capture-recapture methods114 All of these applications, however, 
relied on responses from relatively small groups of experts, which probably reflects 
the rarity of persons working in this field with sufficient knowledge and experience. 
This study was similarly weakened by the modest participation rate (12/21) of 
nominated experts, which illustrates the difficulty or reluctance experts had in 
quantifying parameters. However, this study differs in design from its 
predecessors 80'114, which did not report on elicitation of injector incidence and 
cessation, thereby enabling a check to be made, as here, on internal as well as external 
coherence. 
Expert consensus on IDU prevalence indicated that the scale of the injecting 
problem in Glasgow had been minimal between 1960 and 1975 and epidemic 
throughout the 1980s. Whilst these findings conform with the reports outlined 
above' 18,119, it must be highlighted that the early years, in particular 1960,1965 and 
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1970, encountered the most non-responses from experts. This is likely to have been 
caused by either limited experience, problems with recall or lack of empirical data, 
which admittedly raises concerns about the reliability of the Delphi approach. Experts 
revealed that their estimates had also been shaped according to the rise in laboratory 
reports of hepatitis B virus infections during the early 1980s120. Figure 2.2 illustrates 
the sharp rise in these reports among those aged 15 to 24 years - indicative of the age 
at which IDUs commence injecting - during the early to mid 1980s, which aligns well 
with the estimated incident number of IDUs derived from this study. The number of 
HBV reports decreased during the late 1980s and 1990s as a result of reduced 
injecting risk behaviours126 and vaccination against HBV. 
For 2000, experts over-estimated the prevalence of IDU (median consensus 
11,930; 90% certainty range 7,900-15,950) compared to that derived in a capture- 
recapture study (central estimate 7,190,95% CI 6,090-8,620) published in September 
2001100. Experts were unaware of the findings from the capture-recapture study for 
the year 2000 when they provided their opinions. The wide certainty range 
surrounding experts' central consensus on prevalence in 2000 reflected their difficulty 
in quantifying this unknown. The high prevalence reported by experts for 2000 may 
also have been influenced by a Needs and Resources Report 127 published in 2000, in 
which the number of Glasgow problem drug misusers (defined by the regular use - 
either injecting or non-injecting - of heroin, benzodiazepines, cocaine and/or 
amphetamines) was indicated, based on limited data and methods, to be in the range 
12,400-15,400. 
The collection of opinion on incidence and cessation of IDU in this study, 
although a challenge to experts (as indicated by the extent of non-responses and wide 
certainty ranges around parameters), provided an opportunity, not previously 
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explored, to combine these data and examine coherence with estimates of prevalence. 
Experts' opinions on prevalence, incidence and cessation were neither internally nor 
externally coherent, but coherence was enforced by an adaptation of rejection 
sampling. Through this process, experts were shown to have under-estimated the 
number of incident injectors and over-estimated the percentage ceasing injecting 
during 1985-2000. The simulations also indicated that whilst cessation of IDU had 
risen throughout the 1990s, a finding which is in keeping with the expansion of the 
methadone prescribing and other drug treatment services in Glasgow128, there is 
however cause for concern at the rise in the incident number of injectors in the year 
2000 compared to that in 1995. 
The external point estimates and confidence intervals on prevalence were 
essential to anchor experts' opinions, although wide certainty ranges still remain 
around parameters; ideally, external data on incidence and cessation would have been 
incorporated, if available, into the rejection sampling process. Clearly, further efforts 
are required to collect data which will allow accurate estimation of the incidence and 
cessation of IDU both regionally and temporally. These data are necessary to inform 
policy-making, in terms of determining coverage and assessing the effectiveness of 
preventive measures and treatment options targeted at injectors. 
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Chapter 3: Modelling the spread of hepatitis C virus infection among 
injecting drug users in Glasgow 1960-2000 
3.1 Introduction 
Injecting drug users (IDUs) are at high risk of acquiring hepatitis C virus (HCV) 
infection through the multi-person use of injection equipment, principally 
needles/syringes129. High seroprevalences of HCV antibodies, in the range 50-90%, 
have been detected in surveys of IDUs throughout the developed world12'13o HCV, 
generally, has a long and variable asymptomatic incubation period before it causes 
severe liver disease 131. The enormous health and economic burden this infection 
presents is increasingly being recognised 80'82 
HCV has been circulating among IDUs in Scotland since at least the early 
1980s2° when there were reports of a rapid rise in the number of IDUs in 
Glasgow' 18'120, Scotland's largest city. In 1990, Glasgow had approximately 8,500 
IDUs'8, almost half of Scotland's injecting population 108, and one of the highest 
population prevalences (2.7% of 20-29 year olds) in Europe. The prevalence of HCV 
antibodies among IDUs, having reached 74% by 1990-9147, suggests that HCV spread 
rapidly throughout this population during the 1970s/1980s. During the 1990s, an 
ecological association between reductions in HCV prevalence and the development of 
harm reduction initiatives was evident47'132; nevertheless, the incidence of HCV 
remained high in 1999/200050 
Because of the extent of the past, current and likely future burden of HCV - 
and the wealth of available epidemiological data - it was considered both necessary 
and feasible to model the relationship between needle/syringe sharing and the 
incidence of HCV among IDUs in Glasgow during 1960-2000. This model would 
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inform on the past incidence of HCV infection in this population and permit the 
gauging of changes in risk behaviours required to effect appreciable reductions in the 
incidence of HCV infection. Such insights will inform those responsible for 
developing new ways to prevent HCV transmission among IDU populations. 
3.2 Methods 
3.2.1 Overview 
Stochastic modelling was used to simulate (day by day) the transmission of HCV, 
during 1960-2000, through the sharing of used needles/syringes among current IDUs, 
on an individual basis, from their onset of injecting drug use. Individuals were given 
the potential to progress through three states of infection: susceptibility, acute and 
chronic. As detailed below, the models were designed to use available information on 
(a) the incidence and cessation of injecting drug use in Glasgow (population factors), 
(b) the frequencies with which Glasgow IDUs injected and shared needles/syringes, 
and the numbers of different persons they shared with (behavioural factors) and (c) 
the susceptibility, transmissibility and carriage of HCV infection (viral factors). 
Generated outcomes were (i) estimates of the actual prevalence and incidence of HCV 
infection (from needle/syringe sharing) during 1960-2000 and (ii) scenario data on the 
prevalence and incidence of HCV infection during 1988-2000 assuming that there had 
been either no or more effective interventions to reduce needle/syringe sharing. 
Models were developed using S-PLUS software122 
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3.2.2 Model design 
3.2.2.1 Population factors: Incidence and cessation of injecting drug use 
Previously, in Chapter 2, estimates of the size of Glasgow's active IDU pool in 1960 
and the number of individuals who entered (i. e. commenced injecting) and who left 
(i. e. either permanently stopped injecting or died) this pool each calendar year 
thereafter till 2000 were generated through a modified Delphi approach which 
combined expert opinion with capture-recapture prevalence data. Figure 3.1 illustrates 
the estimates of (a) the incident number of IDUs and (b) the percentage ceasing to 
inject in Glasgow per annum during 1960-2000 which, together with an assumed 1- 
2% per annum mortality rate123, provided estimates of the prevalent number of IDUs 
per annum as shown in Figure 3.1(c). Ten percent of the actual population size was 
used in the simulations to reduce the computer time required to process data; as a 
sensitivity check, simulations were also performed at 30% of the actual population 
size and produced comparable findings. We assumed that individuals entered and left 
the IDU pool on random days throughout a year; IDUs were randomly selected with 
equal probability to leave the pool. 
3.2.2.2 Behavioural factors 
3.2.2.2.1 Sources of data 
Two principal sources of needle/syringe sharing data were available: multi-site, 
community-wide surveys undertaken in Glasgow during 1990-1994 and 199951,133 
and those performed in Edinburgh - Scotland's capital city, 70km from Glasgow - 
during 1992-1993126. The former provided estimates of injecting and needle/syringe 
sharing (injecting with needles/syringes previously used by someone else) frequency 
and numbers of persons shared with during the previous six months (adjusted to 
48 
twelve months, explained in footnote to Figure 3.2), while the latter provided, for 
every year since 1980, estimates of the proportions of injectors who had shared at 
least once. A study comparing behaviours among IDUs in Edinburgh and Glasgow 134, 
undertaken in 1985, indicated that the proportions sharing at least once in both cities 
were very similar; accordingly, the above Edinburgh data were used as a surrogate for 
sharing behaviour in Glasgow during the 1980s (note: only data on the proportion 
sharing at least once were used; data on the numbers of partners were not 
exchangeable because Edinburgh IDUs had a much greater number than Glasgow's 
IDUs134). No needle/syringe sharing data were available for the period prior to 1980. 
The following behavioural sections describe the model process each year for 
generating (a) the frequency with which IDUs injected drugs, (b) the percentage of 
IDUs who had shared a needle/syringe, (c) the number of needle/syringe sharing 
partners, (d) the assignment of number of needle/syringe sharing partners to each 
IDU, (e) the selection of actual needle/syringe sharing partners for each IDU, and (f) 
the frequency with which IDUs shared needles/syringes. 
3.2.2.2.2 Frequency of injecting 
Glasgow IDUs reported a high and consistent frequency of injecting (from 1990-1994 
surveys: 23% injected less than twice a day and 77% injected at least twice a day'33). 
For simplicity, we assumed that all IDUs injected three times per day for 48 weeks 
per year, thus accounting for four weeks' abstinence from injecting135; abstinence was 
increased to 12 weeks during 1995-2000, an adjustment based on survey data51, which 
correlates with an increased prescribing of methadone to IDUs124. On a given day, the 
number of times an individual shares needles/syringes from their three injections was 
randomly assigned using a binomial distribution with probability equivalent to the 
49 
proportion of their injecting episodes spent sharing (see "Frequency of needle/syringe 
sharing", 3.2.2.2.7 below). Then, for each sharing occasion, the partner from whom 
they receive their used needle/syringe was randomly selected from their group of 
sharing partners; if the selected partner was an HCV carrier, transmission occurred 
with probability as described below (see "Transmissibility", 3.2.2.3.2 below). 
3.2.2.2.3 Percentage of ID Us per year who had shared a needle/syringe at 
least once 
The percentage of IDUs who were assigned to share a needle/syringe at least once 
during a particular calendar year in the model was generated by sampling from a 
uniform distribution, where limits were varied in four epochs: 1960-1976 (a period of 
minimal injecting), 1977-1985 (a period of injecting epidemic growth), 1986-1990 (a 
period of HIV awareness and introduction of harm reduction initiatives), and 1991- 
2000 (era of harm reduction). Based on observed data for Glasgow and Edinburgh 
(Figure 3.2), rates in the ranges 70-89% and 35-49% were used for the respective 
periods 1977-1985 and 1991-1997, and a linear reduction in the range was applied 
during the intermediate epoch. A range of 40-54% was applied in years 1998-2000 to 
reflect the recent rise in needle/syringe sharing observed in Glasgow51. Data on the 
behaviours of IDUs during the 1960s/1970s were not available; therefore, a broad 
range of 50-89% was applied to encompass the prevalence of needle/syringe sharing 
in the first epoch 1960-1976. 
3.2.2.2.4 Number of needle/syringe sharing partners 
The number of IDUs with whom Glasgow respondents reported needle/syringe 
sharing at least once in the previous six months (referred to as partners) is shown in 
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Figure 3.3; very few respondents reported more than 20 partners. The number of 
partners reported by respondents was heavily skewed, with a mean of 3 and 2 partners 
reported in the 1990 and 1991-1994 surveys, respectively; a survey of IDUs attending 
general practices in Glasgow during the early to mid 1980s revealed a mean of 8 
partners (range 1-30)134. Geometric distributions, as illustrated in Figure 3.3, were 
used to generate the number of partners, Xi, k, for the pool of needle/syringe sharing 
IDUs each year (see Appendix in Section 3.5.1). The mean number of partners 
amongst IDUs who were assigned to share needles/syringes each year was assumed to 
be eight, two and three during the periods 1977-1985,1991-1997 and 1998-2000, 
respectively; a linear reduction in the mean number of partners was employed during 
1986-1990. Due to the low prevalence of IDUs in the earlier period 1960-1976, a 
conservative mean of two partners was applied. 
3.2.2.2.5 Assignment of number of needle/syringe sharing partners to each 
IDUper annum 
In any given year k, a vector for the number of partners, denoted as Xi, k, was generated 
(described above) and each element of X ,k was assigned 
to a person in the pool of nk 
IDUs through a process of either random (i. e. equal probability) or weighted selection. 
The latter refers to an increased likelihood of an IDU selecting a number of partners, 
in a given year, which is the same or near to the number of partners they had been 
assigned in the previous year (see Appendix in Section 3.5.2). 
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3.2.2.2.6 Selection of actual needle/syringe sharing partners for each IDUper 
year 
At the beginning of each year in the model, for individuals who were assigned a lower 
number of partners than in the previous year, established partnerships would be 
randomly deselected. The remaining established partnerships would be retained for 
that year, and others formed until the required number of partnerships was reached. 
An IDU selects their actual partner(s) based on either random or weighted selection, 
where the latter refers to an increased likelihood of an IDU selecting a partner who 
has the same or near to the same "number of partners" as they have in that year (see 
Appendix in Section 3.5.3). 
3.2.2.2.7 Frequency of needle/syringe sharing 
The frequency with which Glasgow IDUs shared needles/syringes correlated strongly 
with the number of sharing partners reported (Figure 3.4). For each calendar year in 
the model, individuals were randomly assigned a frequency of sharing, according to 
the number of partners they had, based on the Glasgow 1990-1994 data; for example, 
for IDUs with one sharing partner, 49%, 33%, 4%, 2%, 2%, 1%, 0%, 1%, 0%, 0% and 
8% recipient-shared needles/syringes for 0.5%, 5%, 15%, 25%, 35%, 45%, 55%, 
65%, 75%, 85% and 95% of their injecting episodes, respectively. 
3.2.2.3 Viral factors 
3.2.2.3.1 Susceptibility 
All new initiates to injecting who entered the IDU pool were regarded as being 
susceptible to infection (Figure 3.5). HCV has been circulating for many decades; 
thus, an IDU from the original pool in 1960 was randomly assigned as an HCV carrier 
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allowing them to transmit the virus to others. A susceptible individual was considered 
to have been exposed to HCV only when he/she injected with a needle/syringe 
previously used by an individual who was an HCV carrier. Transmissions through 
other routes, such as sexual intercourse 136, occur relatively infrequently and thus these 
were not considered in the model. 
3.2.2.3.2 Transmissibility 
Upon exposure to HCV, the probability of an individual becoming acutely infected 
was assumed to be, on average, 2-3% (range 0-10%), based on reported rates of 
transmission occurring among health care workers after needle-stick injuries137'13s A 
beta distribution (mean 0.03, variance 0.0001) was used to generate probabilities for 
transmission after each exposure. A short period (6-8 weeks) of high viraemia139 
follows infection with HCV, a phenomenon similar to that observed for HIV; using 
knowledge which exists for HIV140,141, but not HCV, the effect of a 10-fold increase 
in infectivity during the initial high viraemia phase was explored. During acute 
infection, HCV RNA - indicating infectiousness - has been detected in blood within 
two weeks of exposure 142; accordingly, in the model, individuals became infectious 
two weeks post infection. 
3.2.2.3.3 Carriage 
Of individuals with newly acquired HCV, between 15-40% spontaneously recover 
from their acute infection, generally within two years3'4. A beta distribution (mean 
0.25, variance 0.001) was used to generate probabilities for viral clearance among 
newly infected individuals and a geometric distribution (parameter 1/290 days) was 
used to generate intervals from infection to recovery. Partial immunity against HCV 
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re-infection and persistence may be acquired in individuals who have had previous 
infection and cleared their virus143'144 Thus, in the model, individuals who recover 
from their acute HCV infection re-entered the susceptible population, but, according 
to Farci et al. 143, were half as likely to develop new viraemia following re-exposure 
and were twelve times less likely to develop chronic infection following acute status. 
Individuals who do not recover from their acute infection develop chronic HCV and 
remain infectious. 
3.2.3 Model outcomes 
3.2.3.1 Prevalence of HCV infection 
The prevalence of HCV antibodies among current IDUs each year between 1960 and 
2000 was simulated. Different models were specified to assess the effect on HCV 
seroprevalence of (i) increasing the infectivity of newly HCV infected individuals 
during the short period of high viraemia following seroconversion, (ii) weighting the 
assignment of number of sharing partners to each IDU, and (iii) weighting the 
selection of actual partners for each IDU. For each model, 100 simulation runs were 
performed; HCV seroprevalence was summarised by reporting the 10th, 5 0th and 90th 
percentiles separately for each year. 
The fit of models was determined by comparing modelled with observed HCV 
seroprevalences at different calendar years: principally, community-wide surveys of 
Glasgow IDUs reported that HCV seroprevalence declined between 1990 (79%) and 
1999 (61 %)47. HCV seroprevalence estimates were also available from IDUs who had 
tested hepatitis B surface antigen positive and negative in 1973-80 (81% and 65%, 
respectively) and positive in 1984 (65%) (Personal communication: Sheila Cameron, 
Glasgow Regional Virus Laboratory). 
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3.2.3.2 Incidence of HCV infection 
The incident number of HCV infections each year was obtained from the models for 
susceptible current IDUs who either (i) had no previous infection or (ii) had cleared 
their previous infection; for (i), the incidence was calculated as the number of new 
infections during the year divided by the total number of injector-years contributed by 
HCV antibody negative IDUs. 
3.2.3.3 Potential impact of harm reduction measures on the prevalence and 
incidence of HCV infection 
Data on HCV incidence were generated by applying the high levels of needle/syringe 
sharing from the early to mid 1980s in Glasgow to the period 1988-2000. By 
comparing models with and without this high risk behaviour, estimates of the number 
of HCV infections averted among Glasgow IDUs during the period of harm reduction 
(1988-2000) were obtained. 
3.2.3.4 Potential impact of hypothetically lower risk behaviours on the 
prevalence and incidence of HCV infection 
The impact of the following hypothetical reductions in risk behaviour, for the period 
1988-2000, on the prevalence and incidence of HCV was examined: 
(i) the percentage of IDUs who had shared per year was reduced to 1-10%, 11- 
20%, 21-30%, 31-40%, and 41-50% (from the estimated actual rates, 
described above in 3.2.2.2.3, of 45-79%, 35-49% and 40-54% in years 1988- 
1990,1991-1997 and 1998-2000, respectively); 
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(ii) the mean number of needle/syringe sharing partners per annum was reduced to 
1,1.5 and 2 (from the estimated actual numbers, described above in 3.2.2.2.4, 
of 3-6,2 and 3 in years 1988-1990,1991-1997 and 1998-2000, respectively); 
(iii) the percentage of injecting episodes shared was reduced to below 10% (from 
that illustrated in Figure 3.4). 
3.3 Results 
3.3.1 Modelled prevalence of HCV infection 
Significantly more simulations generated by model (a), which employed a ten-fold 
higher infectivity to newly HCV infected IDUs during the short period of high 
viraemia following seroconversion, than by model (b), without the higher infectivity 
constraint, produced HCV seroprevalences in the ranges of those obtained through 
community-wide surveys of Glasgow IDUs in years 1990-1993 (56-92%), 1994-1996 
(53-86%) and 1999 (50-75%) (Figure 3.6) (87% compared to 55% of 100 simulations, 
respectively; p=0.0001). The best fitting model (a) was used below to estimate the 
incidence of HCV infection and to examine changes in this with different scenarios of 
higher and lower risk behaviour. 
The process of assigning sharing partners to each IDU per year was weighted 
(described in Methods and Appendix 3.5.2-3.5.3, such that the mean z score for years 
1977-1987 ranged 1.4-2.4 (versus 5.4-6.9) under weighted (versus random) selection, 
and for years 1991-2001 ranged 0.4-0.8 (versus 1.1-1.9)), but the effect on HCV 
seroprevalence was marginal: for years 1977-1987, median ranged 70-80% (versus 
74-77%) under weighted (versus random) selection; and for years 1991-2000, median 
ranged 57-61 % (versus 62-69%) under weighted (versus random) selection. 
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3.3.2 Modelled incidence of HCV infection 
The annual incident number of HCV infections among current IDUs in Glasgow was 
estimated, by model (a), to be low during 1960-1976 (median new infections among 
IDUs who had no previous infection and had cleared their previous infection: 10-60 
and 0-20 per annum, respectively), rising steeply during the early 1980s to peak in 
1985 (1,120 and 210, respectively), stabilising during 1991-1997 (510-610 and 100- 
140, respectively) and rising again during 1998-2000 (710-780 and 130-150, 
respectively) (Figure 3.7). 
The median percentage of HCV antibody negative IDUs who acquired new 
HCV infection per annum was estimated to be in the ranges 5-27%, 43-48% and 14- 
20%, which corresponds to incidences of 6-40,78-89 and 18-30 per 100 susceptible 
injector-years, during periods 1960-1976,1977-1986 and 1990-2000, respectively 
(Figure 3.8). 
3.3.3 Potential impact of harm reduction measures on the prevalence and 
incidence of HCV infection 
Carrying forward the high levels of needle/syringe sharing from the early 1980s to 
1988-2000 generated higher prevalences of HCV during this latter period (median 83- 
91%) than were determined through model (a) with the lower estimated actual levels 
of needle/syringe sharing among Glasgow IDUs (62-75%) (Figure 3.6 (c) and (a), 
respectively). The median cumulative number of newly HCV infected IDUs during 
1988-2000 in Glasgow from models (c) and (a), with and without the higher levels of 
risk behaviour, were 13,420 and 8,910 (10th to 90th percentiles: 11,370-16,290 and 
7,720-10,340), respectively, which indicates that potentially as many as 4,500 (2,400- 
7,700) HCV infections had been prevented as a result of established harm reduction 
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measures during this period - that is, around half as many prevented as actually 
occurred. 
3.3.4 Potential impact of hypothetically lower risk behaviours on the prevalence 
and incidence of HCV infection 
Reductions in three key risk parameters - (i) the percentage of IDUs who had shared a 
needle/syringe per year, (ii) the mean number of needle/syringe sharing partners per 
year, and (iii) the percentage of injecting episodes shared - all impacted on the 
prevalence and incidence of HCV infection by varying amounts (Figure 3.9). 
Assigning either 1-10%, 11-20%, 21-30%, 31-40% or 41-50% of IDUs to have shared 
a needle/syringe per year during 1988-2000 would have reduced the HCV prevalence 
to a median of 18%, 33%, 46%, 55% and 63%, respectively, and the incidence to a 
median of 1,7,14,20 and 28 infections per 100 susceptible injector-years, 
respectively, by the year 2000; while the median cumulative number of newly HCV 
infected IDUs during 1988-2000 would have been 1,310,3,700,5,860,7,550 and 
8,960, respectively. 
Alternatively, assigning the mean number of partners per annum to 1.0,1.5 
and 2.0 during 1988-2000 among needle/syringe sharing IDUs would have reduced 
the HCV prevalence to a median of 33%, 48% and 58%, respectively, and the 
incidence to a median of 5,13 and 21 infections per 100 susceptible injector-years, 
respectively, by the year 2000; the median cumulative number of newly HCV infected 
IDUs during 1988-2000 would have been 3,650,6360 and 7,990, respectively. 
Finally, limiting the percentage of injecting episodes shared to less than 10% among 
needle/syringe sharing IDUs during 1988-2000 would have resulted in a median HCV 
prevalence of 48% and incidence of 14 infections per 100 susceptible injector-years 
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by 2000; the median cumulative number of newly HCV infected IDUs during 1988- 
2000 would have been 6,280. As changes in one risk parameter will likely correlate 
with changes in another, these findings may have under-estimated the collective effect 
of reduced risk behaviours on HCV prevalence and incidence. 
3.4 Discussion 
This chapter presents the findings of a model designed to estimate the impact of 
established, and hypothesised, harm reduction interventions on HCV incidence by 
simulating the transmission of HCV among Glasgow IDUs according to their self- 
report of needle/syringe sharing. Since the introduction, in the late 1980s, and 
continual expansion, during the 1990s, of needle/syringe exchanges and other harm 
reduction interventions targeted at IDUs, reductions in both needle/syringe sharing145 
and the incidence of HCV47'50 have been evident in Glasgow. It is possible that some 
of the behaviour change resulted independently of the harm reduction activities; 
however, with several studies undertaken in Glasgow and elsewhere demonstrating a 
strong association between HCV prevalence reduction and harm reduction 
initiatives 146, it is plausible that such interventions were responsible for averting, 
during 1988-2000, many of the 4,500 HCV infections (10th and 90th percentiles: 
2,400-7,700) indicated by scenario analysis. 
Full advantage of available behavioural and epidemiological data was taken to 
model the heterogeneity typical of an entire IDU population. Inevitably with a model 
designed to reproduce a complex process, there were limitations which need to be 
considered: (i) biases may exist as a result of IDUs' under- or over-reporting risk 
behaviour, although previous studies have found IDUs to be generally reliable in their 
self-report of this' 47,148,149, and findings from the Glasgow surveys have been 
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corroborated by other investigations 150; (ii) a broad range for needle/syringe sharing 
was applied in the 1960/1970s epoch to allow for the absence of data, but this did not 
hinder the estimation of the incident number of HCV infections because so few 
individuals were injecting during this period; (iii) previous infectious disease models 
among IDUs have been limited by the lack of data on the changing size of this 
population151; whilst this model was designed to allow individuals to enter and leave 
the current IDU population, further data are needed to corroborate our estimates on 
the incidence and cessation of injecting drug use; (iv) IDUs were all posed with an 
annual mortality rate in the range of 1-2%, although recent work has indicated that 
IDUs' mortality is higher for males and increases with age152; (v) behavioural data 
specifically on the change in needle/syringe sharing partners from one timeframe to 
the next and the propensity to share with different partners are needed to refine the 
model; importantly, weighted selection employed to minimize the change in number 
of partners from one year to the next per IDU did not affect model results. Future 
modelling also needs to consider differences in risk behaviour in the initial versus 
subsequent years following onset of injecting drug use133; (vi) individuals were only 
exposed to HCV through the sharing of needles/syringes; it has been suggested that 
HCV can be contracted through other injecting equipment 153, but only limited 
evidence of transmission efficiency for this existslsa, iss Since infections occurring 
through means other than needle/syringe sharing, including unprotected sexual 
intercourse and tattooing, were judged to be relatively small and the behavioural data 
for these were not available, they were not considered in this model (as in previous 
HCV transmission models among IDUs'56"57); (vii) the cleaning of used 
needles/syringes and its influence on HCV transmission, believed to be considerably 
less-effective than with HIV157, was not considered; (viii) while the aim was to 
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capture the behavioural heterogeneity of IDUs, it is appreciated that the detailed data 
requirements of the model will influence its generalizability. 
Despite these limitations, modelled data on HCV prevalence agreed well with 
observed trends among current IDUs in Glasgow. The model which discounted the 
effect of higher infectivity among newly HCV infected IDUs, a criticism of previous 
HCV transmission models158, under-estimated the prevalence of HCV during the 
1990s compared to data from community-wide surveys of Glasgow IDUs. The lower 
than expected HCV prevalences could be explained by the omission of transmissions 
occurring through other routes such as indirect sharing of injecting equipment. 
Alternatively, considering higher infectivity during acute viraemia after infection in 
the model produced HCV prevalences consistent with survey data, and suggests that 
this phenomenon is an important factor in the spread of HCV, as recognised with 
HIV 140,141 
Further validation of the behavioural assumptions used in the model was 
attained by adapting the viral characteristics to monitor the spread of HIV among 
IDUs in Glasgow (details provided in Appendix, Section 3.5.4). This showed that the 
prevalence of HIV remained low and stable (median of 0.4-1.0% during years 1983- 
2000; 1 0th and 90th percentiles ranged 0-0.3% and 2.3-7.9%, respectively); a finding 
that is consistent with detected rates among Glasgow IDUs159. Corroborating a 
previous modelling application in Australia15', these results demonstrate that the ten- 
fold higher infectivity of HCV compared to HIV129,160 largely explains the difference 
in the spread of these two viruses among IDUs. 
Observed data on HCV incidence among IDUs in Scotland are confined to the 
1990s and have been derived from cross-sectional (centrally estimated 20-27 per 100 
person-years among recent-onset IDUs108) and cohort studies in selected populations 
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(28 per 100 person-years; 95% Cl 16-51161), which compare favourably with our 
modelled estimates of HCV incidence during the same period (18-30 per 100 
susceptible injector-years). The incident numbers of IDU-related HCV infections 
estimated historically are central to the development in Chapter 6 of models to project 
the number of people likely to progress to HCV disease in the future80'108 
HCV transmission thus continues to occur at an alarming rate among 
Glasgow's IDUs. The main public health message - "not to share needles/syringes" - 
used in this population to control HIV transmission has proved inadequate for the 
control of HCV. A previous study had indicated that improving IDUs' access to 
sterile injecting equipment is likely to result in reductions in sharing'33; accordingly, 
research is underway in Glasgow to determine the effect on behaviours of removing 
government restrictions on the numbers of needles/syringes distributed. We cannot 
ignore, however, that some IDUs share needles/syringes despite having sufficient 
access to harm reduction services. Our model indicates directions for public health 
strategies to reduce the incidence of HCV infection. Incidence can be more 
successfully reduced if IDUs who, unavoidably, share needles/syringes confine their 
borrowing of used equipment to one person, ideally someone they know well and who 
has recently tested HCV antibody negative; with this strategy alone (i. e. reducing the 
mean number of partners to one during 1988-2000), an estimated 5,300 HCV 
infections (10th and 90th percentiles: 4,100-6,700) could have been averted during 
1988-2000 among Glasgow IDUs. Alternatively, permitting only 11-20% of the IDU 
population to share a needle/syringe annually during 1988-2000 would have similarly 
averted an estimated 5,200 HCV infections (10th and 90th percentiles: 4,200-6,600). 
Determining the most effective means of communicating risk reduction strategies to 
IDUs should be a priority in HCV prevention plans. The ability of existing HCV 
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testing and counselling practices to change behaviour and prevent further transmission 
among IDUs remains unclear'6a'163 A thorough evaluation of such services164 is 
required to determine if the HCV testing of current IDUs should be promoted. 
Based on a study which examined the direct medical costs associated with 
HCV infection among IDUs in Australia76, the estimated 550 to 920 new HCV 
infections among IDUs in Glasgow during 2000 could equate to approximately three 
to five million pounds in health care spending in the future as sequelae become 
manifest. A serious commitment to model in advance, implement and audit strategies, 
which could achieve appreciable reductions in risk behaviours and HCV transmission 
among IDUs, is urgently needed to influence the future course of this epidemic. 
Otherwise the mounting HCV burden of illness and cost will continue. Meanwhile, 
"off-injecting" remains a key public health message both for HCV prevention and 
treatment. Behavioural surveillance of IDUs should also be expanded to keep abreast 
of potential changes in blood-borne virus transmission and inform HCV prevention 
efforts. 
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3.5 Appendix 
3.5.1 Generating the number of needle/syringe sharing partners per year 
The following expression was applied: 
Xj, k = G(1/pd +1 for i= 1) .... , sk; where 
k= 1960, ...., 2000; 
0 for i= sk+,, ...., nk; where 
k= 1960, ...., 2000; 
to generate a vector, Xi, k, of the number of partners to assign to nk IDUs, in a given 
year k, where sk was the number of the nk IDUs who had been determined to share 
needle/syringes on at least one occasion during year k, and G(1/pk) were non-negative 
integers randomly generated from the geometric distribution with probability 1/pk, 
where Pk was the mean number of partners for year k. 
3.5.2 Weighting the probability of assigning a number of needle/syringe sharing 
partners to each IDU per annum according to the number of partners assigned 
in the previous year 
The following expression was used to weight the probability of selecting each element 
of X ,k 
for the jth person in the pool of nk IDUs: 
w; j k= 1/6x; k- yj, k_J1+1)2 for i=1, ..., nk and j=1, ..., nk; where 
k=1960,..., 2000, - 
,, 
where Xi, k represents the number of partners to assign to each person in the pool of nk 
IDUs for year k and Yj, k_I represents the number of partners the jth IDU had been 
assigned in the previous year. 
As a simplified example: for a given year, say 1990, in a pool of four IDUs 
(i. e. n= 4), where the first IDU had been assigned zero partners in the previous year 
(i. e. 
,y1,1989 
= 0), if a vector x,, 1990-(0,0,2,2O) 
(i. e. X1,1990-0, X2,1990-0, x3,1990-2, and 
X4,1990=20) had been generated for the number of partners to assign to these four IDUs 
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in 1990, then the weights associated with the first IDU selecting elements of x;, 1990 
would be: 
WJ, J, J990 = 1/(I0-01+1)2 = 1; W2, J, 1990 = 
1/(IO-OI+1)2 = 1; 
W3,1,1990 = 1/(12-0l+1)2 = 1/9; w4,1,1990 = 1/(120-0I+1)2 = 1/441. 
Normalizing these weights (1,1,1/9,1/441) produces a vector of probabilities (0.473, 
0.473,0.052,0.001) associated with the first IDU selecting elements of x;, 199o, under 
random selection, the vector of selection probabilities would have been (0.25,0.25, 
0.25,0.25). If we assume that x], 1990 was assigned to the first IDU under weighted 
selection, this selection process would continue for the second IDU without replacing 
the chosen number of partners in the vector (i. e. x;, 1990 would reduce to (0,2,20)). 
The following expression was calculated at the start of each year to compare 
the average change in the number of partners assigned to IDUs between random and 
weighted selection: 
nk 
Y j, k-1 Y j, k 
Zk for j=1, ..., nk; where 
k=1961,..., 2000; 
nk 
where yj, k_J and yj, k represent the number of partners the jth IDU, from a total of nk 
IDUs, had been assigned in years k-1 and k. 
3.5.3 Weighting the probability of selecting actual needle/syringe sharing 
partners for each IDU per year according to the number of partners each IDU 
has been assigned 
The expression 1/(]x;, k-xj, kH+l)2 was applied to weight the probability of the 
jh IDU 
selecting as a partner the ith IDU of the remaining pool of sharing individuals where 
XJ, k and Xj, k represent the number of partners assigned to these respective individuals in 
a given year k. 
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3.5.4 Viral factors used in HIV transmission model 
Further, to validate the model findings, the transmission of HIV infection was also 
simulated among the current IDUs in Glasgow by applying the same population and 
behavioural factors as described in Sections 3.2.2.1 and 3.2.2.2, respectively, and 
accommodating the following viral characteristics: 
(i) The first case of HIV among Glasgow IDUs was introduced in 1983165; 
(ii) Individuals were only exposed to HIV through the sharing of needles/syringes. 
Sexual transmission of HIV is more common than HCV, however 
needle/syringe sharing is generally regarded as the most important means of 
spread between IDUs141'151 
(iii) The transmission probability for HIV was assumed to be ten times lower (i. e. 
mean 0.3%) than that of HCV129,16o A short period (6-8 weeks) of high 
viraemia139,142 follows infection with HIV, and has been related to increased 
infectivity 14o It was therefore assumed that infectiousness increased 10-fold 
during this initial high viraemia phase '51,141; 
(iv) The latency period for HIV was taken to be 50 days166; 
(v) All individuals who acquired HIV developed chronic infection and remained 
infectious 129 
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Chapter 4: Severe disease burden associated with hepatitis C virus 
infection in Scotland, 1991-2001: record-linkage study 
4.1 Background 
Progression to severe sequelae of hepatitis C virus (HCV) infection, namely 
hepatocellular carcinoma (HCC) and decompensated cirrhosis, generally takes several 
decades and varies according to age, gender, alcohol consumption and co-infection 
with other blood-borne viruses5. An epidemic of severe liver disease has been 
predicted in Australia and the United States as a consequence of the large numbers of 
people who became infected with HCV through injecting drug use in the 1970s and 
1980s8183,167. To monitor the emergence of such a problem requires national 
surveillance systems, currently lacking in the UK and elsewhere, which detect not 
only advanced liver disease but also the aetiological factors. 
Numerous studies have examined national trends in HCC but few have 
provided data on the underlying cause. The increasing burden of HCV infection is a 
likely explanation for the rise in HCC incidence over the past two to three decades 
reported in Japan 168, North America 169,170, Australia171 and parts of Europe172'173 
Alcohol was discounted as the predominant risk factor, except in Japan174, because of 
declining rates in consumption169'l70'»1'1'2'173 One study, confined to US veterans, 
deduced HCV from medical history records to be the most important underlying cause 
for the increase in hospitalisation for primary liver cancer175. In 80 patients presenting 
to a Scottish hospital, who had available stored serum samples, HCV infection was 
identified as a major risk factor for the development of HCC39. Moreover, the age- 
specific incidence of HCC has progressively shifted toward younger people169 
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It has also been suggested that HCV has played a role in the rise in alcohol 
related deaths, mostly due to liver damage, in England between 1983 and 1999176 
Disproportionately high prevalences of HCV infection have been found in alcoholic 
patients with liver disease (43% from two studies with 61177 and 40178 patients), 
compared to those without liver disease (2% (1/45) 177 and 10% (6/60)178, 
respectively). Further, the prognosis among patients with high alcohol consumption 
and HCV antibodies was significantly worse than for those without HCV 
antibodies 179,180,181 Among patients hospitalised in Japan with liver cirrhosis, a 
considerably higher percentage of those with both HCV and alcohol present had 
developed HCC (51%, 151/297) compared to those with only one of these two risk 
factors (HCV-alone: 37%, 156/420; alcohol-alone: 17%, 20/119)182. In direct contrast, 
a recent study of 213 patients reported that survival in alcoholic cirrhosis patients was 
not influenced by the presence (72) or absence (141) of HCV infection 183. This 
apparent discrepancy may have been due to confounding factors' 84. Determining the 
extent to which alcohol and other factors, such as HIV, influence the course of HCV 
epidemics will inform (i) the development of appropriate interventions and (ii) models 
to forecast the future burden of severe disease. 
There is thus an urgent need in Scotland and elsewhere185 to provide accurate, 
up-to-date information about the current burden of HCV-related severe disease to help 
policymakers prioritise health interventions and allocate resources accordingly. To 
improve our understanding of the epidemiology of HCV infection in Scotland, a 
nationwide surveillance system was established to collect laboratory data on all 
persons diagnosed HCV antibody positive' 
86. The existence of this and other high- 
quality national computerised databases on hospital discharges, cancer registrations 
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and deaths'87 afforded an opportunity to adopt a record-linkage approach to examine 
the occurrence of liver failure and cancer associated with HCV infection in Scotland. 
4.2 Aims 
The aims of the work presented in this chapter were to: 
(i) estimate the annual number of new diagnoses for decompensated cirrhosis and 
HCC related to HCV infection in Scotland; 
(ii) examine the epidemiological characteristics, in particular the presence of alcohol 
and HIV infection, of HCV-related decompensated cirrhosis and HCC cases in 
Scotland; 
(iii) determine the influence of epidemiological risk factors on the development of 
decompensated cirrhosis and HCC among HCV diagnosed persons in Scotland; 
(iv) determine the mortality rate following hospitalisation with decompensated 
cirrhosis and HCC among HCV diagnosed cases in Scotland; 
(v) estimate the prevalence of diagnosed HCV infection among all decompensated 
cirrhosis and HCC cases in Scotland. 
Estimates of (i) were also produced for Greater Glasgow to allow validation of 
the model, in Chapter 6, designed to estimate and project the burden of HCV-related 
disease among IDUs in this area. Data from (ii), (iii) and (iv) provide a Scottish 
perspective on the natural history of HCV infection. Data from (v) will provide an 
understanding of the contribution of HCV in the rising incidence of severe liver 
disease reported in the UK and in other developed countries. 
78 
4.3 Methods 
4.3.1 Design overview 
Scotland's database of HCV diagnosed persons was linked with other nationally held 
databases on hospital admissions, cancer registrations and deaths to determine HCV 
diagnosed patients' development of, and mortality from, severe sequelae (namely 
HCC and decompensated cirrhosis) during 1991-2001. Not all instances of the above 
severe disease outcomes related to HCV infection would be detected through this 
approach - for example, due to undiagnosed HCV infection - and thus hospital data 
were adjusted to account for this (described below). Data on epidemiological risk 
factors - in particular excessive alcohol use and coinfection with HIV - acquired 
through the record-linkage process, were assessed in relation to the development of 
decompensated cirrhosis and HCC. The mortality rate following hospitalisation with 
HCV-related decompensated cirrhosis and HCC cases in Scotland was also 
determined. Finally, the numbers of new hospitalisations and deaths from HCC and 
decompensated cirrhosis related to diagnosed HCV infection were compared with all 
new hospitalisations and deaths from these causes (i. e. regardless of HCV status) in 
Scotland during 1996-2001 to estimate the prevalence of diagnosed HCV infection in 
end-stage liver disease. 
4.3.2 Study population 
The study population comprised all persons who had been diagnosed HCV antibody 
positive in Scotland up to the 31st December 2001. Epidemiological data on 
laboratory reported HCV diagnoses are held at the Scottish Centre for Infection and 
Environmental Health (SCIEH)' 86; laboratory under-reporting is not an issue because 
diagnoses are confirmed by virology laboratories in which dedicated surveillance staff 
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collate and forward the data to SCIEH. The database consists of cases who were 
diagnosed since testing first began in 1991 and a minority (<I%) who were 
retrospectively tested HCV antibody positive prior to this. Data collected include date 
of the earliest positive specimen, source of specimen (e. g. hospital, general practice, 
genito-urinary medicine clinic, prison), risk information and a limited set of personal 
identifiers ((a) forename initial, (b) surname initial, (c) surname soundex'88, (d) date 
of birth, (e) gender and (f) postcode district of residence at diagnosis) to eliminate 
repeat tests; full names are not held to preserve patient confidentiality188. Records are 
updated (but, regrettably, date of updating is not registered) if missing data on risk or 
other relevant epidemiological information become available from subsequent tests. 
At the end of December 2001, records from 13,519 persons in Scotland diagnosed 
with HCV were held on the database189 
4.3.3 Data sources used to identify information on disease outcomes and other 
epidemiological risk factors 
4.3.3.1 Scotland's hospital discharge, cancer and deaths databases 
The Information and Statistics Division (ISD) in Edinburgh holds national 
computerised data on (i) hospital (general acute inpatient and day case) discharge 
records for non-psychiatric, non-obstetric specialties 
190, (ii) cancer registrations 190 and 
(iii) Registrar General's death records 191 Diagnoses pertinent to either the patient's 
hospital stay, cancer registration or cause of death were coded according to the 
International Classification of Diseases (ICD) Ninth192 (in years 1980-1995 for 
hospital discharges and 1980-1999 for deaths records) and Tenth Revisions193 (in 
years 1996-2001 for hospital discharges, 1980-1998 for cancer and 2000-2001 for 
deaths records; data were only available up to 1998 for cancer registrations and 
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therefore were merely used to assess the reliability of hospital discharge data). 
Records on these databases contained full identifying information, including the 
limited set of identifiers listed (a)-(f) above, required to link to the HCV diagnoses 
database. A measure of a patient's deprivation status was also available with each 
record and had been derived from their postcode of residence based on the Carstairs 
and Morris index, which combines four census indicators (overcrowding, 
unemployment, social class and car ownership), judged to represent material 
disadvantage in the population, into a single composite seven-point score, ranging 
from very affluent (1) to very deprived (7), for each postcode sector in Scotland' 94,195 
4.3.3.2 Scotland's HIV test database 
SCIEH holds epidemiological non-named data on all persons who have had a personal 
HIV antibody test in Scotland since 1989196. These data are collected through the use 
of a national HIV test request form, which accompanies the blood specimen sent for 
HIV testing to the appropriate laboratory' 97. Data retained at SCIEH include date of 
specimen, HIV antibody test result, risk category associated with HIV test and 
identifiers (a)-(f) listed above. 
4.3.4 Record-linkage process 
The HCV diagnoses database was linked to (i) hospital discharge records, (ii) cancer 
registrations and (iii) death records by ISD's Record Linkage Team using a previously 
developed probability matching approach'87. The identifier fields used in the linkage 
process were as listed (a)-(f) above. ISD have estimated that both the false negative 
rate (the proportion of truly matched pairs which the system fails to link) and the false 
positive rate (the proportion of linked pairs of records which do not refer to the same 
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individual) with this approach to be less than 5%187, similar to that found recently in 
an independent assessment of matching using non-name-based case registries19ß. ISD 
also performed an internal linkage of records on the HCV diagnoses database to 
identify any overlooked duplicate cases (see Results). These linkages were approved 
by the Privacy Advisory Committee, which oversees issues of confidentiality 
involving data on National Health Service patients in Scotland. Once these linkages 
were completed, ISD provided SJH with data from the hospital, cancer and deaths 
registries on HCV diagnosed persons for subsequent analyses as described below. 
To secure further data on the injecting and HIV positive status of HCV 
diagnoses, a linkage of the HCV diagnoses database with a subset of the HIV test 
database (on records of those who had indicated that they had injected drugs or who 
had tested HIV positive) was performed by SJH. The surname soundex of HIV tested 
persons was incomplete and thus excluded from the linkage process. Individuals who 
matched exactly on forename initial, surname initial, date of birth and gender were 
assumed to be the same person; the sensitivity and specificity of matching based only 
on these identifiers was assumed to be in excess of 95%198. 
4.3.5 Definition of disease outcomes and other epidemiological risk factors 
4.3.5.1 Hepatocellular carcinoma (HCC) 
HCC was identified on the hospital discharge, cancer and deaths databases by a 
diagnosis of primary liver cancer (ICD-9 code 155.0; ICD-10 code C220). The cancer 
database was also able to identify those who had histologically confirmed HCC. 
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4.3.5.2 Decompensated cirrhosis 
Decompensated cirrhosis was defined as ascites, oesophageal varices with bleeding, 
hepatic encephalopathy, chronic hepatic failure and alcoholic hepatic failure 
(identified as ICD-9 codes: 456.0,571.3,572.2,572.8,789.5; ICD-10 codes: 1850, 
1982, K704, K709, K721, K729, R18). 
4.3.5.3 Epidemiological risk factors 
For each HCV diagnosed case, their linked hospital discharge and death records were 
searched for mention of alcohol (as defined by ICD-9 codes: 291,303.9,305.0,571.0- 
571.3; ICD-10 codes: F 10, K70), hepatitis B virus (HBV) (ICD-9 codes 070.2,070.3; 
ICD-10 codes: B 16, B 170, B 180, B 181) and opiate dependence (ICD-9 codes: 304.0, 
304.7; ICD-10 codes: F 11). A second variable for alcohol abuse (as defined by ICD-9 
codes: 291,303.9,305.0; ICD-10 codes: F10) was also created which excluded 
alcoholic liver disease. Data on opiate use (from a hospital admission or death record) 
and injecting drug use (with a HIV test) were used to establish the IDU risk status of 
HCV diagnosed persons for whom no risk factor information were available. The 
maximum Carstairs and Morris deprivation score recorded in patients' linked hospital 
discharge and death records was used to establish if HCV diagnosed persons had 
resided in an area of high deprivation (represented by scores 6 and 7). 
4.3.6 Analyses 
4.3.6.1 Characteristics of HCV diagnosed persons 
A comparison of HCV diagnoses' characteristics (i. e. year and age at diagnosis, 
gender, risk group, health-board of residence, referral source) was made between 
those who had sufficient and insufficient identifiers for linkage with other databases; 
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insufficient identifiers amounted to absence of date of birth or both forename and 
surname initials. Uni-factorial and multi-factorial logistic regression were used to 
determine the factors significantly associated with non-linkage of HCV diagnosed 
cases. 
4.3.6.2 Epidemiological risk factors of HCV diagnosed persons 
The HIV diagnosis, deprivation, alcohol and HBV status of HCV diagnosed persons 
were obtained from examining their HIV test, hospital discharge and death records. 
The IDU status of HCV diagnosed persons was sourced from four databases (i. e. 
HCV diagnoses, HIV test, hospital discharge and death databases; data on opiate use, 
instead of IDU, was only available from the latter two databases). Log-linear 
modelling199 was then used to analyse the overlaps in the number of HCV diagnosed 
IDUs among the four data-sources and estimate the total (including hidden) number of 
HCV diagnosed IDUs. Stepwise regression was used to find a model which 
adequately described the data with as few parameters as possible; retention of 
interaction terms was further assessed by comparison of the residual deviance with the 
x2 distribution. 
4.3.6.3 Characteristics of HCC and decompensated cirrhosis cases among 
HCV diagnosed persons 
The epidemiological characteristics of new diagnoses (first hospital admissions) and 
deaths (both underlying and all causes) from HCC and decompensated cirrhosis 
during 1991-2001 were examined. In particular, the proportion of deceased cases with 
each condition (i. e. HCC and decompensated cirrhosis) who 
had also been 
hospitalised with this condition was determined (for purposes of adjusting observed 
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data, as described below). Additionally for HCC, the proportions of hospitalised and 
deceased cases who had been registered on the cancer database (complete to 1998) 
were also determined. 
4.3.6.4 Annual numbers of new diagnoses for HCC and decompensated 
cirrhosis related to HCV infection 
The annual number of first hospital admissions for HCC and decompensated cirrhosis 
among individuals who were already HCV diagnosed prior to hospitalisation or within 
14 days were adjusted to account for (i) the inability to link a proportion of HCV 
diagnosed cases due to insufficient identifiers, (ii) the non-hospitalisation of HCC and 
decompensated cirrhosis cases (estimated from the proportion of deaths not 
previously hospitalised for these conditions), and (iii) the non-diagnosis of HCV 
infection among HCC and decompensated cirrhosis cases (estimated from the 
proportion of those hospitalised for decompensated cirrhosis who were not diagnosed 
with HCV infection until >14 days after their hospitalisation); details given in 
footnote to Table 4.6. No adjustment was made for the high sensitivity and specificity 
of the record-linkage process. Adjusted annual diagnoses for HCC and 
decompensated cirrhosis were restricted to the period 1996-2001, due to limited HCV 
testing prior to this period. 
4.3.6.5 Risk factors for development of HCC and decompensated cirrhosis 
among HCV diagnosed persons 
Cox proportional hazards regression200 was used to assess the influence of 
epidemiological factors on the development of outcomes (i) HCC and (ii) 
decompensated cirrhosis among diagnosed HCV positive persons in Scotland. The 
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period of observation used in calculating the risk of either outcome began at the date 
of first HCV positive specimen and ended at the date of hospitalisation for the 
relevant outcome (either HCC or decompensated cirrhosis), date of death, or the end 
of December 2001, whichever came first. Covariates examined included baseline 
characteristics at the time of HCV diagnosis (i. e. gender, risk group, health-board of 
residence and referral source) and time-dependent covariates (i. e. current age, first 
hospitalisation for alcohol abuse and HBV, and diagnosed HIV infection). Analysis 
was confined to persons who were outcome free at the start of follow-up and thus 
cases who were admitted to hospital for the relevant condition (i. e. HCC or 
decompensated cirrhosis) prior to or within 14 days of HCV diagnosis were excluded; 
furthermore, those who had been retrospectively diagnosed with HCV and had their 
first positive test result prior to 1991 were also excluded from analyses. Models were 
assessed for HCV diagnosed cases referred from all settings and separately on cases 
referred only from non-hospital settings. In an additional analysis, the risk period was 
defined in terms of age (i. e. from age at first HCV positive specimen to age at end of 
follow-up) to examine the influence of other characteristics on the development of 
decompensated cirrhosis as age advances. 
4.3.6.6 Mortality related to HCC and decompensated cirrhosis among HCV 
diagnosed persons 
Following first hospitalisation for HCC, the number of deaths from all causes and 
from HCC (given as the underlying cause or contributing cause with the underlying 
cause stated as liver or HCV related) and the number of cases who had been in 
hospital for a liver transplant (ICD-9 code: V42.7; ICD-10 codes: Z94.4), according to 
gender and age at time of hospitalisation for HCC, were 
determined. The person-years 
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at risk were calculated as time in years from date of first hospitalisation for HCC to 
date of death, date of liver transplant or the end of December 2001, whichever came 
first; cases who had either (i) died on the same day as or (ii) received a liver transplant 
prior to first admission with HCC were excluded (i. e. for HCC: (i) 0 and (ii) 2 cases 
excluded; also for decompensated cirrhosis: (i) 2 and (ii) 5 cases excluded). Cox 
proportional hazards regression was used to assess the influence of gender and age on 
mortality from (i) HCC and (ii) all causes following first hospitalisation with HCC; 
the probability of death from (i) and (ii) at one and two years since first hospitalisation 
with HCC were also estimated. The number of deaths, liver transplants, person-years 
and mortality associated with cases hospitalised for decompensated cirrhosis were 
similarly assessed. 
4.3.6.7 Prevalence of diagnosed HCV infection among all HCC and 
decompensated cirrhosis cases in Scotland 
Data on all first hospital admissions and deaths associated with HCC and 
decompensated cirrhosis in Scotland during 1996-2001 by gender, age, history of 
alcohol abuse and HCV diagnoses status (sourced from hospital discharge records, 
death records and linkage with SCIEH's HCV diagnoses database) were examined. 
Decompensated cirrhosis was defined as above (ascites, oesophageal varices with 
bleeding, hepatic encephalopathy, chronic hepatic failure and alcoholic hepatic 
failure) except that cases without mention of liver disease (ICD-9 codes 570-573; 
ICD-10 codes: K70-K77) or hepatitis (ICD-9 codes 070; ICD-10 codes: B 16-B 18) 
were excluded, to discount non-liver-related conditions associated with ascites and 
oesophageal varices, from this analyses. 
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4.4 Results 
4.4.1 Characteristics of HCV diagnosed persons 
Of the 13,535 entries on the HCV diagnoses database as at the end of 2001,164 
(1.2%) were recognised as duplicate records based on probability matching methods 
carried out by ISD. A further 1,275 (9.5%) of the remaining 13,371 records on the 
database either had date of birth (277) and/or both forename and surname initials 
(1,034) identifiers missing so that linkage was inhibited. 
Table 4.1 shows the characteristics of the 12,096 HCV diagnosed cases who 
had sufficient identifiers for record-linkage compared with those of the remaining 
1,275 cases who had insufficient identifiers and were not linked. The majority of all 
diagnosed cases were first tested positive in 1998-2001 (56%), male (69%), aged 20- 
34 years (63%), IDUs (90% of known risk cases) and 47% were referred from 
hospital settings. Referrals from GUM and drug/counselling clinics were significantly 
more likely than hospital referred patients to have insufficient identifiers for record- 
linkage (unadjusted odds ratios: 31.0 and 3.5; 95% CI 25.9-37.1 and 2.9-4.2, 
respectively). The completeness of identifier information varied by health-board of 
residence - highest in Lothian (94%), Tayside (93%), then Glasgow (91%) and lower 
in the rest of Scotland (88%). Persons diagnosed recently in years 1998-2001 
(compared to pre 1994) and those aged 20-34 years (compared to 35 years and older) 
were significantly more likely to have insufficient identifiers recorded and thus were 
less represented in the subsequent record-linkage exercise. 
Table 4.2(a) shows the characteristics of the 12,096 HCV diagnosed cases who 
had sufficient identifiers for record-linkage by risk group. Those who reported a non- 
IDU risk were more likely to have been diagnosed pre 1994 and resided outside 
Glasgow than either IDUs or not known risk groups. Those who reported IDU were 
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more likely to be male and younger than those belonging to non-IDU and not known 
risk groups. Finally those for whom a risk could not be ascribed were more likely than 
the reported IDUs and non-IDUs to have been referred from a hospital setting. 
4.4.2 Epidemiological risk factors of HCV diagnosed persons 
Of the 12,096 HCV diagnosed cases, 17% and 6% had alcohol and HBV mentioned 
on either a hospital discharge or death record, respectively, and 3% were diagnosed 
HIV positive (Table 4.2). Over half of linked cases (5469/9813) had resided in an area 
of high deprivation (measured by Carstairs score 6-7). 
Sixty-eight percent (8244/12096) of HCV diagnosed persons had IDU (or 
opiate use) mentioned with at least one of their (i) HCV diagnosis, (ii) HIV test, (iii) 
hospital discharge or (iv) death records (Table 4.3). Log-linear modelling estimated 
that there were a further 2,404 HCV diagnosed persons who had not been identified as 
IDUs from these four data-sources. The model yielded an overall estimate of 10,648 
HCV diagnosed IDUs (95% Cl 9,753-12,047), which represents 88% (95% Cl 81- 
100%) of all 12,096 diagnosed cases. An additional analysis, which excluded persons 
who reported a non-IDU risk with their HCV diagnosis, provided a similar estimate of 
the total number of HCV diagnosed IDUs (10,578 (95% CI 9,682-11,978)). 
4.4.3 Characteristics of HCC and decompensated cirrhosis cases among HCV 
diagnosed persons 
During 1991-2001,71 HCV diagnosed persons were hospitalised for the first time 
with HCC (Table 4.4), of whom 58 (82%) had also died during this period (43 from 
underlying cause HCC, 5 contributing cause HCC and 10 other causes). In total, 67 
persons died with HCC as their underlying (59) or contributing cause (8), of whom 50 
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(75%) had been hospitalised with HCC previously (48 during 1991-2001 and 2 pre 
1991) and 17 (25%) had not been identified as having been hospitalised with HCC 
(24% (14/59) and 38% (3/8) of deceased cases with HCC as underlying or only as 
contributing cause, respectively). Of the eight who had died with contributing cause 
HCC, five (63%) had liver disease or HCV as their underlying cause. For those who 
had been hospitalised or died with HCC during 1991-1998,95% (40/42) and 91% 
(39/43), respectively, were registered with HCC on the cancer database; 24% (13/54) 
of HCC cases on the cancer database had not been hospitalised with this diagnosis. 
During 1991-2001,514 HCV diagnosed persons were hospitalised for the first 
time with decompensated cirrhosis, of whom 312 (61%) had also died during this 
period (65 and 98 from underlying and contributing cause decompensated cirrhosis, 
respectively, 27 HCC, 36 from other diseases of the liver, 15 HCV and 71 other 
causes). In total, 196 persons died with decompensated cirrhosis as their underlying 
(75) or contributing cause (121), of whom 168 (86%) had been hospitalised with 
decompensated cirrhosis previously (163 during 1991-2001 and 5 pre 1991) and 28 
(14%) had not been identified as having been hospitalised with decompensated 
cirrhosis (9% (7/75) and 17% (21/121) of deceased cases with decompensated 
cirrhosis as underlying or only as contributing cause, respectively; of note, a high 
proportion (24%: 5/21) of the latter group had been diagnosed with HIV antibodies). 
Of the 121 who had died with contributing cause decompensated cirrhosis, 7 (6%) had 
HCC and 60 (50%) had liver disease or HCV as their underlying cause. A further 73 
deaths with underlying cause liver disease or HCV and without either decompensated 
cirrhosis or HCC were identified during 1991-2001. 
The majority of HCC (73%), and less so decompensated cirrhosis (52%), 
hospitalisations were among HCV diagnosed cases without a risk group. A higher 
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proportion of HCC than decompensated cirrhosis first hospitalisations were aged 50 
years or more (82% vs 31%, respectively) and were male (85% vs 75%, respectively). 
Only 6% of HCV-related HCC hospitalisations were not diagnosed with HCV 
antibodies until after 14 days following first admission with HCC, compared to 17% 
(90/514) of HCV-related decompensated cirrhosis hospitalisations. Of these latter 90 
cases, 55 (61%) were diagnosed with HCV within a year of their first hospital 
admission for decompensated cirrhosis and of the remaining 35,31% were HCV 
diagnosed within 14 days of a subsequent hospital re-admission for decompensated 
cirrhosis. Further, 81% of the 90 cases had either alcoholic hepatic failure or ascites 
(but not hepatic encephalopathy, chronic hepatic failure or varices) recorded with 
their first hospitalisation for decompensated cirrhosis (compared to 58% (245/424) of 
those who were diagnosed with HCV before or within 14 days of their first 
decompensated cirrhosis hospitalisation). 
Alcohol use was associated with 41 % of HCC hospitalisations and deaths, and 
71% of decompensated cirrhosis hospitalisations rising to 97% of deaths with 
underlying cause decompensated cirrhosis. HIV and HBV were associated with only a 
small proportion of HCC (0% and 9%, respectively) and decompensated cirrhosis (5% 
and 13%, respectively) hospitalisations. 
4.4.4 Annual numbers of new diagnoses for HCC and decompensated cirrhosis 
related to HCV infection 
Table 4.6 shows the estimated numbers of new diagnoses for HCC and 
decompensated cirrhosis related to HCV infection according to region (as described in 
footnote to Table 4.6, by accounting for (i) the inability to link a proportion of HCV 
diagnosed cases due to insufficient identifiers, (ii) the non-hospitalisation of HCC and 
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decompensated cirrhosis cases, and (iii) the non-diagnosis of HCV infection among 
HCC and decompensated cirrhosis cases). There was a 30% increase in the estimated 
number of new diagnoses for decompensated cirrhosis related to HCV infection from 
230 (95% CI 220-250) in 1996-1998 to 300 (280-320) cases in 1999-2001 for all 
Scotland. In contrast, there was no change in HCC new diagnoses related to HCV 
infection in Scotland: 52 (95% CI 46-60) cases in 1996-1998 and 49 (42-57) in 1999- 
2001. 
4.4.5 Risk factors for the development of HCC and decompensated cirrhosis 
among HCV diagnosed persons 
The relative hazards in Tables 4.7 and 4.8 show the change in risk of HCC and 
decompensated cirrhosis, respectively, for each of the epidemiological factors. The 
highest risk for the development of HCC was associated with cases aged 50 years and 
above, which remained the only significant factor in the multi-factorial model 
restricted to referrals for HCV diagnosis from non-hospital settings (relative hazard 
(RH) 35 with 95% CI 7-169). Cases hospitalised with alcohol abuse (3.4), referrals for 
HCV diagnosis from hospital (2.8) and males (2.6) were also significantly associated 
with an increased risk of HCC in the multi-factorial model for all diagnosed cases. 
Increasing age was also highly associated with a raised risk of decompensated 
cirrhosis in the multi-factorial model restricted to referrals from non-hospital settings 
(RH 4.6 (95% Cl 2.2-9.6), 8.8 (3.5-22.0) and 10.7 (3.1-37.5) for those aged 30-49,50- 
69 and 70+ years, respectively, compared to those aged <30 years). Significantly 
increased risk of decompensated cirrhosis was also found with hospitalisation for 
alcohol abuse and HBV, diagnosis with HIV infection and non-IDU risk for HCV 
infection (RHs 6.1 (95% Cl 4.0-9.1), 2.0 (1.1-3.6), 3.9 (2.2-7.0) and 2.4 (1.4-4.2), 
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respectively). Broadening to referrals from all settings, cases with unknown risk for 
HCV infection, referrals for HCV diagnosis from hospital and residents of Lothian 
also had significantly increased risk of progression to decompensated cirrhosis; males 
did not have a significantly different risk from females. 
Figure 4.1 illustrates the development of decompensated cirrhosis among 
HCV diagnosed cases according to age and alcohol abuse. Development of 
decompensated cirrhosis by 50 years of age increased from 14% (95% Cl 10-17%) to 
46% (37-54%) among cases without and with a history of hospitalisation with alcohol 
abuse, respectively; restricting to non-hospital referrals for HCV diagnosis, these 
proportions reduced marginally to 11% (7-15%) and 44% (29-55%), respectively. 
4.4.6 Mortality related to HCC and decompensated cirrhosis among HCV 
diagnosed persons 
Tables 4.9(a) and 4.9(b) examine the mortality of HCV diagnosed patients following 
first hospitalisation for HCC and decompensated cirrhosis during 1991-2001 in 
Scotland, respectively. The probability of death from HCC and all causes following 
first hospitalisation with HCC was 57% and 68% at 1 year increasing to 63% and 79% 
at 2 years, respectively; the risk of death following first hospitalisation with HCC was 
higher among patients aged 50 years or more and men but neither reached statistical 
significance. The probability of death from decompensated cirrhosis and all causes 
following first hospitalisation with decompensated cirrhosis was 18% and 42% at 1 
year increasing to 39% and 72% at 5 years, respectively. The risk of all cause death 
following first hospitalisation with decompensated cirrhosis was significantly higher 
among those aged 50 years or older at hospitalisation compared to younger patients 
(RH 1.85; 95% CI 1.46-2.35, p<0.0001). The probability of having a liver transplant 
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within the first two years following first hospitalisation for decompensated cirrhosis 
was 4.2% (95% Cl 1.5-6.9%). 
4.4.7 Prevalence of diagnosed HCV infection among all HCC and decompensated 
cirrhosis cases in Scotland 
Seven hundred first hospital admissions and 617 deaths from HCC occurred during 
1996-2001 in Scotland (Table 4.10), of which 9.7% (68/700) and 8.1% (50/617) were 
determined as known to be infected with HCV, respectively. Of the 68 known HCV 
infected persons hospitalised with HCC, 51 (75%) were determined as HCV infected 
according to both their SCIEH and either hospital or death records, 6 (9%) from only 
their SCIEH record and 11 (16%) from either their hospital or death records; 39 
(78%), 5 (10%) and 6 (12%) were similarly recognised as known HCV infected 
among the 50 HCC deaths. Prevalence of known HCV infection was highest among 
HCC cases aged 30-49 years (39% of 44 new hospitalisations and 40% of 25 deaths). 
The aetiological factors potentially responsible for HCC were only explained by either 
(a) alcohol, (b) HBV or (c) HCV recorded in 38% of hospitalised cases (a: 178; b: 13; 
c: 33; a&b: 5; a&c: 28; b&c: 3; and a, b&c: 4) and 38% of deaths (a: 169; b: 12; 
c: 28; a&b: 3; a&c: 21; anda, b&c: 1) 
New hospital admissions and deaths from decompensated cirrhosis occurred in 
10,588 and 3,936 cases, respectively, during 1996-2001 in Scotland (Table 4.10), of 
which 4.2% (442/10588) and 3.4% (134/3936), respectively, were determined as 
known to be infected with HCV. Of the 442 known HCV infected persons 
hospitalised with decompensated cirrhosis, 286 (65%) were determined as HCV 
infected according to both their SCIEH and either hospital or death records, 64 (14%) 
from only their SCIEH record and 92 (21%) from either their hospital or death 
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records; 84 (63%), 23 (17%) and 27 (20%) were similarly recognised as known HCV 
infected among the 134 decompensated cirrhosis deaths. Prevalence of known HCV 
infection was highest among decompensated cirrhosis cases aged under 50 years (9% 
of new hospitalisations and 8% of deaths). Alcohol was identified as a factor in 83% 
of all decompensated cirrhosis new hospitalisations (other aetiological factors: alcohol 
(a): 8412; HBV (b): 28; HCV (c): 105; a&b: 53; a&c: 278; b&c: 17; and a, b&c: 
42) and 89% of deaths (a: 3378; b: 12; c: 26; a&b: 16; a&c: 88; b&c: 4; and a, b& 
c: 16). 
4.5 Discussion 
To help policymakers to prioritise HCV-related interventions and research and to 
allocate healthcare resources accordingly, accurate information about the current 
burden of this disease is essential. The greatest burden from HCV infection will come 
from the long-term complications of this chronic liver disease, namely decompensated 
cirrhosis and HCC. In the United States, examination of trends in deaths from non-A, 
non-B viral hepatitis and the frequency of inpatient care for HCV-related diagnoses 
highlighted that the mortality and healthcare utilisation associated with long-standing 
HCV infection had increased over the past decade'85'2oi These data, however, relied 
on the accurate reporting of hepatitis C on death and hospital records and thus, likely, 
under-estimated the true mortality and morbidity burden. Unless countries introduce 
national surveillance systems for registration of HCV-related decompensated cirrhosis 
and HCC, akin to that for AIDS diagnosis, the record-linkage approach developed 
here is the only means to ascertain these data. The laboratory reporting of diagnostic 
positive tests for HCV antibodies in Scotland linked electronically to clinical data 
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gathered from hospital and death records therefore provided a unique national 
epidemiological dataset on diagnosed HCV infection. 
Approximately 500 and 200 diagnosed HCV antibody positive persons in 
Scotland had developed and died of liver failure, respectively, by the end of 2001. The 
number of persons with newly developed HCV-related decompensated cirrhosis in 
Scotland was estimated to increase by 30% from 230 (95% CI 220-250) in 1996-1998 
to 300 (280-320) cases in 1999-2001. The number of confirmed HCV antibody 
positive persons who had presented to hospital with decompensated cirrhosis and 
HCC by 2001 was, however, a small fraction - only 4.2% (514/12,096) and 0.6% 
(71/12,096), respectively - of the total HCV diagnosed population in Scotland. This 
observation may be reassuring for a patient newly diagnosed with HCV, but 
represents a growing significant burden on healthcare resources. 
Estimates of the proportion of chronic liver disease attributable to HCV 
infection vary considerably, ranging from 8-15% in the United States201 and New 
Zealand202 to 62-74% in Italy203 and Egypt204. Back-calculation models in France 
assumed that 36%, and more recently 27%, of HCC deaths were attributable to 
HCV78'79. Much higher prevalences of HCV antibodies were reported among selected 
HCC patients in Japan (60-95%) 205,206 and other parts of Europe (45-75%) 
207,208 
except in England (22% of 37) and Greece (14% of 56)209. Australian projections 
estimated that 7% (5-8%) of HCC cases in 1998 were due to HCV infection81. HCV 
was detected in 30% of 80 HCC patients, with stored serum samples, presenting to a 
single hospital in the East of Scotland between 1985 and 199439 
In comparison, low prevalences of diagnosed HCV infection were found 
among individuals with HCC and decompensated cirrhosis (DC) presenting to 
hospital (10% and 4%, respectively) or having died (8% and 3%, respectively) in 
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Scotland during 1996-2001. The underlying prevalence of HCV in these groups could 
be higher at 13% (i. e. hospitalised with HCC), 6% (hospitalised with DC), 11% (died 
with HCC) and 5% (died with DC), respectively, after accounting for infections which 
were not identified through record-linkage, because (i) 10% of HCV diagnosed 
persons could not be included in the record-linkage due to insufficient identifiers, and 
(ii) a proportion (estimated to be 17.5%, based on the proportion who were HCV 
diagnosed after hospitalisation with decompensated cirrhosis) of HCV-infected HCC 
and decompensated cirrhosis cases were not tested and diagnosed with HCV. 
Estimates were restricted to 1996-2001 to minimise the influence of the sharp increase 
in HCV antibody testing of patients with liver disease during the early 1990s. 
Misclassification of the ICD code on the hospital or death record represents a further 
source of error, although this appears to be minor given that 95% and 91% of HCV 
diagnosed individuals who had been hospitalised or had died with HCC, respectively, 
were also registered with HCC on the cancer database. HCC and hepatic 
decompensation - as manifested by ascites, hepatic encephalopathy or gastrointestinal 
bleeding - generally necessitate inpatient hospital care. However, 25% and 14% of 
deaths from HCC and decompensated cirrhosis, respectively, were not identified with 
these conditions in the hospital register and therefore the hospital morbidity data alone 
may under-estimate the incidence of severe HCV-disease. 
The extent of alcohol- compared to HCV- related hepatic failure is sobering, 
with hospitalisations associated with the former outnumbering the latter 20-fold, and 
underlines alcohol as the major cause of chronic liver disease currently in Scotland; 
although, HCV is forecast to become a more prominent cause in the future (as 
suggested from projections derived in Chapter 6). Alcohol was also a prominent 
feature among HCV diagnosed persons who either died or were hospitalised with 
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decompensated cirrhosis during 1996-2001 (78% and 72%, respectively). The 
younger age of decompensated patients presenting to hospital with both HCV and 
alcohol (78% <50 years old) suggests that the combined effect of these two factors 
accelerates liver disease progression more than with only one (HCV: 48%; alcohol: 
33%) or none of these factors (17%). In multiple regression analysis, a history of 
hospitalisation with an alcohol-related diagnosis was associated with a 5- to 6- fold 
increased risk of developing decompensated cirrhosis among HCV diagnosed 
antibody positive individuals in Scotland. A limitation of the hospital data was the 
absence of information on the quantity of alcohol consumed by patients. Heavy 
alcohol consumption, particularly above 350g per week, has previously been 
correlated with increased liver disease progression in individuals infected with 
HCV95'21° and is the focus of further study in Chapter 5. In keeping with the literature 
on the natural history of HCV diseases, the proportional hazards multifactorial 
regression also identified older age, HIV and HBV co-infection as factors associated 
with higher risk of decompensated cirrhosis. 
Injecting drug use represents the most common risk factor for HCV infection 
throughout the industrialised world211. However a substantial proportion of persons 
who test positive for HCV antibodies report no risk factors for infection. Thirty 
percent of persons with acute HCV in the United States during 1991-1995 denied a 
specific exposure associated with acquiring infection during the six months preceding 
onset of their illness, although over half of these reported a previous history of drug 
use212. In England and Wales, 43% of confirmed HCV infections during 1992-1996 
lacked risk factor information 213. It follows that either the potential risk factors for 
HCV acquisition were not carefully elicited or that there may be a significant 
undefined source of viral transmission. A study in the United States showed that the 
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route of HCV acquisition could be delineated in 88% of HCV chronically infected 
patients using a systematic interview approach; in nearly all cases, the initially 
unreported risk factor for HCV transmission was a remote history of injecting drug 
use214. This application in Scotland of capture-recapture methodology is the first to 
demonstrate the use of log-linear modelling, based on record-linkage data from four 
sources (i. e. HCV diagnoses, HIV test, hospital and death records), to estimate the 
proportion of IDUs among HCV diagnosed persons. Of 12,096 HCV antibody 
positive persons studied, 61% reported injecting drug use with their HCV diagnosis 
and a further 27%, yielding a total of 88%, were established as IDUs through log- 
linear modelling. 
This study provided the first estimates of the current morbidity and mortality 
associated with diagnosed HCV infection in Scotland, which is of particular 
importance in terms of validating HCV projections in Chapter 6, and highlighted the 
impact of alcohol on the course of this epidemic. The extent of heavy drinking among 
IDUs - reported from other countries to be in the range of 20% to 50%215,216,217,218 _ 
has received insufficient attention in the treatment and care of this client group. 
Further research is required to assess the influence on drinking behaviour of testing 
IDUs, including those who have ceased injecting, for HCV antibodies and counselling 
them about the consequences of alcoho1219. In light of the apparent synergistic effect 
between alcohol and HCV, limiting the alcohol consumption of chronically infected 
individuals is essential to help prevent future morbidity and mortality related to HCV 
infection. 
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Table 4.1: Characteristics of HCV diagnosed individuals in Scotland up to the end of 2001: comparison between 
12,096 and 1,275 cases who had sufficient (linked) and insufficient (non-linked) identifiers, respectively, as 
required to allow record-linkage with other data sources. 
HCV diagnosed persons Odds Ratio for non-linked 
N (%) (95% CI) 
Linked Non-linked Uni-factorial Multi-factorial 
N=12,096 N=1,275 
Year of HCV diagnosis Pre 1994 1187(10%) 52 (4%) 0.35 (0.27-0.47) 0.24 (0.14-0.40) 
1994-1997 4257(35%) 396 (31%) 0.75 (0.66-0.85) 0.87 (0.73-1.05) 
1998-2001 6652(55%) 827 (65%) 1.00 (Baseline) 1.00 (Baseline) 
Gender Male 8345 (69%) 831 (71%) 1.00 (Baseline) 1.00 (Baseline) 
(129 not known) Female 3723 (31%) 343 (29%) 0.93 (0.81-1.05) 0.90 (0.75-1.09) 
Age at HCV diagnosis (years) < 20 563 (5%) 59 (6%) 1.05 (0,80-1.39) 0.93 (0.63-1.37) 
(277 not known) 20-34 7507 (62%) 747 (75%) 1.00 (Baseline) 1.00 (Baseline) 
35-49 3154(26%) 179(18%) 0.57 (0.48-0.67) 0.51 (0.41-0.64) 
2 50 872 (7%) 13 (1%) 0.15 (0.09-0.26) 0.23 (0.13-0.42) 
Risk group IDU 7327(61%) 716 (56%) 1.00 (Baseline) 1.00 (Baseline) 
Non-IDU 895 (7%) 45 (4%) 0.52 (0.38-0.70) 1.19 (0.76-1.86) 
None reported 3874(32%) 514 (40%) 1.36 (1.20-1.53) 2.82 (2.32-3.42) 
Healthboard of residence Greater Glasgow 4513 (37%) 445 (35%) 1.00 (Baseline) 1.00 (Baseline) 
for HCV diagnosis Lothian 1859 (15%) 112 (9%) 0.61 (0.50-0.76) 0.51 (0.38-0.69) 
Grampian 1360(11%) 209 (16%) 1.56 (1.31-1.86) 1.97 (1.48-2.62) 
Tayside 986 (8%) 72 (6%) 0.74 (0.57-0.96) 0.84 (0.57-1.22) 
Rest of Scotland 3378(28%) 437 (34%) 1.31 (1.14-1.51) 2.30 (1.86-2.85) 
Referral source for HCV diagnosis Hospital 5755 (49%) 311 (25%) 1.00 (Baseline) 1.00 (Baseline) 
(384 not known) GP 2633 (22%) 67 (5%) 0.47 (0.36- 0.61) 0.57 (0.38- 0.85) 
Drug/Counselling Clinic 1047 (9%) 195 (16%) 3.45 (2.85- 4.17) 11.68 (9.09- 15.01) 
Prison 1054 (9%) 55 (4%) 0.97 (0.72- 1.30) 1.60 (1.12- 2.30) 
GUM clinic 316 (3%) 529 (42%) 30.98 (25.87-37.09) 124.94 (96.47-161.80) 
Other 933 (8%) 92 (7%) 1.82 (1.43- 2.33) 1.03 (0.61- 1.74) 
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Table 4.2: Epidemiological characteristics of HCV diagnosed individuals in Scotland, who were linked to 
hospital admission, deaths and HIV testee databases, by risk group. 
Risk Group reported with HCV diagnosis 
IDU Non-IDU None reported 
N =7327 N=895 N=3874 
(a) Characteristics extracted from the HCV diagnosis record 
Year of HCV diagnosis Pre 1994 534 (7%) 327 (37%) 326 (8%) 
1994-1997 2467 (34%) 315 (35%) 1475 (38%) 
1998-2001 4326 (59%) 253 (28%) 2073 (54%) 
Gender Male 5245 (72%) 583 (65%) 2517 (65%) 
(28 not known) Female 2075 (28%) 31 1 (35%) 1337(35%) 
Age at HCV diagnosis (years) < 20 346 (5%) 107 (12%) 110 (3%) 
20-34 5344(73%) 344(38%) 1819(47%) 
35-49 1577 (22%) 290(32%) 1287(33%) 
>_ 50 60 (1%) 154(17%) 658(17%) 
Healthboard of residence Greater Glasgow 2845 (39%) 253 (28%) 1415 (37%) 
For HCV diagnosis Lothian 1182(16%) 208(23%) 469(12%) 
Grampian 978 (13%) 74 (8%) 308 (8%) 
Tayside 618 (8%) 99(11%) 269 (7%) 
Rest of Scotland 1704 (23%) 261 (29%) 1413 (36%) 
Referral source for HCV diagnosis Hospital 2936(41%) 322(37%) 2497(67%) 
(358 not known) GP 1901 (27%) 177 (20%) 555 (15%) 
Drug/Counselling Clinic 865 (12%) 33 (4%) 149 (4%) 
Prison 890(12%) 8 (1%) 156 (4%) 
GUM clinic 263 (4%) 28 (3%) 25 (1%) 
Other 308 (4%) 305 (35%) 320 (9%) 
(b) Characteristics extracted from matched records on the hospital admission and deaths databases 
Matched to hospital & deaths No 1274 (17%) 148 (17%) 799 (21%) 
databases Only deaths 31 (<I%) 1 (<I%) 11 (<I%) 
Only hospital 5259 (72%) 630 (70%) 2520 (65%) 
Both hospital and deaths 763 (10%) 116(13%) 544 (14%) 
Deprivation status High 3655 (61%) 281 (38%) 1533 (50%) 
on matched records (62 missing) Low-Medium 2360(39%) 455 (62%) 1529(50%) 
Alcohol mentioned Yes 1251 (21%) 99 (13%) 657 (21%) 
on matched records No 4802 (79%) 648 (87%) 2418 (79%) 
Hepatitis B virus mentioned Yes 558 (9%) 36 (5%) 188 (6%) 
on matched records No 5495 (91%) 711 (95%) 2887 (94%) 
(c) Characteristics extracted from matched records on the HIV testee database 
Diagnosed HIV positive Yes 354 (5%) 42 (5%) 15 (<1%) 
No 6973 (95%) 853 (95%) 3859 (100%) 
* The highest deprivation score recorded on any matched hospital admission or death record, where deprivation was assigned according to carstairs 
seven-point scale with high categorised as score 6-7 and low-medium as score 1-5. 
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Table 4.3: IDU status of 12,096 HCV diagnosed individuals in Scotland according to 4 data-sources (HCV 
diagnoses, HIV test, hospital discharge and death databases) and the estimated number of HCV diagnosed IDUs 
from log-linear modelling. 
IDU identified from 4 data sources 
(Y=yes; N=no) 
Observed 
number of 
Estimated number of HCV 
diagnosed IDUs 
(A) 
HCV 
Diagnoses 
(B) 
HIV test 
(C) 
Hospital 
Discharge 
(D) 
Death 
HCV 
diagnosed 
persons 
from log-linear model* 
Y Y Y Y 50 53 
N y y Y 11 8 
Y N Y Y 23 24 
N N Y Y 8 7 
Y Y N Y 117 113 
N Y N Y 18 22 
Y N N Y 40 40 
N N N Y 34 34 
Y Y Y N 1027 1024 
N Y Y N 142 145 
Y N Y N 859 858 
N N Y N 248 249 
Y Y N N 2383 2387 
N Y N N 456 452 
Y N N N 2828 2828 
N N N N - 2404 
Total number of HCV diagnosed IDUs identified from data-sources 8244 8244 
Total number of HCV diagnosed IDUs, including those not identified from data-sources 
(95% confidence interval) 
10648 
(9753 - 12047) 
* Log-linear model (residual deviance of 2.6 on 3 df) included main effects for data-sources (A) HCV diagnoses, (B) HIV test, 
(C) hospital discharge and (D) deaths (model coefficients (standard errors): A -0.63 (0.03); B 0.05 (0.04); C 0.58 (0.04); D 1.73 
(0.04)), with interactions between data-sources A and B (0.28 (0.03)); A and C (0.17 (0.03)); B and C (0.11 (0.04)); B and D 
(0.23 (0.04)); C and D (0.10 (0.04)); A, B and C (0.10 (0.03)); and B, C and D (0.07 (0.03)). 
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Table 4.5: Year of HCV diagnosis for cases hospitalised for the first time with decompensated 
cirrhosis during 1996-2000. 
Hospitalisations 
for decomp. 
cirrhosis 
HCV diagnosed 
prior to or in 
year of 
hospitalisation 
Year of HCV diagnosis for cases diagnosed after 
hospital admission 
Year N N, 1997 1998 1999 2000 2001 Total 
1996 42 39 0 3 0 0 0 3 
1997 58 53 - 1 0 3 1 5 
1998 71 68 - - 2 1 0 3 
1999 78 74 - - - 2 2 4 
2000 66 59 - - - - 7 7 
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Chapter 5: Influence of alcohol on the progression of hepatitis C virus 
infection: a meta-analysis 
5.1 Introduction 
Cohort studies of hepatitis C virus (HCV) infection in community-based settings have 
reported a generally slow course of liver disease94, although several viral, host and 
environmental factors appear to accelerate this progression5'22°. Elucidation of the 
factors that influence progression to severe HCV disease is essential, both at an 
individual level, to counsel those affected and help make decisions regarding antiviral 
therapy, and at a population level, to accommodate covariate influences in projection 
models aimed at estimating the future burden of disease. An understanding of the 
parameters affecting the natural history of HCV would also inform models of the cost- 
effectiveness of preventive and therapeutic interventions 220. 
Characteristics commonly associated with an increased risk of progression to 
cirrhosis include male sex, older age at HCV acquisition and co-infection with 
HIVS'22°. A recent meta-analysis estimated the overall relative risk of decompensated 
liver disease or histological cirrhosis to be 2.9 (95% CI 1.7-5.0) in HIV and HCV co- 
infected patients compared to those with only HCV infection221. Similar relative risks 
for cirrhosis have been reported in studies of HCV chronically infected persons with 
heavy alcohol consumption, defined at different thresholds: 2.9 (95% CI 1.6-5.4) 
222 
and 2.8 (1.1-7.4)223 with at least 560g and 20 units (equivalent of approximately 240g) 
of alcohol per week, respectively. Some studies however have failed to identify a 
significant correlation between heavy alcohol consumption (defined in the range of at 
least 240 to 560g per week) and development of severe HCV disease 210'224'225'226,227 
Meanwhile, a case-control study (involving 285 cases with liver decompensation and 
417 controls with acute diseases unrelated to alcohol) has demonstrated the combined 
multiplicative effect of alcohol and HCV infection, with a9 (95% CI 2-43), 15 (7-32) 
and 147 (42-514) times higher odds of developing cirrhosis in HCV-infected patients 
who had never consumed alcohol and in HCV-uninfected and HCV-infected patients 
with lifetime daily alcohol intake of at least 175g, respectively, compared to HCV- 
uninfected patients who had never consumed alcohol 180 
The long-term follow-up of acute non-A, non-B hepatitis cases in the United 
States provided an early indication of the importance of alcohol in progression to 
cirrhosis, with almost four-fifths of liver disease deaths (14/18) associated with 
alcoholism228. The record-linkage of 12,096 HCV diagnosed positive persons in 
Scotland to hospital admission data, presented in Chapter 4, identified alcohol as a 
factor in 71% of 514 cases developing HCV-related liver failure during 1991-2001. 
Populations in which heavy alcohol consumption is relatively common - such as 
injecting drug users (IDUs)215'216'217'218, the group most affected by HCV infection in 
resource-rich countries - will therefore likely experience a higher burden of advanced 
liver disease among those with chronic HCV than estimated from community-based 
studies (with 10% heavy alcohol intake) 93 
A convincing, yet inconsistent, pattern has emerged which demonstrates 
increased progression of HCV-related liver disease with heavy alcohol use. The aim 
in this chapter was to perform a meta-analysis of published studies that explored the 
relationship between advanced liver disease and the consumption of alcohol among 
HCV chronically infected persons. Estimation of the relative risk of cirrhosis 
associated with heavy alcohol use will inform the design of the HCV projection model 
described in Chapter 6. Further, the effect of potential sources of heterogeneity - 
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particularly, the threshold used to define heavy alcohol use - on the pooled relative 
risk estimate was examined to help explain the inconsistency between study findings. 
5.2 Methods 
5.2.1 Literature search 
A literature search was performed via the MEDLINE database of English-language, 
peer-reviewed publications covering the period January 1989 to March 2004. A 
search for terms "alcohol", "cirrhosis" and either "hepatitis C" or "HCV" in titles, 
abstracts or key words was used to identify articles, which had examined the 
association between alcohol use and cirrhosis risk among persons infected with HCV. 
The references of articles obtained from the MEDLINE search and review 
papers 229,230,231,232 were also examined for relevant studies. 
5.2.2 Criteria for inclusion of articles 
Twenty articles, identified through the literature search, were included in the meta- 
analysis, which fulfilled the following criteria: 
(i) study members were infected with chronic HCV, as determined by a positive result 
in serum from a first-, second- or third-generation enzyme-linked immunosorbent 
assay and confirmed by means of recombinant immunoblot assay or polymerase chain 
reaction233; 
(ii) study outcomes included a histopathological diagnosis of cirrhosis (graded based 
234,235,236,237,238,239,240,241 
on established scoring systems ), decompensated cirrhosis 
(defined clinically by the presence of bleeding oesophageal varices, ascites, hepatic 
encephalopathy, or hyperbilirubinemia), or advanced fibrosis (which includes both 
, 
240,241 
bridging fibrosis with many septa and cirrhosis237,238 ); 
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(iii) sufficient information was presented in the article to estimate the relative risk 
(RR) or odds ratio (OR) of the outcome, and its variance, associated with a category 
of high compared to low alcohol consumption. 
Eighteen articles, which were identified through the literature search and had 
reported on the alcohol intake and liver disease progression of persons infected with 
HCV, were excluded from the meta-analysis because either (a) the study outcome 
included moderate fibrosis 242,243,244,245, (b) the study was confined to patients with 
minimal or mild chronic hepatitis246, (c) the study outcome was analysed as a rate of 
change in fibrosis progression 247,248,249,250, (d) heavy alcohol (defined as at least 
280g251,252 and 350g253 per week) users were excluded, (e) alcohol had not been 
analysed in terms of categories 2sa, 
255,2s6, zsý g, or (f) members of the study were included 
in another article selected (with the most relevant data) for the meta-analysis25s, 259 
5.2.3 Extraction of data from articles 
The unadjusted and/or adjusted RRs or ORs, with 95% CIs or P values, for the 
outcome (either cirrhosis, decompensated cirrhosis or advanced fibrosis) associated 
with categories of alcohol consumption were extracted directly from the article; 
unadjusted risk ratios were not presented in eleven 
articles 224,260,2 but were calculated based on available crude 
data. Serfaty et al. 270 conducted a case-control study matched for age, gender, route 
and duration of HCV infection, and the OR for cirrhosis extracted from this article 
was taken as an adjusted value. Alcohol consumption measures were converted into 
grams (g) per week (assuming that one unit or drink of alcohol equalled 12g252). Three 
articles21o, 263,27o analysed alcohol consumption in terms of more than two categories 
(e. g. low, medium and high), and the risk estimate used in the meta-analysis from 
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these studies was the one that had compared the highest with the lowest or baseline 
category of alcohol intake. Given the reported higher alcohol intake and generally 
faster HCV disease progression among men compared to women271'272, it was also of 
interest to examine the differential risk of severe HCV disease by sex in these studies 
that had considered the effect of excessive drinking; thus, risk ratios associated with 
males compared to females were similarly extracted from these articles. 
5.2.4 Statistical analyses 
To derive pooled risk estimates, the RRs or ORs from each study were first 
transformed to the natural log scale and the associated variances calculated from 
either the published 95% CIs or P values273. Random- or fixed- effect methods, 
described by DerSimonian and Laird274, were used to obtain pooled relative risk 
estimates from the included studies, dependent on whether the test for heterogeneity 
(Q-statistic) was or was not significant at the 5% level, respectively 273 
Sensitivity analyses were carried out to examine the effect on the pooled 
relative risk estimate of the following possible sources of heterogeneity: analysis scale 
(i. e. odds ratio or relative risk), disease outcome (advanced fibrosis, cirrhosis or 
decompensated cirrhosis), and threshold for heavy alcohol intake (210-260,280-504 
or 560 grams per week; the middle category included one study which had defined 
heavy alcohol intake as >280g for women and >420g for men266). In addition, 
weighted linear regression models were performed to determine the significance of 
the effect of these study characteristics (i. e. analysis scale, disease outcome, and 
threshold for heavy alcohol intake) on the risk estimate (i. e. log RR or OR), weighted 
according to the precision of the risk estimate (i. e. inverse of the variance). S-PLUS 
software was used for all analyses 
122,275 
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5.3 Results 
5.3.1 Characteristics of studies 
The characteristics of the twenty articles that fulfilled the inclusion criteria for the 
meta-analysis are shown in Table 5.1. Thirteen studies were carried out in European 
countries (one of these also included participants from the United States), three in 
North America, two in Australia, one in South America and one in Japan. The studies 
ranged in size from 59 to 5,789 participants and together totalled 15,187 HCV 
chronically infected individuals. Of this total, 2,716 (18%) had progressed to 
advanced liver disease, defined as cirrhosis in 13 studies (77%: 2,090/2,716), 
advanced fibrosis in four studies (19%: 527/2,716), decompensated cirrhosis in two 
studies (3%: 74/2,716) and cirrhosis/HCC in one (1%; this study involved 20 subjects 
with cirrhosis only, 4 with both cirrhosis and HCC and one with HCC only267). 
HCV infection was attributed to injecting drug use and transfusion in 45% and 
35%, respectively, of all subjects included in these studies. In the range of 42% to 
100%, and overall 64%, of studies' participants were male and their average age at 
recruitment to the clinic or biopsy ranged between 31 and 61 years (Table 5.1). Six 
studies 210,264,266,269,270,276 excluded, and one study277 was confined to, HIV antibody 
positive individuals. Overall, 15% of 13,181 participants, from studies that reported 
data, were co-infected with HIV. Of the six studies that reported a prevalence of HIV 
infection above 5%, all except that by Thomas et a!. 
263 found a significantly increased 
risk of severe disease with HIV positivity (Table 5.2). 
The threshold for heavy alcohol consumption used in the analyses of these 
twenty studies ranged from 210g to 560g per week; the latter threshold was the most 
commonly applied in eight studies, followed by 350g per week used in three studies. 
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Wiley et a!. 266 and Roudot-Thoraval et al. 260 defined different levels of heavy alcohol 
intake between males (>420g and >504g per week, respectively) and females (>280g 
and >420g per week, respectively). Uptake of alcohol ranged from only 5% 
consuming >350g per week in the study by Poynard et a1.276 to 51 % consuming >420g 
and >290g among men and women, respectively, per week by Wiley et al. 266. An 
estimated 3,123 HCV chronically infected persons (21% of the total 15,187) were 
analysed as heavy alcohol users (though heterogeneously defined) in the twenty 
studies. 
5.3.2 Studies' risk estimates of severe HCV disease associated with heavy alcohol 
consumption 
The extracted risk estimates, and confidence intervals, of severe HCV disease 
associated with the consumption of alcohol from the twenty studies are presented in 
Table 5.2 (i). The matched case-control study by Serfaty et a!. 270 found a raised, but 
not significant, risk of cirrhosis with >560g of alcohol per week. Adjusted RR 
estimates of severe disease associated with heavy alcohol intake (defined in the range 
of at least 240g to 560g per week), presented in the other ten articles, were all 
significant at the 5% level and ranged from 1.6 to 11.8. Of the remaining nine studies, 
eight failed to identify a significant association between heavy alcohol consumption 
(defined in the range of at least 240g to 560g per week) and development of severe 
HCV disease 210,224,225,226,227,265,268,269' only unadjusted risk estimates of this association 
were reported in these nine studies and were included with the adjusted results from 
the other eleven studies in the following meta-analysis. 
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5.3.3 Meta-analysis of the risk of severe HCV disease associated with heavy 
alcohol consumption 
The pooled RR estimate of severe disease (i. e. advanced fibrosis, cirrhosis or 
decompensated cirrhosis) associated with heavy alcohol intake (defined in the range 
of at least 210 to 560g per week) from the twenty studies was 2.14 (95% CI 1.61- 
2.85) by the random effects model, as the test for heterogeneity was highly significant 
(p<0.0001). Table 5.3 shows the pooled RR estimates of severe disease associated 
with heavy alcohol intake according to three possible sources of heterogeneity: 
analysis scale (i. e. odds ratio or relative risk), disease outcome (advanced fibrosis, 
cirrhosis or decompensated cirrhosis), and threshold for heavy alcohol intake (210- 
260,280-504 or 560 grams per week). The four studies that examined the association 
between heavy alcohol intake and advanced fibrosis produced the lowest pooled RR 
estimate (1.63; 95 % Cl 1.22-2.17), compared to those studies that examined the risk 
of cirrhosis (2.14; 1.45-3.17) or decompensated cirrhosis (3.54; 2.14-5.85). 
Figure 5.1 shows the individual study risk ratios and pooled RR (2.33; 95% CI 
1.67-3.26) from the sixteen studies that examined the association between heavy 
alcohol intake and development of cirrhosis or decompensated cirrhosis. No 
difference in risk of cirrhosis or decompensated cirrhosis was found between studies 
that calculated either relative risks (pooled: 2.3 1; 95% CI 1.33-4.02) or odds ratios 
(2.36; 1.52-3.65) (Table 5.3). Surprisingly, the pooled RR estimates for cirrhosis or 
decompensated cirrhosis decreased with a higher threshold of alcohol intake: 3.54 
(95% Cl 2.14-5.85), 2.30 (1.18-4.47) and 1.94 (1.26-2.99) with at least 210-260,280- 
504 and 560 grams of alcohol per week, respectively. However, the three 
studies 263,267,278 that used the threshold of 210-260g of alcohol per week had assessed 
the outcome of decompensated cirrhosis and therefore their relative risk estimates are 
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not directly comparable with those from the other thirteen studies that examined the 
outcome of cirrhosis. 
5.3.4 Studies' risk estimates of severe HCV disease for men compared to women 
Table 5.2 (ii) shows the risk ratios of severe HCV disease for men compared to 
women extracted from eleven, of the twenty, studies. Serfaty et al. 270 matched for 
gender in their case-control study and Khan et al. 268 confined theirs to males; thus 
both were unable to examine the risk of severe disease by this factor. In the remaining 
seven studies, three 222,260,279 reported no significant difference in prevalence of 
cirrhosis between men and women, but no data were presented to calculate the risk of 
severe disease by gender. Seven of the eleven studies, which reported risk ratios, 
failed to identify a significantly different risk of severe HCV disease between men 
210,225,226,227,261,266,269 and women Unadjusted and adjusted RR point estimates of 
severe disease for men compared to women (presented in nine and four articles, 
respectively) ranged from 0.6 to 3.6 and 1.0 to 2.6, respectively. Unadjusted risk 
ratios associated with gender, from articles that had not presented adjusted estimates, 
were combined with adjusted results in the following meta-analysis. 
5.3.5 Meta-analysis of the risk of severe HCV disease for men compared to 
women 
The pooled RR estimate of severe disease (i. e. advanced fibrosis, cirrhosis or 
decompensated cirrhosis) for men compared to women from the nine studies was 1.38 
(95% Cl 1.13-1.69) by the fixed effects model, as the test for heterogeneity was not 
significant (p=0.1). Table 5.4 shows the RR estimates of severe disease for men 
compared to women pooled according to the analysis scale and disease outcome used 
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in studies; results were not pooled in this analysis according to the threshold of heavy 
alcohol intake applied because only a minority of studies had adjusted gender effect 
estimates for alcohol consumption. A significantly higher pooled estimate was 
obtained from studies that calculated relative risks (2.31; 95% CI 1.51-3.52) rather 
than odds ratios (1.18; 0.94-1.49). The three studies that used the outcome of 
advanced fibrosis produced a lower pooled estimate (1.13; 95% CI 0.82-1.57) than 
those studies that examined the risk of cirrhosis (1.39; 1.05-1.84) or decompensated 
cirrhosis (2.94; 1.53-5.65). 
A pooled RR of 1.56 (95% CI 1.21-2.03) for men compared to women was 
generated from the eight studies that examined the outcome of cirrhosis or 
decompensated cirrhosis. A higher, but not significantly different, risk of cirrhosis or 
decompensated cirrhosis was found with the studies that calculated relative risks 
(pooled: 2.31; 95% CI 1.51-3.52) compared to odds ratios (1.24; 0.89-1.72) (Table 
5.4). 
5.4 Discussion 
In chronic HCV, progression to cirrhosis is almost always the precursor to 
development of complications such as HCC and liver failure6. Thus, determining the 
factors that accelerate the rate of progression to cirrhosis is a priority for HCV natural 
history research. Excess alcohol consumption is likely to result in more severe hepatic 
injury, promoting pathologic progression to cirrhosis among patients with chronic 
HCV280. This meta-analysis estimates the pooled RR of cirrhosis, including 
decompensated cirrhosis, associated with heavy alcohol intake (defined in the range 
of at least 210 to 560g per week) to be 2.33 (95% Cl 1.67-3.26), derived from sixteen 
studies involving a total of 13,706 HCV chronically infected persons. 
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Studies investigating the risk of HCV-related cirrhosis with alcohol involved 
subjects who had presented to liver clinics, with the exception of those recruited 
during the Dionysos general population survey267, and had undergone a liver biopsy. 
This biased accrual will tend to dampen the estimated regression effect of prognostic 
indicators as recruited subjects will likely have more advanced liver disease, causing 
them to present for clinical assessment, and be more prognostically alike than other 
members of the HCV chronically infected populations where they resided. Moreover, 
heavy alcohol users could have been under-represented in some studies, as patients 
consuming alcohol at toxic levels may have been precluded from biopsy265 and those 
with histological features of alcoholic hepatitis were excluded from some 
analyses 
265,266 Such selectivity may have under-estimated the regression effect of 
alcohol on progression to cirrhosis in the meta-analysis. 
The extent of alcohol consumption in these studies is necessarily based on 
self-reporting, since no other marker is able to establish past intake231. Responses 
could therefore be affected by patients' inability to recall past consumption levels, 
unwillingness to admit true intake and changes in drinking habits281. Questionnaires 
asking about recent and lifetime alcohol ingestion nevertheless appear to have 
satisfactory test-retest reliability2g2'2g3'284. Lifetime alcohol consumption, or that 
overlapping with duration of HCV infection, has been suggested as the most 
appropriate measure to assess the dose determining liver damage' 
80,255 Most 
investigators have instead measured alcohol intake over short periods of time, such as 
during the one to five years prior to HCV diagnosis or histological examination. None 
of the studies included in the meta-analysis analysed alcohol use as a time-dependent 
covariate to accommodate the changing behaviour of patients, particularly in response 
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to medical advice following HCV diagnosis, and explore the impact of curtailed 
drinking on liver disease progression. 
Studies varied widely in their definition of significant alcohol intake, ranging 
between 210 and 560g per week, and so the true threshold above which alcohol 
accelerates HCV disease progression remains uncertain231. The same levels of intake 
have been reported with an increased risk of alcoholic liver disease285. In a large 
population-based prospective study of 13,285 individuals, the risk of alcohol-induced 
liver disease increased significantly from as low as 84-156g per week for women and 
168-324g per week for men, and continued to increase with higher levels of alcohol 
intake272. In contrast, the meta-analysis found a slightly lower pooled RR estimate for 
HCV-related cirrhosis with a higher threshold of alcohol intake: 2.30 (95% CI 1.18- 
4.47) and 1.94 (1.26-2.99) with at least 280-504 and 560g of alcohol per week, 
respectively. It is possible that some studies chose the threshold of heavy alcohol use 
in the range of 280-504g per week during, rather than prior to, the analyses stage as a 
result of a significant association with cirrhosis; the product of which would have 
inflated the pooled RR for this group. 
Analyses of different endpoints of severe disease have also made it difficult to 
compare findings on the relationship between alcohol and chronic HCV. The risk of 
HCV-related disease associated with heavy alcohol intake increased with the severity 
of the outcome: the lowest (1.63; 95% CI 1.22-2.17) and highest (3.54; 2.14-5.85) 
pooled RR estimates were obtained for advanced fibrosis and decompensated 
cirrhosis, respectively. 
Chronic HCV has been shown to be histologically milder in women than 
men276. Wiley et al. 
266 indicated that the difference in risk of HCV-related cirrhosis 
between the sexes could be explained by the higher consumption of alcohol among 
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men compared to women. A complicating factor is that there is also evidence to 
suggest that women may be more susceptible to the adverse effects of alcohol at lower 
levels of consumption than men. The population-based Dionysos study found the risk 
of cirrhosis was twice as high in women as in men with the same amount of alcohol 
intake286. Poynard et al. 276 and Harris et al. 278 both reported a significantly increased 
risk of HCV-related severe disease (cirrhosis and decompensated cirrhosis, 
respectively) for men compared to women (risk ratios: 2.0,95% CI 1.2-3.3; and 2.6, 
1.1-5.9, respectively), after adjustment for heavy alcohol intake (defined as >350 and 
? 240g per week, respectively) and other factors. Overall, a lower RR estimate (1.56, 
95% Cl 1.21-2.03) comparing men to women was obtained from the eight studies that 
examined, in either unadjusted or adjusted analyses, the outcomes of cirrhosis and 
decompensated cirrhosis. Unfortunately, only three 266'276'278 of these eight studies 
presented risk estimates of HCV-related cirrhosis by gender from multi-factorial 
analyses, and so it was not possible to fully assess if the raised risk for males 
diminished after adjusting for the influence of heavy alcohol use. 
In conclusion, studying the relationship between HCV and alcohol is 
inherently problematic because of difficulties in obtaining an accurate history of 
alcohol use and clinic-recruitment biases. The role of alcohol in HCV-related cirrhosis 
may therefore be under-estimated. Nevertheless, the evidence overwhelmingly shows 
a worsened outcome for those with chronic HCV and concurrent alcohol use. The 
amount of alcohol that can be safely consumed by patients with HCV is unclear; 
published data show that even moderate intake can increase the severity of liver 
disease231. Alcohol consumption should be minimised as much as possible in those 
who have chronic HCV until a safe threshold is more definitively determined. 
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Table 5.3: Pooled¶ relative risk estimates of the outcome (advanced fibrosis, cirrhosis or 
decompensated cirrhosis) associated with heavy alcohol intake compared to less than heavy alcohol 
intake among HCV chronically infected patients: results of a meta-analysis. 
Study characteristics Number of Pooled Relative Risks Heterogeneity Significance of 
studies (95% Cl) Q-statistic (P-value) characteristic: 
P-value 
ALL STUDIES 
Total 20 2.14 (1.61-2.85) 70.1 (<0.0001) - 
Analysis scale Odds ratio 14 2.08 (1.48-2.94) 49.3 (<0.0001) Baseline 
Relative risk 6 2.31 (1.33-4.02) 17.2 (0.004) 0.34 
Outcome Advanced fibrosis 4 1.63 (1.22-2.17) 3.9 (0.3) 0.14 
Cirrhosis 13 2.14 (1.45-3.17) 55.3 (<0.0001) Baseline 
Decompensated cirrhosis 3* 3.54 (2.14-5.85) 0.4 (0.8) 0.54 
Threshold for heavy 210-260 4 2.38 (1.61-3.52) 6.4 (0.1) Baseline 
alcohol intake (g/week) 280-504 8 2.07 (1.30-3.30) 39.7 (<0.0001) 0.75 
560 8 1.94 (1.26-2.99) 14.7 (0.04) 0.46 
STUDIES WHICH ANALYSED OUTCOMES: COMPENSATED AND DECOMPENSATED CIRRHOSIS 
Total 16 2.33 (1.67-3.26) 57.0 (<0.0001) - 
Analysis scale Odds ratio 10 2.36 (1.52-3.65) 32.9 (<0.0001) Baseline 
Relative risk 6 2.31 (1.33-4.02) 17.2 (0.004) 0.19 
Threshold for heavy 210-260 3 3.54 (2.14-5.85) 0.4 (0.8) Baseline 
alcohol intake (g/week) 280-504 5 2.30 (1.18-4.47) 27.2 (<0.0001) 0.76 
560 8 1.94 (1.26-2.99) 14.7 (0.04) 0.18 
 Pooled estimate was derived using random or fixed effects methods according to whether the test for 
heterogeneity was significant at the 5% level or not, respectively. 
* Included the study by Bellentani et al. 287 that analysed the combined outcome of cirrhosis and HCC. 
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Figure 5.1: Individual study adjusted* and pooled relative risk estimates of cirrhosis associated with 
heavy alcohol intake compared to less than heavy alcohol intake among HCV chronically infected 
patients: results of meta-analysis (excludes four studies which estimated the risk for advanced 
fibrosis). 
Author, year of publication 
Strasser, 1995* 
Serfaty, 1997 
Roudot-Thoraval, 1997 
Verbaan, 1988 
Pol, 1998a 
Pol, 1998b 
Khan, 1998* 
Wiley, 1998 
Bellentani, 1999* 
Khan, 2000; 
Loguercio, 2000* 
Thomas, 2000 
Poynard, 2001 
Di Martino, 2001 
Harris, 2002 
Monto, 2004* 
Pooled 
0.25 1.00 3.25 11.50 45.75 
Relative Risk (95% CI) 
* Studies that reported only the unadjusted relative risk, which are presented above. 
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Table 5.4: Pooled¶ relative risk estimates of the outcome (advanced fibrosis, cirrhosis or 
decompensated cirrhosis) associated with male compared to female HCV chronically infected patients: 
results of a meta-analysis. 
Study characteristics Number of Pooled Relative Risks Heterogeneity Significance of 
studies (95% CI) Q-statistic (P-value) characteristic: 
P-value 
ALL STUDIES 
Total 11 1.38 (1.13-1.69) 17.1 (0.1) - 
Analysis scale Odds ratio 8 1.18 (0.94-1.49) 8.5 (0.3) Baseline 
Relative risk 3 2.31 (1.51-3.52) 1.2 (0.5) 0.03 
Outcome Advanced fibrosis 3 1.13 (0.82-1.57) 1.0 (0.6) 0.45 
Cirrhosis 6 1.39 (1.05-1.84) 9.4 (0.1) Baseline 
Decompensated cirrhosis 2 2.94 (1.53-5.65) 0.2 (0.7) 0.11 
STUDIES WHICH ANALYSED OUTCOMES: COMPENSATED & DECOMPENSATED CIRRHOSIS 
Total 8 1.56 (1.21-2.03) 13.9 (0.1) - 
Analysis scale Odds ratio 5 1.24 (0.89-1.72) 7.4 (0.1) Baseline 
Relative risk 3 2.31 (1.51-3.52) 1.2 (0.5) 0.11 
U Pooled estimate was derived using random or fixed effects methods according to whether the test for heterogeneity was 
significant at the 5% level or not, respectively. 
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Chapter 6: Modelling the current and future disease burden of hepatitis C 
among injecting drug users in Scotland 
6.1 Introduction 
Hepatitis C virus (HCV) is a slowly progressive disease: a systematic review of the 
worldwide literature indicated that 4%-10% of those with active viraemia develop 
cirrhosis after twenty years of infection94. Studies have demonstrated considerable 
variability in rates of HCV disease progression because of the biased selection of 
cohorts with respect to disease stage and host characteristics. Factors most commonly 
shown to accelerate natural history include alcohol, co-infection with HIV, older age 
at HCV acquisition and male gender288. 
In most resource-rich countries, the majority of those with HCV acquired their 
infection in the late 1970s and 1980s167, before the identification of the virus and the 
availability of diagnostic tests. Given that chronic HCV does not result in major 
morbidity for many years, the impact of this infection on health care systems is only 
now becoming apparent. For example, HCV has become the leading cause of liver 
transplantation in the United States15. There are also concerns over the burgeoning 
medical costs of treating chronic HCV. In 2001, UK consensus guidelines on the 
clinical management of HCV infection recommended that antiviral treatment should 
be offered to patients without contraindications such as continued injecting who were 
shown to have moderate disease according to histological appearances289. Persons 
who are HCV seropositive but who are otherwise healthy are likely to represent a 
growing number of candidates for treatment. 
In Scotland, a total of 14,390 persons had been diagnosed with HCV 
antibodies by the end of June 200221. Among those for whom at least one risk factor 
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was known, almost 90% (8719/9728) had injected drugs, 6% (584/9728) had received 
blood or blood products and 4% reported occupational needlestick injuries, tattoos, 
body piercings or sexual contact. By the end of 2000, less than 10% of HCV 
diagnosed persons in Scotland had, however, received antiviral therapy52 and a further 
70-80% of the total HCV infected female population remained undiagnosed53. To plan 
an appropriate public health response to this HCV epidemic, in terms of both 
treatment needs and preventive measures, quantitative estimates of the current and 
future burden of HCV disease are required. 
In this chapter, the objectives were to develop a comprehensive model to 
estimate the numbers of, both current and former, injecting drug users (IDUs) in 
Greater Glasgow and Scotland belonging to different stages of HCV disease now and 
in the future. Modelling was confined to the IDU population because much of the 
epidemiological data available to date and the overwhelming majority of HCV 
transmissions in Scotland have been associated with this risk group. To determine the 
benefit of treating HCV chronically infected patients, the impact of different antiviral 
treatment strategies on the incidence of severe HCV-related disease was explored. 
6.2 Aims 
The primary aims were to develop a model to estimate: 
(i) the number of IDUs (categorised according to current and former status) who 
acquired HCV infection and progressed to mild, moderate and severe HCV 
disease in Glasgow and Scotland between 1960 and 2030; 
(ii) the number of cases of severe HCV-related disease (i. e. decompensated cirrhosis 
and HCC) among IDUs that could be prevented in the future through a range of 
antiviral treatment strategies. 
132 
6.3 Methods 
6.3.1 Overview 
The study involved three stages: (a) the development of an HCV disease progression 
model for the IDU population in Greater Glasgow (a region which has approximately 
a third of all IDUs in Scotland108 and a wealth of epidemiological data); (b) using the 
model developed in (a), a comparison of the impact of different antiviral treatment 
scenarios on severe sequelae of HCV infection; and (c) the extension of the model 
developed for Greater Glasgow in (a) to the entire Scottish IDU population. 
The progression model (a) was designed to incorporate both the knowledge 
and uncertainty about major parameters relating to (i) the IDU population (i. e. 
incidence and cessation of injecting and mortality), (ii) the characteristics of the IDU 
population affecting HCV progression (i. e. gender, age, co-infection with HIV and 
heavy alcohol intake), (iii) the incidence of HCV infection among current IDUs, and 
(iv) the rate of HCV disease progression (including the influence of host factors and 
the current uptake of antiviral therapy). Local data were used to inform parameters (i), 
(ii) and (iii), available up to 2000 (estimates from this year were applied in subsequent 
years, 2001-2030), and the world-wide literature was reviewed to inform on (iv). 
Modelled outcomes were fitted to available epidemiological data on the prevalent 
number of current IDUs, the prevalence of HCV infection among current IDUs, and 
the incident number of HCV-related decompensated cirrhosis cases among IDUs. 
6.3.2 Model structure 
In annual cycles between 1960 and 2030, Markov modelling was used to simulate 
individuals' progression from commencement of injecting drug use through 
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predefined HCV disease states until death (Figure 6.1). Progression annually from one 
state to another was based on transition probabilities derived from a comprehensive 
review of the literature (described below). The model distinguishes between HCV 
uninfected, chronically infected, and previously, but no longer, infected persons. Once 
chronically infected, cases had the potential to progress sequentially to moderate 
disease, compensated cirrhosis, and then either decompensated cirrhosis or HCC. For 
example, each year, former IDUs with mild chronic HCV infection could either 
develop moderate disease, remain stable with mild disease or die from causes 
unrelated to HCV. Transplantation was also a possibility for decompensated cirrhosis 
cases. 
Persons belonging to the group with moderate disease benefit most cost- 
effectively54 from, and should therefore be offered, antiviral therapy as recommended 
by the Royal College of Physicians of London and the British Society of 
Gastroenterology289 (i. e. those with histological appearances of 3-5/6 on fibrosis score 
and/or > 3/18 on necroinflammatory score240). In the model, persons were further 
characterised according to age, gender, heavy alcohol use and co-infection with HIV 
(described below) to explore the influence of these factors on progression from 
chronic HCV infection to cirrhosis. Persons exit the model upon death from causes 
unrelated (specified separately for current and former IDUs) and related to HCV (i. e. 
decompensated cirrhosis, HCC and post-transplantation). By tracking individuals' 
development of HCV-related complications each year, during 1960-2030, the model 
estimates past, current and future HCV-related morbidity and mortality. The software 
used to generate simulations was SPLUS122. 
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6.3.3 Model parameters 
6.3.3.1 The IDU population: incidence and cessation of injecting and mortality 
Estimates of the incidence and cessation of injecting and mortality among current 
IDUs, each calendar year between 1960 and 2000 in Glasgow, were derived through 
the use of (i) a modified Delphi approach, which combined expert opinion with 
capture-recapture IDU prevalence estimates (Figure 3.1), and (ii) an annual rate of 
mortality, from overdose and other causes (unrelated to HCV and HIV), in the range 
of 1-2%I23,124,290,291 In the HCV progression model, current IDUs were assumed to 
have ceased injecting by 50 years of age, because individuals newly attending drug 
services in Glasgow, who report injecting in the past month, were almost all aged 
under 50 years (99.9% of 8,362 during years 1995-2001; Scottish Drug Misuse 
Database, ISD, Edinburgh). The annual mortality of former IDUs from causes 
unrelated to HCV and HIV was also accounted for, and assumed to be two to five 
times higher83'292 than the average annual age- and gender-specific rates for the 
general Scottish population293 
6.3.3.2 The characteristics of the IDU population affecting HCV progression 
6.3.3.2.1 Gender and age 
The gender and age distributions of newly initiated IDUs were based on those 
reported among representative samples of current IDUs surveyed in Glasgow during 
the 1990s110: 27.5% (standard deviation of 2.5%) were assumed to be female 
(generated according to the normal distribution) and the mean age at commencement 
of injecting was assumed to be 17.5 years up until the mid 1980s, increasing linearly 
thereafter to 23.5 years by 2000 (generated according to the lognormal distribution, 
with a standard deviation on the logarithm scale of 0.2). 
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6.3.3.2.2 Co-infection with HIV 
The majority of HIV infections among IDUs in Scotland occurred during 1983-85 (an 
estimated 1,000 of whom only 15% resided in the Greater Glasgow area294). Mortality 
among HIV infected IDUs was based on data generated by the Collaborative Group 
on AIDS Incubation and HIV Survival295, and adjusted down (i. e. hazard rate reduced 
by 75%) for the period after 1995 to allow for increased survival due to the impact of 
Highly Active Anti-Retroviral Therapy. 
6.3.3.2.3 Heavy alcohol use 
Heavy alcohol intake, such as that above 50g per day (or 350g per week), increases 
the rate of liver disease progression in the HCV chronically infected person9s, 2io5 
some, but not all, studies have found even lower thresholds to be associated with an 
increased rate of progression 270,263 Alcohol consumption among current and former 
IDUs in Scotland, however, has not been well studied. Studies of drug users receiving 
drug treatment in England have reported prevalences in the range of 15- 
45%218,219,296,297 for either problem drinking or drinking above the recommended safe 
limits of 14 units (168g) per week for women and 21 units (252g) for men; further, no 
change in alcohol intake was detected among 276 opiate users pre and post initiation 
to methadone treatment298. To accommodate this range of uncertainty, three rates 
(0%, 20% and 40%) of heavy alcohol use were explored in the HCV projection 
model. 
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6.3.3.3 The incidence of HCV infection among current IDUs 
Estimates of the percentage of (i) uninfected current IDUs who acquired HCV and did 
not clear their infection (i. e. chronic infection), (ii) uninfected current IDUs who 
acquired HCV and spontaneously cleared their infection, and (iii) previously infected 
(but cleared their infection) current IDUs who were re-infected with HCV and did not 
clear their re-infection (i. e. chronic infection), each calendar year between 1960 and 
2000 in Glasgow, were generated (Figure 3.7). Briefly, stochastic simulation had been 
used to model the transmission of HCV according to the needle/syringe sharing 
behaviours of current IDUs in Glasgow and the characteristics (i. e. transmissibility 
and chronicity) of HCV infection; of note, 15-40% of current IDUs with newly 
acquired HCV were assumed to recover from their acute infection spontaneously 3'4 
and become susceptible to re-infection with HCV. Only those estimates of (i), (ii) and 
(iii) which provided modelled estimates of HCV seroprevalence consistent with 
survey data, obtained through community-wide studies of Glasgow IDUs between 
1990 and 199947, were used in the projection model (Chapter 3, Figure 3.6; 85% of 
1000 simulation runs were consistent with survey data). Model parameter values for 
the year 2000 were applied in subsequent years up to 2030. Given the slow course of 
HCV disease progression, cases newly infected in 2001-2030 would not impact 
greatly on the estimated burden of severe disease during this period. 
6.3.3.4 The rate of HCV disease progression 
In the progression model, individuals infected with chronic HCV were followed 
through a series of disease states, as shown in Figure 6.1. The transition rates, by 
which individuals progress from one disease state to another, were obtained through a 
review of the literature (described below). 
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6.3.3.4.1 Chronic HCV to moderate disease and compensated cirrhosis 
Progression from chronic HCV to compensated cirrhosis was modelled based on a 
Weibull distribution with cirrhosis prevalence estimated at 6.5% (95% CI 3.5-9.5%) 
and 20% (10-40%) after 20 and 40 years, respectively, according to a recent 
systematic review of nine community-based studies94'9s Progression from chronic 
HCV to moderate disease (defined as 3-5/6 on fibrosis stage and/or >3/18 on 
necroinflammation grade240), similarly, was estimated from these community-based 
studies (except that only three of the nine studies reported relevant data, Table 6.1). 
An estimated 56% (43-70%) of chronically infected cases had moderate disease after 
20 years. 
An increased rate of progression to cirrhosis among chronically HCV infected 
individuals who were (i) male (relative risk 1.56,95% CI 1.21-2.03; Chapter 5), (ii) 
older at HCV acquisition (1.08 per year, 1.04-1.12)299, (iii) co-infected with HIV 
(2.92,1.70-5.01)221, and (iv) heavy alcohol users (2.33,1.67-3.26; Chapter 5) was also 
explored in the model. The assumed risks of cirrhosis at 20 and 30 years following 
chronic infection according to these characteristics are detailed in Table 6.2. 
6.3.3.4.2 Compensated cirrhosis to decompensated cirrhosis, HCC and death 
The transition rates of HCV chronically infected persons following the development 
of compensated cirrhosis are detailed in Table 6.3 and referred to as transitions (i)- 
(vii). The annual probability of liver transplantation (iii) among decompensated 
cirrhosis cases was based on the Scottish data presented in Chapter 4.4.6. For the 
remaining transition rates, pertinent English-language papers were identified through 
the PubMed database which was searched to the end of January 2004 using the terms 
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"hepatitis C" and either "cirrhosis", "hepatocellular carcinoma" or "liver 
transplantation", and augmented by additional citations from these papers. 
Quantitative data were extracted from each paper on (A) the cumulative 
probability (s(t)) of not progressing to the outcome (or who had survived) at t years 
(t=5 for transitions (i), (ii), (iv), (vii); t=2 for (v); t=1 for (vi)); (B) the total number of 
subjects (n); and (C) the number (or estimate of the number) of subjects censored 
(c(t)) prior to t years; probabilities s(t) were converted into average annual 
progression rates (i. e. 1-s(t)11) and are presented in Table 6.3. Pooled estimates (with 
95% CIs) of s(t) were derived using random effects 273'275, where the variance of s(t) 
was estimated using Peto's method300 (i. e. s(t)(1-s(t))/(n-c(t)) ), and then converted 
into annual progression rates as above; the 95% Cl ranges of the pooled annual 
progression rates were used in the model (Table 6.3). 
6.3.3.4.3 Current uptake of antiviral therapy 
The model was also designed to take account of chronically HCV infected former 
IDUs' (with moderate disease) initiation on, and response to, antiviral therapy. Other 
factors influencing eligibility for treatment in clinical practice (e. g. heavy alcohol use, 
HIV co-infection and psychiatric status) were not considered. Clearance of the virus 
was estimated at 20%, 40% and 50% with interferon alone, interferon plus ribavirin 
and pegylated interferon plus ribavirin, respectively3oi, 3oz, s Compliance to HCV 
treatment once initiated was assumed to be 90%303,304 Re-treatment of non-responders 
to initial course of antiviral therapy was not considered in the model. The number of 
IDUs who had been initiated on antiviral therapy in Scotland by the end of 2003 was 
estimated, optimistically, at 1,500 based on limited data52; a third were assumed to 
reside in Greater Glasgow and 25%, 30% and 45% were assumed to have received 
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treatment during 1993-97 (with interferon alone), 1998-2000 (with interferon plus 
ribavirin) and 2001-03 (with interferon plus pegylated interferon), respectively. 
Uptake of treatment in subsequent years was set the same as in 2003; different uptake 
rates were also applied to assess the potential of antiviral therapy to reduce the 
incidence of severe HCV disease in the future (described below). 
6.3.4 Model fitting 
The aim of the model fitting process was to assess the validity of model assumptions - 
in particular, progression to compensated cirrhosis and the influence of host factors 
(Table 6.2) - to generate outcomes consistent with available epidemiological data. 
Each simulation generated estimates of the number of new decompensated cirrhosis 
cases per year (Si) which were compared with the expected number determined 
through record-linkage (R), for years 1996-2001 (Table 4.6), using a standard x2 
goodness-of-fit measure. If the goodness-of-fit test statistic 
cool (S - R' 
)2 
was 
i=1996 
Rr 
less than 20.52, the 99.9% critical value for the x2 distribution on 5 degrees of 
freedom, the simulated data were regarded as consistent with the record-linkage data; 
the 99.9%, instead of 95% (i. e. 11.07), critical value was chosen to allow for 
uncertainty in the number of cases derived through record-linkage. Simulations were 
performed until 1,000 accumulated which produced simulated results consistent with 
record-linkage data by this criterion. 
6.3.5 Different antiviral treatment scenarios 
The number of HCV chronically infected former IDUs initiated on antiviral therapy in 
Glasgow in 2005, and in each year thereafter, was increased from the estimated 
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current uptake of 75 to a range of maxima of 250,500, and 1,000 per year. The stage 
of chronic HCV disease at which former IDUs were initiated on treatment was varied 
between (i) moderate disease only, (ii) a combination of moderate disease and 
compensated cirrhosis, and (iii) a combination of mild disease and moderate disease; 
the response to antiviral therapy was assumed the same irrespective of the stage of 
chronic HCV disease. The number of severe HCV-related events (i. e. decompensated 
cirrhosis and HCC) potentially prevented among IDUs in Glasgow as a result of the 
above different treatment scenarios during 2005-30 was estimated. 
6.3.6 Extension of model to the entire Scottish IDU population 
The model developed for Glasgow was adapted to the whole of Scotland, based on 
available epidemiological data, by adjusting four key parameters. First, the number of 
individuals who commenced injecting each calendar year was increased (2-fold that 
used for Glasgow by 1980, increasing to 3-fold by 1990 and 4-fold by the mid-1990s) 
in accordance with data on the prevalence of current IDUs in Scotland'°°"°g 
Secondly, the percentage of current IDUs who acquired HCV infection each calendar 
year was halved for Scotland compared to that for Glasgow in 1987 onwards, in 
accordance with HCV seroprevalence data among current IDUs in Scotlandso, ioo 
Thirdly, 1,400 current IDUs were infected with HIV in Scotland during 1983-2000 
(the majority during 1983-85 as described in 6.3.3.2.2). Fourthly, 1,500 former IDUs 
with chronic HCV infection and moderate disease in Scotland were assumed to have 
been initiated on antiviral therapy by the end of 2003 (as described in 6.3.3.4.3). All 
other parameters on cessation of injecting, characteristics of IDUs, HCV disease 
progression and mortality rates were retained the same as in Glasgow. The model for 
Scotland was fitted to record-linkage data on the estimated incident number of 
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decompensated cirrhosis cases for 1997-2001 (as described in 6.3.4; however, the 
period here was restricted to 1997-2001 because of the steeper rise in cases between 
1996 and 1997 in Scotland (42%) than in Glasgow (30%), which may have resulted 
from later implementation of widespread HCV antibody testing across all regions). 
6.4 Results 
6.4.1 Assessment of HCV disease progression model 
Models which excluded and included the relative risk effect of covariates (i. e. gender, 
age, co-infection with HIV and heavy alcohol use) on progression to cirrhosis and a 
range of uptake rates for heavy alcohol use (i. e. 0%, 20% and 40%) were assessed. 
Excluding the effect of covariates on progression to cirrhosis under-estimated the 
incident number of decompensated cirrhosis cases among ever IDUs in Glasgow 
between 1996-2001 (a mean total of 72 was modelled compared to 158 estimated 
through record-linkage, Table 4.6); and in only 9% of simulations was consistency 
achieved with record-linkage results. Model consistency improved to 15%, 27% and 
40% following the inclusion of the covariate effects with rates of heavy alcohol use at 
0%, 20% and 40%, respectively. Covariate-specific relative risk estimates for 
progression to cirrhosis among HCV chronically infected individuals produced by 
consistent simulations were similar to those employed a priori: 1.57 (95% Cl 1.20- 
2.06) for males, 1.08 per year (1.04-1.12) for age at HCV acquisition, 2.82 (1.74-4.97) 
for HIV co-infection, and 2.38 (1.72-3.43) for heavy alcohol use. 
Simulations which achieved consistent results had employed a higher 
progression to cirrhosis at 20 years than had been assumed initially based on 
published studies (i. e. 6.5%, 95% CI 3.5-9.5%). Therefore, increasing the overall 
progression to cirrhosis at 20 years to 7.5% (95% Cl 5-10%) generated higher 
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consistency still: 53% in the Glasgow model with covariate effects and 40% uptake of 
heavy alcohol use, and 27% with the equivalent model for Scotland. The consistent 
simulations from these models were used to generate outcomes hereafter. Applying a 
different model fitting approach, which compared simulated results with 50 
realisations from the Poisson distribution using a x2 goodness-of-fit measure with a 
95% critical value, produced a slightly higher consistency for the Glasgow model of 
59%. 
6.4.2 Comparison of modelled and available epidemiological data 
6.4.2.1 The prevalent number of current IDUs 
The modelled prevalent numbers of current IDUs in Glasgow (mean and 95% CI for 
years 1990 and 2000: 8,400,7,500-9,700; and 7,000,6,200-8,400, respectively) and 
Scotland (mean and 95% Cl for years 1990 and 2000: 22,200,18,700-26,700; and 
26,000,19,000-37,200, respectively) were consistent with published estimates 
generated mainly through capture-recapture studies (Glasgow 1990 and 2000: 8494, 
95% Cl 7,490-9,72018; 7187,95% CI 6,085-8,615100, respectively; and Scotland 1990 
and 2000: 21,700108 and 25,140 respectively). 
Of the modelled mean of 7,000 current IDUs in Glasgow during 2000,28%, 
59% and 13% were estimated to be aged <25,25-34 and >35 years, respectively; a 
distribution which was slightly younger than that derived through capture-recapture 
techniques (23%, 63% and 14%, respectively; personal communication: Dr. Gordon 
Hay, University of Glasgow). For all Scotland, 31%, 58% and 11% were estimated to 
be aged <25,25-34 and >35 years, respectively; a distribution which was comparable 
with that derived through capture-recapture techniques (30%, 56% and 14%, 
respectively; personal communication: Dr. Gordon Hay, University of Glasgow). 
143 
6.4.2.2 The annual number of drug-related deaths 
The modelled mean annual number of deaths among current IDUs, unrelated to HCV 
and HIV, was in the range 100-110 (limits of 95% CIs: 70-160) and 350-390 (220- 
640) between 1999-2002 for Glasgow and Scotland, respectively. Given that 90% of 
these deaths were drug-related305, these ranges compare reasonably with the reported 
number of drug-related deaths during this period by the Scottish General Register 
Office of 96-126 for Glasgow and 291-382 for Scotland3o6 
6.4.2.3 The prevalence of HCV infection among current IDUs 
The modelled seroprevalences of HCV among current IDUs in Glasgow (mean and 
95% CI for years 1990 and 2000: 71%, 62-81%; and 62%, 53-73%, respectively) and 
Scotland (mean and 95% CI for years 1990 and 2000: 58%, 46-67%; and 45%, 38- 
52%, respectively) were generated in accordance with published epidemiological data 
(Glasgow 1990-91 and 2000: 74%, 95% CI 67-82%47; 62%, 95% CI 58-66%s°1 
respectively; and Scotland 2000: 44%, 95% CI 30-54%100 
6.4.2.4 The incident number of HCV-related decompensated cirrhosis cases 
Figure 6.2 presents the modelled and expected annual incident number of 
decompensated cirrhosis cases among HCV chronically infected IDUs in (a) Glasgow 
and (b) Scotland during 1980-2030. The number of IDUs with newly developed 
decompensated cirrhosis each year was estimated to double approximately between 
2000 and 2020 in Glasgow (26 to 61; 95% CIs 16-38 and 33-99, respectively) and 
Scotland (81 to 154; 95% CIs 61-101 and 90-236, respectively). During periods 1990- 
1995 and 1996-2001,15-23% and 7-12% of HCV-related decompensated cases in 
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Scotland, respectively, were estimated to be co-infected with HIV (compared to 5- 
10% and 2-4% in Glasgow, respectively), which contributed to the sharp rise in cases 
during the earlier period. 
6.4.3 Modelled HCV disease burden among IDUs in Glasgow and Scotland 
Figure 6.3 illustrates the rise in the prevalent number of HCV infected (both current 
and former) IDUs in (a) Glasgow and (b) Scotland from only 1,700 (95% CI 800- 
2,800) and 3,800 (1,900-6,100) in 1980 to 15,700 (12,700-20,600) and 37,800 
(28,000-53,200) in 2000, respectively. The prevalent number continued to increase 
during 2001-30 as a result of applying the estimated incidence of HCV infection from 
2000 in subsequent years. In 2000,12,100 (9,700-15,800) and 28,700 (21,200-40,700) 
in Glasgow and Scotland, respectively, were estimated to have chronic HCV 
infection; 8,700 (6,300-12,600) and 19,900 (13,700-29,200) of these, respectively, 
were among former IDUs (Table 6.4). Among HCV chronically infected former IDUs 
in Glasgow, the number with moderate disease was estimated to increase 2.5,3.7 and 
4.1 -fold between 2000 (a mean of 2,100; 95% CI 1,200-3,700) and 2010 (5,200; 
3,600-7,400), 2020 (7,800; 5,800-10,300) and 2030 (8,600; 5,600-12,300), 
respectively. The prevalent number of cirrhotic HCV infected (both current and 
former) IDUs in Glasgow were estimated to rise 1.6,2.4 and 2.6 -fold between 2000 
(mean of 500; 95% Cl 400-700) and 2010 (800; 600-1,200), 2020 (1,200; 700-1,800) 
and 2030 (1,300; 700-2,400), respectively. 
6.4.4 Modelled stage of HCV disease by age among Glasgow IDUs in 2005 
Figure 6.4 illustrates the estimated increasing severity of HCV disease with age 
among current and former Glasgow IDUs in 2005. The mean prevalence of moderate 
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disease and cirrhosis increased from 2% and 0% among (both current and former) 
IDUs aged under 30 years to 32% and 17% among those aged 50 years or more, 
respectively. Of relevance in terms of targeting HCV treatment, the mean estimated 
prevalence of moderate disease in 2005 was 16% and 27% among all former IDUs 
aged 30-39 and 40-49 years, respectively. 
6.4.5 Modelled HCV disease progression over 45 years among Glasgow IDUs 
who commenced injecting in 1985 
Figure 6.5 illustrates the mean progression of a cohort of Glasgow IDUs through 45 
years following their commencement of injecting in 1985 (at mean age of 17.5 years). 
The mean percentage of IDUs who had died from HCV-related causes (i. e. liver 
failure and HCC) was 11 % within 45 years of their injecting debut, and a further 11 % 
and 40% had died from causes unrelated to HCV (or HIV) as current and former 
IDUs, respectively. 
6.4.6 Modelled impact of different treatment scenarios on severe HCV disease 
A total of 2,180 IDUs in Glasgow were estimated to develop severe HCV disease 
(consisting of 1,460 and 720 cases of decompensated cirrhosis and HCC, respectively) 
during 2005-2030, with no uptake of antiviral therapy. Table 6.4 (a) shows the 
number of cases of severe HCV-related disease that could be prevented during 2005- 
30 among IDUs in Glasgow through a range of antiviral treatment strategies. An 
estimated 60 cases, and only 3% of the total number, of severe disease could be 
prevented over 2005-30 with the current level of treatment to former IDUs (with 
moderate HCV disease) in Glasgow of 75 treated cases per year. Increasing the 
number initiated on antiviral therapy from 75 to 250,500 and 1,000 former IDUs 
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(with moderate disease) per year was estimated to prevent a further 100,230 and 350 
severe HCV disease cases, respectively. Almost twice as many severe HCV events 
could be prevented if former IDUs with compensated cirrhosis had the same 
opportunity to be initiated on, and if they could respond as well to, antiviral therapy as 
those with moderate disease. 
Of the 2,180 IDUs in Glasgow who were estimated to develop severe HCV 
disease during 2005-2030,1,690 (78%) had become cirrhotic post 2005. Tables 6.4 
(b) and (c) show the number of severe HCV-related disease events during 2005-30, 
among the 1,690 who had become cirrhotic post 2005, which could potentially be 
prevented and not prevented (i. e. unsuccessfully treated), respectively, by a range of 
antiviral treatment strategies. Only 3% to 27% of severe HCV-related events during 
2005-30, among those who became cirrhotic post 2005, could be prevented by 
treatment of 75 to 1,000 former IDUs, respectively, with either mild or moderate 
HCV disease; however, a further 6% to 43% had been treated unsuccessfully, 
respectively. Thus, treatment with more effective antiviral therapies, than currently 
available, of 75 to 1,000 former IDUs (with either mild or moderate HCV disease) 
could potentially prevent in the ranges 3-9% and 27-70% of severe HCV-related 
events during 2005-30, respectively. Similarly, treatment of 75 to 1,000 former IDUs 
- with either moderate disease or compensated cirrhosis - could potentially prevent in 
the ranges 4-15% and 28-96% of severe HCV-related events during 2005-30, 
respectively (Table 6.4). 
6.5 Discussion 
This is the first attempt to estimate the current and future burden of HCV disease in 
Scotland related to injecting drug use, which will aid the planning of a public health 
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response to this epidemic. A total of 17,400 (95% CI 14,300-22,200) and 42,900 
(32,400-60,600) persons, who had ever injected drugs, were estimated to be living 
with HCV antibodies by the end of 2003 in Glasgow and Scotland, respectively. This 
compares with approximately 5,000 (29%) and 13,900 (32%) diagnosed, respectively 
(assuming 77% of all diagnosed cases were IDUs and alive at the end of 2003, 
Chapter 4). Of these HCV-infected IDUs in Glasgow and Scotland, 13,200 (95% CI 
10,800-16,900) and 32,200 (24,300-45,500) were estimated to be living with chronic 
HCV and therefore at risk of developing cirrhosis. In Glasgow and Scotland 
respectively, it was further estimated that 210 (95% CI 140-330) and 750 (490-1,060) 
HCV-infected IDUs had died prematurely from liver failure by the end of 2003, 
mainly over the last decade; this compares with 38 and 352 IDUs known to have died 
from AIDS in Glasgow and Scotland, respectively (Personal Communication: Glenn 
Codere, SCIEH). 
The number of IDUs developing HCV-related decompensated cirrhosis in 
Scotland is estimated approximately to double between 2000 and 2020. Modelling 
efforts in other countries have predicted similar rises in HCV-related complications: 
mortality from HCV-related liver disease is estimated to increase 2-fold between 2000 
and 2020 in the United States82'84,2.5-fold between 1990 and 2020 in France 79, and 
1.9-fold between 1998 and 2020 in Switzerland86; in Australia, the number of people 
living with HCV-related cirrhosis is estimated to more than triple between 2000 and 
202081. 
Several countries have developed models to forecast the future course of their 
HCV epidemic, but few have validated their predictions, as in this study, by fitting 
model outcomes to past epidemiological trends relating to HCV and its 
consequences79'83. The aim here was to capture the essential features of the HCV 
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epidemic among IDUs, initially in Glasgow because more epidemiological data exist 
for this region than elsewhere in Scotland, and calibrate model parameters with data, 
principally, on the prevalent number of current IDUs, the prevalence of HCV 
infection among current IDUs and the incident number of HCV-related 
decompensated cirrhosis cases among IDUs. Insights gained from the model fitting 
process in Glasgow, such as on the rate of progression to cirrhosis, were used to apply 
the model to the whole of Scotland. 
The importance of including the effect of age and gender on the progression of 
chronic HCV in models has reviousl been illustrated 79'83 py but the potential 
limitation, in terms of under-estimating HCV disease burden, of excluding the 
influence of alcohol abuse and HIV co-infection has mostly only been 
acknowledged 79'82'86. Discounting the influence of these four factors on disease 
progression and assuming a prevalence of cirrhosis at 20 years of 6.5% (95% CI 3.5- 
9.5%), consistent with a recent systematic review94, under-estimated the number of 
IDUs developing liver failure in Glasgow during 1996-2001 by more than half that 
expected from the record-linkage data (Chapter 4). For Glasgow, consistency between 
model and record-linkage data improved by allowing disease progression rates to 
depend on age at HCV acquisition, gender, HIV co-infection and heavy alcohol use. 
However, the results still indicated that either (i) the prevalence of cirrhosis at 20 
years was higher than the mean of 6.5% assumed, (ii) the increased rate of disease 
progression by co-factors - age, gender, HIV co-infection and alcohol - had been 
under-estimated, or (iii) the heterogeneity in progression had not been fully explained. 
Projections clearly rely on the accuracy of the model assumptions used to 
derive them. The expected numbers of IDUs developing decompensated cirrhosis, 
data which are integral to the model fitting process, were based on the number of 
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HCV diagnosed individuals admitted to hospital with this complication, which were 
then adjusted to account for the proportion associated with injecting drug use (88%) 
and the non-hospitalisation (14%) and non-HCV-diagnosis (18%) of decompensated 
cases (Chapter 4). To allow for the uncertainty in the estimated number of IDUs 
developing decompensated cases, the 99.9% critical value with the x2 test statistic was 
used to assess the goodness-of-fit. The specification of ranges around model 
parameters were derived, through the synthesis of numerous sources of data from 
various studies, to encompass the full span of plausible values, but more formal 
methods for developing prior distributions for each parameter might allow a full 
Bayesian approach to model fitting. 
As new data become available, improvements in the modelling of the HCV 
epidemic in Scotland, as elsewhere, will be possible, leading to further refinement in 
these estimates. In particular, further research is needed to validate estimates of the 
incidence and cessation of injecting drug use, to examine the prevalence of heavy 
alcohol use by gender among current and former IDUs, and to assess the influence of 
age and gender on injector mortality152. Although mortality related to heavy alcohol 
use307 was not dealt with separately, the model assumed a raised risk of death from 
causes unrelated to HCV or HIV (i. e. two to five times higher the average age and 
gender general population specific rates)73'292. The annual incidence of HCV infection 
estimated in 2000 was carried forward to years 2001-30, but clearly could be 
influenced by the impact of future prevention initiatives and therefore the numbers 
progressing to moderate, but unlikely severe, disease could be over-estimated. 
It was important to model the progression to moderate disease (defined as 3- 
5/6 on fibrosis and/or >3/18 on necroinflammation grades), even with the 
limited data 
available, because patients reaching this stage are recommended 
for treatment with 
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antiviral therapy289. Progression to moderate disease was based on the prevalence of 
necroinflammation activity, which can fluctuate over time308, either because it is not 
continuously present or identifiable 309, but was regarded as cumulative for the 
purposes of modelling. A comprehensive review of the literature on progression 
following development of compensated cirrhosis revealed higher annual rates to 
decompensated cirrhosis (6.5%) and HCC (3.5%) than had been used in previous 
model applications (4% and 0.5-2%, respective ly)68,73,77,78'80'8z 
Compared to the number of people living with chronic HCV infection in 
Scotland, relatively few have received antiviral therapy. Progress needs to be made in 
(i) identifying individuals who would most benefit from antiviral therapy and (ii) 
retention of those diagnosed with chronic HCV in clinical follow-up. A total of 3,000 
(95% Cl 1,800-4,800) and 6,600 (3,900-10,300) former IDUs were estimated to be 
living with moderate HCV disease in 2003 in Glasgow and Scotland, respectively; if 
the uptake of antiviral therapy continues at the current level, these numbers were 
estimated to double by 2010. As high as 16% and 27% of Glasgow former IDUs in 
2005 aged 30-39 and 40-49 years, respectively, were estimated to have moderate 
disease (32% and 47% of those chronically infected, respectively), which highlights 
the potential benefit of targeting HCV testing at these age groups of former IDUs. 
Treatment of chronic HCV with combination therapy of pegylated interferon 
plus ribavirin has been shown to be cost-effective 73'310 and is expected to reduce 
future disease complications. In France, however, it has been demonstrated that at 
least half of their HCV-infected population would require antiviral therapy to curb the 
future rise in the number of HCV-related deaths and at most reduce the incidence of 
decompensated cirrhosis by almost a quarter over the next twenty years79. Increasing 
uptake of antiviral therapy among former IDUs in Glasgow by more than thirteen- 
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fold, to 1,000 cases per year during 2005-2030, similarly did not have a dramatic 
impact on the future incidence of severe HCV disease, with reductions of only 19 to 
28% depending on whether patients with compensated cirrhosis could be treated and 
respond to therapy as well as those with moderate disease. However, the treatment, 
with more effective antiviral therapies than currently available, of up to 1,000 former 
IDUs per year in Glasgow with moderate HCV disease over the next 26 years (15,000 
cases in total and 62% of those HCV infected by the year 2030) could potentially 
prevent between 24% and 86% of severe HCV-related events during 2005-2030. 
The simulations did not consider the different response to antiviral therapy 
according to genotype, the re-treatment of non-responders or that patients who had not 
responded to antiviral therapy may have benefited from a reduced rate of liver disease 
progression 311 °312 Thus, the model may have under-estimated the potential long-term 
benefit of antiviral therapy, but illustrates that current practice, with treatment of a 
relative minority of HCV infected patients, will scarcely impact on the future burden 
of this disease. 
There is some urgency for action because HCV is frequently asymptomatic 
until cirrhosis develops. Once hepatic decompensation occurs, treatment is limited by 
the shortage of donor transplant organs. Additional research regarding the cost- 
effectiveness of HCV testing strategies targeted at former IDUs should be pursued to 
help formulate public health policy in this area. The identification and treatment of a 
larger proportion of former IDUs with advanced HCV disease, education about the 
importance of minimal alcohol consumption, and the development of better tolerated 
therapies may help to achieve a greater impact on the morbidity and mortality of this 
disease. Meanwhile, the development of initiatives to prevent (i) the further spread of 
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HCV infection among current IDUs and (ii) the initiation of non-IDUs into injecting 
should not be neglected. 
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Table 6.2: Assumed risk of cirrhosis at twenty and thirty years* following infection with 
HCV according to risk profile of HCV chronically infected individuals. 
Characteristics influencing HCV disease progression Prevalence of cirrhosis at: 
(mean and 95% CI) 
Gender Age at HCV 
acquisition (years) 
Co-infected 
with HIV 
Heavy 
alcohol user 
20 years 30 years 
Female 20 No No 3.0% (2.4- 3.0%) 5.8% (4.4- 7.7%) 
Female 20 No Yes 6.6% (3.8- 9.1%) 12.8% (6.9-20.6%) 
Female 20 Yes No 8.4% (3.9-13.1%) 14.8% (7.1-27.9%) 
Female 20 Yes Yes 16.9% (6.2-33.5%) 28.7% (10.9-53.5%) 
Female 30 No No 6.2% (3.3- 8.6%) 12.2% (6.0-19.6%) 
Female 30 No Yes 13.9% (5.6-23.8%) 24.0% (9.9-43.6%) 
Female 30 Yes No 16.1% (5.6-31.5%) 29.0% (10.0-51.3%) 
Female 30 Yes Yes 31.6% (9.2-56.6%) 45.3% (15.9-63.8%) 
Male 20 No No 4.5% (2.9- 6.0%) 8.8% (5.2-14.2%) 
Male 20 No Yes 9.6% (4.6-17.1%) 17.5% (8.5-33.6%) 
Male 20 Yes No 11.8% (4.6-24.1%) 21.3% (8.6-43.4%) 
Male 20 Yes Yes 24.1% (7.7-47.4%) 38.9% (13.4-61.0%) 
Male 30 No No 9.0% (4.2-16.6%) 16.9% (7.6-33.6%) 
Male 30 No Yes 18.7% (6.7-38.1%) 31.8% (12.0-56.5%) 
Male 30 Yes No 22.8% (6.9-47.2%) 36.5% (12.2-60.5%) 
Male 30 Yes Yes 39.2% (11.3-62.2%) 52.7% (18.6-63.9%) 
* Progression to compensated cirrhosis was calculated based on a Weibull distribution with prevalence estimated 
at 6.5% (95% Cl 3.5-9.5%) and 20% (10-40%) after 20 and 40 years, respectively, and adjusted for increased 
progression with older age at HCV acquisition (relative risk 1.08 per year, 1.04-1.12), males (1.56,95% CI 1.21- 
2.03), co-infection with HIV (2.92,1.70-5.01), and heavy alcohol use (2.33,1.67-3.26). 
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Table 6.3: Estimated annual transition probabilities for progression of HCV infected cirrhotic persons. 
Progression between disease states Average annual transition rates estimated from literature Pooled 
Initial state Outcome Point Total number of First author estimate 
estimate subjects (reference no) (95% CI*) 
(mean years of 
follow-up) 
(i) Compensated Decompensated 3.9%1 355 (5.1 years) Fattovich et al. (31R) 6.5% 
cirrhosis cirrhosis 4.9%11 112 (4.5 years) Hu et al. (319) (4,0-9.2%) 
(1 unrelated to 6.4%1 136 (6.6 years) Fattovich et at. (320) 
HCC) 9.1%9 44 (3.3 years) Serfaty et al. (321) 
9.7%t 257 (5.3 years) Gines et al. (322) 
(ii) Compensated HCC 0.7% 124 (6.1 years) Takano et al. (323) 3.5% 
cirrhosis 1.0%t 405 (8.0 years) Gentilini et al. (324) (2.4-4.6%) 
1.4%1 384 (5.1 years) Fattovich et al. (318) 
2.1%t 112 (4.5 years) Hu et al. (319) 
2.1% 136 (6.6 years) Fattovich et al. (320) 
2.5%# 163 (5.3 years) Bruno et al. (325) 
2.8%x 416 (5.7 years) Degos et al. (326) 
3.4%1 396 (4.2 years) Mandelli et al. (327) 
4.6% 166 (5.5 years) Chiaramonte et al. (328) 
4.7% 349 (5.8 years) Ikeda et al. (329) 
5.1%t 228 (3.7 years) Imberti et al. (330) 
5.1% 44 (3.3 years) Serfaty et al. (321) 
6.9% 45 (5.5 years) Nishiguchi S at at. (331) 
12.3%t 400 (3.0 years) Tsai et at. (332) 
(iii) Decompensated Liver transplant 2.1% 507 (1.9 years) Hutchinson et al. (Ch. 4) 2.0%* 
cirrhosis 
(iv) Decompensated Death 12.6% 24 (-) Fattovich et at. (320) 18.6% 
cirrhosis 12.9%t 65 (2.0 years) Fattovich et al. (318) (13.7-25.0%) 
14.0% 49 (-) Hu et al. (319) 
22.3% 507 (1.9 years) Hutchinson et al. (Ch. 4) 
30.7%t 121 (-) Gines et al. (322) 
(v) HCC Death 54.0% 70 (0.7 years) Hutchinson et al. (Ch. 4) 60.5% 
57.6%t 60 (-) Degos et al. (326) (54.5-67.6%) 
63.9%t 2573 (-) EI-Serag et al. (333) 
(vi) Liver transplant Death in first year 5.2% 58 (3.1 years) Paik et al. (334) 14.6% 
(for decompensated 6.0% 97 (-) Ascher et at. (335) (11.1-18.2%) 
cirrhosis) 7.0% 54 (3.4 years) Shuhart et al. (336) 
10.0% 128 (2.7 years) Wali et at. (337) 
13.0% 209 (4.1 years) Neumann et al. (338) 
16.0% 510 (2.5 years) Ghobrial et al. (339) 
20.0% 3084 (-) Detre et at. (340) 
21.0% 149 (3.0 years) Gane et al. (34! 
) 
21.8% 715 (9.4 years) Jain et al. (342) 
22.1% 1080 (-) Fagiuoli et al. (343) 
(vii) Liver Death in 2" + 3.0% 149 (3.0 years) Gane et al. (°) 4.4% 
transplant (for years 3.1% 1080 (-) Fagiuoli et al. (343) (3.5-5.3%) 
decompensated 3.5% 715 (9.4 years) Jain et al. (342) 
cirrhosis) 3.6% 209 (4.1 years) Neumann et al. (338) 
5.1% 128 (2.7 years) Wali et al. (337) 
5.1% 3084( -) Detre et al. (340) 
5.1% 510 (2.5 years) Ghobrial et al. (339) 
6.5% 54 (3.4 years) Shuhart et al. (336) 
10.0% 58 (3.1 years) Paik et al. (334) 
Includes HCV antibody negative persons; $ Includes persons who had received anti-viral therapy; (-) Data missing; 
* Range/estimate used in model. 
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Chapter 7: Summary and future work 
7.1 Overview of the approach used to derive HCV projections 
A forward projection approach was used to model the number of, both current and 
former, IDUs who have acquired HCV infection and will either have progressed or 
will progress to mild, moderate and severe HCV disease. The HCV epidemic among 
IDUs in Glasgow was modelled initially because more epidemiological data exist for 
this region than elsewhere in Scotland, and model outcomes calibrated with local data 
relating to HCV and its consequences. Insights gained from the model fitting process 
in Glasgow were then used to extend the model to the rest of Scotland. 
The HCV projection model incorporated both knowledge and uncertainty 
about major parameters relating to (i) the incidence and cessation of injecting drug use 
and mortality from causes unrelated to HCV, (ii) the incidence of HCV infection 
among current IDUs, and (iii) the rate of HCV disease progression. First, incidence 
and cessation of injecting drug use in Glasgow were derived through the use of a 
modified Delphi approach which combined expert opinion with capture-recapture 
IDU prevalence estimates. Mortality from causes unrelated to HCV among current 
and former IDUs was based on estimates from the literature. Secondly, stochastic 
simulation was developed to model the transmission of HCV among current IDUs in 
Glasgow, according to their injecting risk behaviours and the characteristics of the 
virus, and to estimate the past incidence of HCV infection. For the third component of 
the projection model, the worldwide literature was reviewed to inform the rate of 
HCV disease progression and a meta-analysis was performed to quantify the effect of 
heavy alcohol use on progression to cirrhosis in persons with chronic HCV. Finally, 
modelled outcomes were fitted to epidemiological data, in particular the number of 
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IDUs developing HCV-related decompensated cirrhosis each year which had been 
estimated through the record-linkage of Scotland's database of HCV diagnosed 
persons with hospital discharge and death records. 
7.2 Main findings from stages undertaken to derive HCV projections 
The following five sections provide a synopsis of the stages, and the main findings 
presented in Chapters 2-6, undertaken to derive projections: (i) estimating the 
incidence and cessation of injecting drug use in Glasgow, (ii) estimating the past 
incidence of HCV infection among injecting drug users in Glasgow, (iii) estimating 
the severe disease burden associated with HCV infection in Scotland, (iv) estimating 
the influence of alcohol on the progression of HCV infection, and (v) estimating the 
current and future disease burden of HCV among injecting drug users in Glasgow and 
Scotland. 
7.2.1 Estimating the incidence and cessation of injecting drug use in Glasgow 
Glasgow has been at the forefront of injecting drug use prevalence estimation: log- 
linear modelling of capture-recapture data estimated 8,490 (95% CI 7,490-9,720) and 
7,190 (6,090-8,620) current IDUs in 1990 and 2000, respectively. Hitherto, however, 
no consensus had been sought on the size and shape of its IDU epidemic curve. A 
modified Delphi approach was used to elicit one for Glasgow. Twelve experts were 
asked to provide their opinion on the prevalent number, incident number, and 
percentage ceasing injecting each year for quinquennia during 1960-2000. Instead of 
the usual iterative process to refine experts' consensus, the elicitation of IDU 
incidence and cessation provided an opportunity, not previously explored, to combine 
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these data and examine coherence with capture-recapture estimates on the prevalent 
number of injectors during 1990 and 2000. 
Scrutiny of consensus data indicated that experts had under-estimated 
incidence during 1985-1990, and over-estimated prevalence during 1995-2000 and 
cessation during 1985-2000. Coherent estimates indicated that prevalence (median 
estimates: 149 to 557), incidence (28 to 49) and cessation (1 to 2%) remained low and 
stable during 1960-1975, rose steeply between 1975-1985 (median prevalence from 
557 to 4,438; incidence from 49 to 1,335; cessation from 2% to 6%), and by 2000 
there had been a decline in incidence (1,195) but further rises in prevalence (6,809) 
and cessation (15%). Point prevalence estimates from capture-recapture studies were 
essential to anchor experts' consensus and derive coherent data. The rise in the 
cessation of IDU throughout the 1990s is a promising finding in the context of the 
expansion of methadone prescribing and other harm reduction services in Glasgow. 
7.2.2 Estimating the past incidence of HCV infection among injecting drug users 
in Glasgow 
Stochastic simulation was used to model quantitatively the transmission of HCV 
through the sharing of used needles/syringes among current IDUs in Glasgow during 
1960-2000. The modelling combined information on (a) the incidence and cessation 
of injecting drug use in Glasgow, (b) the frequencies with which Glasgow IDUs 
injected and shared needles/syringes, and the numbers of different persons they shared 
with, and (c) the susceptibility, transmissibility and carriage of HCV infection. 
The model that considered higher infectivity during acute viraemia following 
infection produced seroprevalences (median: 62-72%) and incidences (18-30 per 100 
susceptible injector-years) consistent with observed data during the 1990s, and 
166 
suggests that this phenomenon may be an important factor in the spread of HCV, as 
recognised with HIV. Discounting this effect would have under-estimated HCV 
prevalence which, alternatively, could have been explained by the model's omission 
of transmissions occurring through other routes such as indirect sharing of injecting 
equipment. The annual number of new HCV infections among current IDUs (who had 
no previous infection) in Glasgow was estimated to be low during 1960-1976 (median 
of 10-60), rise steeply during the early 1980s to peak in 1985 (1,120), stabilise during 
1991-1997 (510-610) and rise again during 1998-2000 (710-780). Scenario analyses 
indicated that potentially as many as 4,500 HCV infections (10th and 90th percentiles: 
2,400-7,700) had been prevented in Glasgow during 1988-2000, as a result of harm- 
reduction measures introduced during this period. 
Scenario analyses also permitted the gauging of changes in risk behaviours 
required to effect appreciable reductions in the incidence of HCV infection. Incidence 
can be successfully reduced if IDUs who, unavoidably, share needles/syringes confine 
their borrowing to one person; with this strategy alone (i. e. reducing the mean number 
of partners to one from an estimated 3-6,2, and 3 during years 1988-1990,1991-1997 
and 1998-2000, respectively), an estimated 5,300 HCV infections (10th and 90th 
percentiles: 4,100-6,700) could have been averted during 1988-2000. Alternatively, 
permitting only 11-20% of IDUs in Glasgow to share a needle/syringe at least once 
annually during 1988-2000 would have similarly averted an estimated 5,200 HCV 
infections (10th and 90t" percentiles: 4,200-6,600). Such insights will inform those 
responsible for developing new ways to prevent HCV transmission among IDU 
populations. A serious commitment to implement, and evaluate the cost-effectiveness 
of, strategies, which could achieve appreciable reductions in risk behaviours among 
IDUs, is urgently needed to influence the future course of the HCV epidemic. 
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7.2.3 Estimating the severe disease burden associated with HCV infection in 
Scotland 
To monitor the emergence of sequelae related to HCV infection requires national 
surveillance systems, currently lacking in the UK and elsewhere, which detect not 
only advanced liver disease but also the aetiological factors. The laboratory reporting 
of diagnostic positive tests for HCV antibodies in Scotland linked electronically to 
clinical data gathered from hospital and death records provided a unique national 
epidemiological dataset on diagnosed HCV infection to estimate the numbers 
developing HCV-related decompensated cirrhosis and HCC. 
A substantial proportion of persons who test positive for HCV antibodies 
report no risk factors for infection: 32% (3,874/12,096) in Scotland. Of 12,096 
diagnosed HCV antibody positive persons studied in Scotland, 61 % reported injecting 
drug use with their HCV diagnosis and a further 27%, yielding a total of 88%, were 
established as IDUs through log-linear modelling of record-linkage data from four 
sources (i. e. HCV diagnoses, HIV test, hospital and death records). 
Approximately 500 and 200 diagnosed HCV antibody positive persons in 
Scotland had developed and died of liver failure, respectively, by the end of 2001. 
Relatively low prevalences of HCV infection were estimated among individuals with 
HCC and decompensated cirrhosis presenting to hospital (13% and 6%, respectively) 
or having died (11% and 5%, respectively) in Scotland during 1996-2001; these 
estimated rates incorporated adjustments to account for (i) the inability to link a 
proportion of HCV diagnosed persons due to insufficient 
identifiers and (ii) the non- 
diagnosis of HCV infection among HCV infected HCC and decompensated cirrhosis 
cases. The hospital morbidity data alone, 
however, under-estimated the incidence of 
168 
severe HCV-disease since 25% and 14% of HCV diagnosed individuals who had died 
- according to death records held by General Registrar Office for Scotland - from 
HCC and decompensated cirrhosis, respectively, were not identified with these 
conditions in the hospital register. The number of persons with newly developed 
HCV-related decompensated cirrhosis in Scotland was estimated to have increased by 
30% from 230 (95% Cl 220-250) in 1996-1998 to 300 (280-320) cases in 1999-2001, 
highlighting HCV as a growing significant burden on healthcare resources in 
Scotland. 
Alcohol was a prominent factor among HCV diagnosed persons who had died 
(78% of 134) or were hospitalised (72% of 442) with decompensated cirrhosis during 
1996-2001 in Scotland. The younger age of decompensated patients presenting to 
hospital in Scotland during 1996-2001 with both HCV and alcohol (78% of 320 were 
aged <50 years) suggests that the combined effect of these two factors accelerates 
liver disease progression more than if only one (decompensated cirrhosis patients with 
only HCV: 48% of 122; and with only alcohol: 33% of 8,465) or neither of these 
factors (17% of 1,681) were present. In light of the potential synergistic effect 
between alcohol and HCV, limiting the alcohol consumption of chronically infected 
individuals is important to help prevent future HCV-related morbidity and mortality. 
7.2.4 Estimating the influence of alcohol on the progression of HCV infection 
The elucidation of the factors that influence progression to severe HCV disease is 
important at an individual level - so that appropriate counselling of those affected and 
help in making decisions regarding antiviral therapy can be given - and at a 
population level - so that covariate influences 
in projection models aimed at 
estimating the future burden of disease can be accommodated. A convincing, yet 
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inconsistent, pattern which demonstrates increased progression of HCV-related liver 
disease with heavy alcohol use has emerged. A meta-analysis which examined twenty 
articles, involving over 15,000 HCV chronically infected persons, published between 
1995 and 2004 was therefore undertaken to explore the relationship between advanced 
liver disease - either advanced fibrosis, cirrhosis or decompensated cirrhosis - and the 
consumption of alcohol. 
The pooled RR of cirrhosis, including decompensated cirrhosis, associated 
with heavy alcohol intake (defined in the range of at least 210 to 560g per week) was 
2.33 (95% CI 1.67-3.26) by the random effects model. The risk of HCV-related 
disease associated with heavy alcohol intake increased with severity of the outcome: 
the lowest (1.63; 95% CI 1.22-2.17) and highest (3.54; 2.14-5.85) pooled RR 
estimates were obtained for advanced fibrosis and decompensated cirrhosis, 
respectively. Studies varied widely in their definition of significant alcohol intake, 
ranging between 210 and 560g per week, and so the true threshold above which 
alcohol accelerates HCV disease progression remains uncertain. 
Studying the relationship between HCV and alcohol is problematic because of 
difficulties in obtaining an accurate history of alcohol intake. Moreover, studies 
investigating the risk of HCV-related cirrhosis necessarily include patients undergoing 
liver biopsy and therefore could under-represent heavy alcohol users, as patients 
consuming alcohol at toxic levels may have been precluded from biopsy. Such 
selectivity may have under-estimated the regression effect of alcohol in the meta- 
analysis. Nevertheless, the evidence overwhelmingly shows a worsened outcome for 
those with chronic HCV and concurrent alcohol use. Alcohol consumption should be 
minimised as much as possible in those who have chronic HCV until a safe threshold 
is more definitively determined. 
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7.2.5 Estimating the current and future disease burden of HCV among injecting 
drug users in Glasgow and Scotland 
To plan a public health response to the HCV epidemic in Scotland, in terms of both 
treatment needs and preventive measures, quantitative estimates of the current and 
future burden of HCV disease are required. The aims were to develop a model to 
estimate (i) the numbers of, both current and former, IDUs who acquired HCV 
infection and progressed to mild, moderate and severe HCV disease in Glasgow and 
Scotland between 1960 and 2030, and (ii) the number of cases of severe HCV-related 
disease (i. e. decompensated cirrhosis and HCC) among IDUs that could be prevented 
in the future through a range of antiviral treatment strategies. Several countries have 
developed models to forecast the future course of their HCV epidemic, but few have 
validated their predictions, as in this study, by fitting model outcomes to past 
epidemiological trends relating to HCV and its consequences. 
A total of 17,400 (95% CI 14,300-22,200) and 42,900 (32,400-60,600) 
persons, who had ever injected drugs, were estimated to be living with HCV 
antibodies by the end of 2003 in Glasgow and Scotland, respectively. This compares 
with approximately 5,000 (29%) and 13,900 (32%) diagnosed, respectively. Of these 
HCV-infected IDUs in Glasgow and Scotland, 13,200 (95% CI 10,800-16,900) and 
32,200 (24,300-45,500) were estimated to be living with chronic HCV and therefore 
at risk of developing cirrhosis. The number of IDUs developing HCV-related 
decompensated cirrhosis in Scotland is estimated approximately to double between 
2000 and 2020. 
Consistency between model and record-linkage data improved by allowing 
disease progression rates to depend on age at HCV acquisition, gender, HIV co- 
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infection and heavy alcohol use. However, the results still indicated that either the 
prevalence of cirrhosis at 20 years was higher than the mean of 6.5% assumed or the 
strength of factors influencing progression had not been fully explained. A review of 
the literature on progression following development of compensated cirrhosis 
revealed higher annual rates to decompensated cirrhosis (6.5%) and HCC (3.5%) than 
had been used in previous model applications (4% and 0.5-2%, respectively). 
A total of 3,000 (95% CI 1,800-4,800) and 6,600 (3,900-10,300) former IDUs 
were estimated to be living with moderate HCV disease in 2003 in Glasgow and 
Scotland, respectively; if the uptake of antiviral therapy continues at the current level, 
these numbers were estimated to double by 2010. As high as 16% and 27% of 
Glasgow former IDUs in 2005 aged 30-39 and 40-49 years, respectively, were 
estimated to have moderate disease (32% and 47% of those chronically infected, 
respectively), which highlights the potential benefit of targeting HCV testing at 
former IDUs who belong to these age groups. 
The treatment with antiviral therapy of 15,000 former IDUs in Glasgow with 
moderate HCV disease over the next 26 years (62% of those HCV infected by the 
year 2030) could potentially prevent between 24% (based on 45% response and 
compliance to therapy) and 86% (based, unrealistically, on 100% response and 
compliance to therapy) of severe HCV-related events during 2005-2030. The 
identification and treatment of a larger proportion of former IDUs with HCV disease, 
education about the importance of minimal alcohol consumption, and the 
development of more effective and better tolerated therapies are needed now to help 
achieve a greater impact on the future morbidity and mortality of this disease. 
Meanwhile, the development of initiatives to prevent (i) the further spread of HCV 
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infection among current IDUs and (ii) the initiation of non-IDUs into injecting should 
not be neglected. 
7.3 Key data required to refine future HCV projection modelling work 
Projections clearly rely on the accuracy of the model assumptions used to derive 
them. As new data become available, improvements in the modelling of the HCV 
epidemic in Scotland, as elsewhere, will be possible, leading to further refinement in 
these estimates. The following six sections outline areas for future work related to 
HCV projections in Scotland. 
7.3.1 Scotland-wide data on the incidence and cessation of injecting drug use 
The importance of estimates on the incidence and cessation of IDU has long been 
recognised, yet few attempts have been made to estimate these in the UK. A modified 
Delphi approach was used to derive these for Glasgow by combining expert opinion 
with capture-recapture IDU prevalence estimates. Given the wide certainty ranges 
surrounding experts' consensus on incidence and cessation, likely brought about by 
the difficulty in quantifying these parameters, other approaches need to be considered 
to validate these estimates in Glasgow and provide data throughout Scotland. 
A lag-correction method has been adapted from AIDS epidemiology to 
estimate recent trends in the incidence of heroin use in south-eastern England by 
adjusting reported numbers of heroin users visiting 
drug treatment agencies for the 
time lag between onset of heroin use and first treatment requests". This approach 
could similarly be applied in Scotland to estimate the relative 
incidence of injecting 
drug use from reports to the Scottish Drugs Misuse 
Database121. This database 
however only dates back to 1992 and therefore 
limits estimation with the lag- 
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correction method to recent trends in injector incidence. Long-term historical data of 
the IDU epidemic are required to estimate completely the past incidence of HCV in 
this population. 
In Australia, the back-calculation approach, using national data on opioid 
overdose deaths, has generated estimates of the numbers of people starting to inject 
heroin between 1960 and 1997112. The validity of the back-projection estimates 
depends on the consistency and completeness of the surveillance data over time. 
Reports of drugs-related deaths in Scotland increased 4-fold between 1993 (33) and 
1994 (139) as a result of an improved system of collecting information on all deaths 
involving drugs or persons known or suspected to be drug-dependent 344 Thus, 
adjusting historical data on the number of drug-related deaths in Scotland for 
inconsistencies caused by the reporting systems is essential in order to use these data 
to generate estimates of the incidence of injecting drug use through back-calculation. 
A study, implemented by SJH, SMB and DJG in 2004, linking SCIEH's national HIV 
test database with Scotland's deaths register will allow the examination of the vital 
status of approximately 12,500 Scottish IDUs, who had tested negative for HIV 
antibodies during 1988-2003, and inform the adjustment of historical reports for 
misclassification of overdose deaths. 
Injecting drug users are a difficult group to follow prospectively, and therefore 
many studies - usually cross-sectional - of this population are restricted to elucidating 
short-term changes in injecting behaviour. However, long-term cohort studies 
measuring the injecting patterns of individuals following commencement of injecting 
drug use are required to allow accurate estimation of the cessation of IDU, both 
regionally and temporally, in Scotland. Meanwhile, the estimation of cessation rates 
may be achieved by combining available data on IDU prevalence and mortality with a 
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greater understanding of the incidence of injecting drug use, using the simulation 
methods outlined in Chapter 2. 
7.3.2 Mortality among current IDUs 
The simplest assumption of a common and constant risk of death was applied among 
current IDUs (1-2% per annum) in the HCV projection model in Chapter 6 and among 
heroin users (0.6-1% per annum for overdose death) in back-calculation models 
estimating the past incidence of injecting heroin use112. However, de Angelis et al. 
have demonstrated the sensitivity of back-calculation estimates to the assumption of a 
common and constant risk of overdose death345, and underlined the need for reliably 
estimated gender and age specific rates. 
Relating reported drug-related deaths in Scotland to the prevalent number of 
current IDUs generated through capture-recapture studies, with assumptions about the 
age and gender distributions, indicated that these deaths were more common among 
men (1.7 times more frequent than among females) and those older than 34 years of 
age (2.1 to 6.6 times more frequent than those younger than 25 years)152. 
Corroboration of these findings is needed from cohort studies of IDUs, which can 
directly calculate mortality by gender and age. The study proposed above linking the 
records of approximately 12,500 Scottish IDUs, who had tested negative for HIV 
antibodies during 1988-2003, to the deaths register provides a relatively cheap 
opportunity to assess the influence of gender and age at 
HIV test uptake on drugs 
related mortality. Scrutiny of the record-linkage data will 
inform on mortality not only 
related to drugs but also alcohol and other causes of 
death. 
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7.3.3 Alcohol intake of current and former IDUs in Scotland 
The meta-analysis in Chapter 5 illustrated a significantly increased risk of cirrhosis 
(RR 2.3; 95% Cl 1.7-3.3) associated with alcohol intake defined in the range of at 
least 210 to 560g per week. The record-linkage of 12,096 HCV diagnosed positive 
persons to hospital admission data, presented in Chapter 4, identified alcohol as a 
factor in 71% of 514 cases developing HCV-related liver failure during 1991-2001 in 
Scotland. Despite the recognition that alcohol is one of the main predictors of a 
worsened outcome with chronic HCV, the drinking patterns of IDUs (the group most 
affected by HCV infection in resource-rich countries) have thus far received little 
attention. A particular concern is that drug injectors who have been treated for their 
drug problems may subsequently substitute their illicit drug use with alcohol346'347 
Studies of drug users receiving drug treatment in England have reported 
prevalences of either problem drinking or drinking above the recommended safe 
limits in the range of 15-45%219'296,297,298 To accommodate this range of uncertainty 
in the HCV projection model, outlined in Chapter 6, three rates (0%, 20% and 40%) 
of heavy alcohol use were explored. Varying disease progression rates according to 
40% uptake (versus 0% and 20%) of heavy alcohol use - along with age at HCV 
acquisition, gender and HIV co-infection - improved the consistency of simulated 
outcomes with record-linkage results. 
Further research is required to determine accurately the prevalence and 
determinants (e. g. gender, current/former injector status and HCV antibody status) of 
heavy drinking among IDUs in Scotland. Building upon the record-linkage work 
developed in Chapter 4, which established that 17% of 12,096 HCV diagnosed 
persons in Scotland had a history of alcohol abuse resulting in either hospitalisation or 
death, the same approach could be used to determine the prevalence of alcohol-related 
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problems among persons presenting for drug treatment in Scotland. The Scottish 
Drugs Misuse Database (SDMD) holds data on all individuals who have sought 
treatment for their drug use for the first time ever or in the last six months: including a 
minimum set of identifiers (i. e. forename and surname initials, fourth letter of 
surname, date of birth and gender) to enable internal and external linkage of records 
and information on ever and recent (i. e. last month) injector status to distinguish 
between non-IDUs, former IDUs and current IDUs. Linkage of the SDMD to hospital 
discharge diagnoses records will therefore help gauge the alcohol abuse patterns of 
current and former IDUs by region in Scotland. A limitation, however, of the hospital 
data is the absence of information on the quantity of alcohol consumed by patients. 
Surveys of current and former IDUs would aid interpretation of the hospital data by 
quantifying the alcohol consumption of those who have and have not been 
hospitalised with an alcohol-related problem. 
7.3.4 Progression of liver disease among HCV chronically infected persons in 
Scotland 
The projection model, outlined in Chapter 6, estimated the increasing severity of HCV 
disease with age among current and former Glasgow IDUs in 2005. The mean 
prevalence of moderate disease increased from 6% among chronic HCV infected 
(both current and former) IDUs aged under 30 years to 29%, 47%, and 53% among 
those aged 30-39,40-49 and 50 years or more, respectively. 
Meanwhile, the mean 
prevalence of cirrhosis increased from 4% among those aged 
30-39 years to 9% and 
28% among those aged 40-49 and 50 years or more, respectively. 
To assess the accuracy of these projection estimates, there 
is need to collate 
information on the histological status - together with the patient's age, gender, risk 
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group of HCV acquisition, health-board of residence, HIV status, and alcohol history 
- of HCV chronically infected patients in Scotland undergoing liver biopsy. A project 
initiated by the Scottish Viral Hepatitis Group, funded by the Scottish Executive and 
currently in the early stages of implementation, aims to collect the above and other 
key epidemiological and clinical data on HCV infected persons in Scotland who are, 
or have been, in clinical care to form the Scottish Clinical HCV database. The factors 
causing patients to present for clinical assessment and undergo a liver biopsy, as 
discussed in the meta-analysis of Chapter 5, will likely influence the histological 
results by over-estimating the prevalence of moderate and severe liver disease; these 
biases would therefore need to be considered when comparing liver biopsy results 
with projection estimates. 
Liver biopsy is internationally recognised as the gold standard for assessment 
of hepatic fibrosis, as non-invasive markers developed to date are unable to predict 
reliably the stage of liver disease348. The importance of liver biopsy for chronic HCV 
was highlighted in a recent study that showed a substantial proportion (68%: 25/37) of 
biopsy proven cirrhosis patients were not identified as cirrhotic through clinical 
diagnosis349, which is important since these patients are generally not offered therapy 
because of concerns over safety and efficacy. Despite this, a recent statement, made at 
the Consensus Conference on HCV in Edinburgh during April 2004350, dismissed the 
role of liver biopsy in the clinical follow-up of certain HCV-infected patients - on the 
basis of the morbidity and mortality risks associated with biopsy and the impressive 
response rates (up to 80%) from clinical trials of pegylated combination therapy for 
some genotypes351. The absence of information on stage of HCV 
disease from liver 
biopsy, or equivalent markers, may however prove to be a major impediment in 
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prioritising patients for HCV antiviral therapy and validating projection models of 
HCV infected persons in Scotland. 
7.3.5 Validating record-linkage estimates of the incidence of HCV-related severe 
disease in Scotland 
Knowledge of the number of HCV-infected IDUs developing decompensated 
cirrhosis each year in Scotland was integral to the fitting of the projection model in 
Chapter 6. Estimates were based on findings from the record-linkage work, as 
described in Chapter 4, of the numbers of HCV diagnosed individuals admitted to 
hospital with decompensated cirrhosis, which were adjusted to account for the 
proportion associated with injecting drug use (88%) and the non-hospitalisation (14%) 
and non-HCV-diagnosis (18%) of decompensated cases. The hospital morbidity data 
alone under-estimated the incidence of severe HCV-disease as 14% of deaths from 
decompensated cirrhosis among HCV diagnosed persons were not identified with this 
complication in the hospital register. In addition, the non-HCV-diagnosis rate was 
taken as the proportion (18%) of hospitalised HCV-related decompensated cirrhosis 
cases who were not diagnosed with HCV infection until >14 days after their 
hospitalisation. 
Further study of the HCV antibody status of patients presenting with severe 
liver disease, particularly those with other aetiological factors such as alcohol abuse, 
is needed to validate the record-linkage results and assess whether or not all HCV- 
infected cases had been estimated using this approach. Matching the identifiers of 
patients either presenting to hospital or dying with 
decompensated cirrhosis and HCC 
in Glasgow and Edinburgh against local Regional Virus Laboratory HCV test records 
will establish the HCV test uptake of cases 
in these regions and inform whether or not 
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current testing practices are adequate to detect HCV infection among persons with 
severe liver disease in Scotland. 
7.3.6 Determining the most cost-effective approaches to testing and treating IDUs 
for chronic HCV in Scotland 
A total of 43,000 persons, who had ever injected drugs, were estimated to be living 
with HCV antibodies by the end of 2003 in Scotland (from modelling work presented 
in Chapter 6), of whom approximately 14,000 (32%) had been diagnosed. Of these 
HCV-infected IDUs in Scotland, 32,000 were estimated to be living with chronic 
HCV and therefore at risk of developing cirrhosis. In comparison, relatively few 
Scottish IDUs have received antiviral therapy (estimated optimistically at 1,500 in the 
projection model). Progress needs to be made in identifying individuals eligible for 
antiviral therapy and in retaining those diagnosed with chronic HCV in clinical 
follow-up. 
The concern is that those who would benefit most from an HCV diagnosis - 
infected persons with moderate hepatitis who do not (or no longer) inject drugs - are 
not being offered and recommended a test or are lost to clinical follow-up. An 
evidence-based approach to chronic HCV case-finding is essential if limited resources 
are to be used effectively in identifying those most in need of antiviral therapy. The 
modelling presented in this thesis highlighted the potential benefit of targeting HCV 
testing at former IDUs aged 30-39 and 40-49 years as 16% and 27% of those in 
Glasgow, respectively, were estimated to have moderate disease in 2005 (32% and 
47% of those chronically infected, respectively). Further research is needed to 
examine the clinical benefits and cost-effectiveness of different HCV testing 
strategies targeted at former IDUs. 
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The projection model, designed and calibrated for IDUs in Glasgow, provides 
the foundation to examine the cost-effectiveness of the latest available treatments for 
chronic HCV among patient subgroups with different stages of disease and host 
factors. A key finding from the HCV projection work undertaken for Glasgow was 
that consistency between model and epidemiological data improved by allowing HCV 
disease progression rates to depend on age at HCV acquisition, gender, HIV co- 
infection and heavy alcohol use. Incorporating this heterogeneity in the natural history 
of chronic HCV into cost-effectiveness models may have important implications for 
treatment decisions in an evolving patient population. 
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